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Abstract 
 
Stroke is a common disorder with dire consequences for the patient and for society and will 
increase in prevalence over the coming years. Following stroke, many patients 
unfortunately suffer a further stroke, and recurrent strokes account for approximately 25% 
of the total. Considerable scope therefore exists to improve both primary and secondary 
stroke prevention.  This thesis has addressed several areas at key stages in the prevention of 
stroke by developing strategies to better identify those at highest risk, attempting to better 
target pre-existing anti-platelet therapy and by beginning the evaluation of xanthine oxidase 
reduction and uric acid lowering therapy in the prevention of stroke. 
 
A clinical scoring system to aid diagnostic recognition in those with suspected transient 
ischaemic attack (TIA) was successfully developed and has the ability to reduce the referral 
of those without cerebrovascular disease to busy TIA clinics. The score was developed on 
data from 3216 patients and included 9 clinically useful predictive variables. After 
adjustment to reflect the greater seriousness of missing true TIA patients, 97% of TIA and 
22% of non-TIA patients were accurately identified. The results were confirmed during 
prospective validation. Use of the score could have a substantial effect on waiting times for 
assessment; there is potential double the numbers seen within the timeframe recommended 
by guidelines with no other change to services. This would be an important advance given 
the recent evidence that rapid assessment and treatment of those with TIA greatly reduces 
stroke risk.  
 
Aspirin resistance was found to be higher in those with cerebrovascular microembolic 
signals (MES) and carotid disease compared to those with equivalent carotid disease and no 
 - 23 - 
MES. This study included sixty-two patients who mostly had symptomatic carotid disease. 
Approximately a quarter had MES. The rate of aspirin resistance on at least one test was 
25.8% (16 patients), with 13 (21%) resistant on PFA-100 testing, 8 (12.9%) using the 
Verify-Now system and 5 (8.1%) resistant on both. Aspirin resistance was more common in 
patients with MES (50% compared to 17.4% without, p=0.018 on Fishers exact test). This 
provides a link to a well established and robust surrogate marker of outcome and thus a 
useful model to further study the benefits of guided anti-platelet strategies. An 
interventional clinical anti-platelet trial based upon individual aspirin responsiveness in 
high risk individuals such as those with MES is now warranted. Aspirin resistance was also 
confirmed to be a common phenomenon in a case-control study of 180 patients. It was 
present in 34% of those with recent stroke and in 18% of those with risk factors but no 
established disease. However, the role of poor compliance with therapy as a cause in a 
substantial number of cases was established; it accounted for approximately half of those 
labelled resistant in the stroke group. Further, when only those with objective evidence of 
recent aspirin ingestion were considered, the prevalence of aspirin resistance was similar in 
both groups (at 26%). This suggests that objective measures to confirm compliance with 
aspirin therapy should be mandatory in future studies of aspirin resistance.   
 
Increasing serum uric acid was found to be a predictor of poor functional outcome 
following acute stroke but not in an independent fashion. In total, 852 patients were 
included in this study and greater uric acid levels were associated with increased odds of 
poor outcome on univariate but not multivariate analysis (OR 1.3, 95% CI 0.73-2.31). 
However, there was no evidence of an association with favourable outcome as other groups 
have found. Increasing serum uric acid was also shown to be predictive of increased risk of 
stroke, total, vascular and coronary mortality in treated hypertensive patients but 
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interestingly, the relationship between stroke mortality and serum uric acid appears J-
shaped and most apparent in females. 
  
A study of the use of allopurinol in those with diabetes showed that xanthine oxidase 
inhibition improves cerebral nitric oxide bioavailability suggesting a beneficial effect of 
allopurinol on cerebrovascular health. This study included 14 participants who had 
impaired baseline cerebrovascular nitric oxide bioavailability. Allopurinol led to a 
significant improvement in responses to NG-monomethyl-L-arginine (L-NMMA) when 
compared to placebo (p=0.032, median improvement in ICA flow reduction following L-
NMMA of 3144 (95% CI 375 to 7143)) mls). L-NMMA is an inhibitor of endothelial nitric 
oxide synthase which reduces cerebral blood flow in healthy volunteers; the bigger the 
reduction, the greater the endothelial health. However, a study of the effect of allopurinol 
treatment on cerebrovascular reactivity (as measured by response to acetazolamide 
infusion) in a group of patients with recent subcortical stroke revealed no positive effect.  
Cerebrovascular reactivity was unchanged by treatment with allopurinol. This raises 
interesting questions regarding the longevity of any positive effect of allopurinol as this, 
and other studies of 3 month duration, have revealed no benefit. Further, subjects in this 
study did not, on balance, have elevated serum uric acid and it has recently been suggested 
that only those with significantly elevated levels benefit in the setting of congestive cardiac 
failure.  Whether this is also true in those with stroke also requires to be clarified. A large 
study of the effect of allopurinol on carotid intima-media thickness, a robust and modifiable 
marker of vascular risk, in those with recent stroke is planned to address these questions. 
 
The studies in this thesis therefore include a number of pragmatic findings which could 
improve care at all stages in the prevention of stroke. The TIA scoring system could 
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improve recognition of the high risk condition TIA, a useful model has been developed in 
which to study a population of patients truly resistant to aspirin and important lessons have 
been learned to aid further evaluation of xanthine oxidase inhibition; a promising therapy 
for the prevention of stroke. 
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A stroke is defined by the World Health Organization (WHO) as a syndrome of “rapidly 
developing clinical symptoms and/or signs of focal (or at times global) disturbance of 
cerebral function lasting more than 24 hours (unless interrupted by surgery or death), with 
no apparent cause other than of vascular origin.” The majority are ischaemic, secondary to 
arterial occlusion by in-situ thrombus or embolus (1), with the remainder being due to 
intracerebral haemorrhage or sub-arachnoid haemorrhage. 
 
1.01 Burden of Stroke / Recurrent Stroke 
 
The WHO estimates that 17 million people die annually from heart disease and stroke. In 
the United Kingdom, stroke remains the single biggest cause of major disability (2) and is 
the third leading cause of death.  The condition has a profound effect on patients and 
relatives and is associated with a vast economic burden (2;3). In the United Kingdom and 
other countries, these costs are on the rise and consistently consume around 5% of health 
care resources (4), costing the NHS and wider economy approximately £7 billion per year 
(5).   
 
The incidence of stroke appears to be similar or perhaps higher in Scotland than in other 
parts of the United Kingdom and in other European and Western countries (6-11). The 
Scottish Borders Stroke Study (11) attempted to ascertain all stroke events in this area over 
a two year period (from 1998-2000). The crude annual incidence rate per 100,000 per year 
was 280 (95% CI 258-304) for all stroke subtypes with 197 (95% CI 179–217) due to 
cerebral infarction, 24 (95% CI 17–31) due to intracerebral haemorrhage, 11 (95% CI 7–
16) due to subarachnoid haemorrhage and 49 (95% CI 40–59) of undetermined subtype. 
Incidence rates were higher in males and increased dramatically with age, particularly 
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above the age of 65 years, who accounted for 80% of the first ever in a lifetime strokes. In 
total, 790 strokes occurred during the study, 194 (24.7%) of which were recurrent strokes. 
 
The MONICA Project provides further extensive data on stroke incidence, case fatality and 
mortality rates across 16 European countries and China during the period 1985-87. The 
incidences of first-ever and recurrent stroke were greater among men than women in all 
populations. The incidence (age standardized) of stroke was higher in China than in West 
or Central Europe apart from in Finland (for example, incidence was 242 per 100,000 in 
China compared with 361 in Kuopio, Finland and 130 per 100,000 in Göteborg, Sweden) 
(12). Rates were higher in Eastern Europe than in West or central Europe. Approximately 
20% of stroke events recorded in the MONICA project were recurrent events. The 
incidence of recurrent stroke was highest in men and women from Beijing and men in 
Russia (Novosibirsk) but was lowest in Sweden (12). 
 
Stroke is, of course, a global problem and that the incidence and impact of stroke differs 
among ethnic groups (13). The majority of stroke deaths occur in low and middle income 
countries and among non-Western populations (14) and Black, Chinese, South Asian and 
Japanese populations have a higher incidence of stroke compared with Caucasians (2). In 
some Asian populations (excluding India), the burden of cerebrovascular disease exceeds 
that of coronary heart disease (CHD). In China, for example, stroke is the second leading 
cause of death in urban areas (15) and it is estimated that three times as many Asian people 
die from stroke than from CHD (16). 
 
Trends in stroke incidence (age standardised) were also evaluated in the MONICA cohort 
(between 1985 and 1990). Incidence fell in most MONICA centres except in several 
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Eastern European regions (17;18). Other studies also support the notion that age 
standardised stroke rates and mortality are decreasing (19;20).  However, the age of the 
population in most developed nations, including the UK is projected to increase 
considerably in the next half century – the proportion of individuals aged over 65, who 
account for approximately 80% of strokes, is likely to increase by near two-fold (from 20 to 
35%) (21).  It is estimated that the number of individuals in the UK aged over 65 years will 
increase from approximately 9,684,000 to 16,528,000 from 2005 to 2050.  The number of 
stroke events will therefore increase. Even if age standardised rates of stroke remain stable 
or decrease slightly it is projected that the incidence of stroke per annum in the European 
region will rise by over 30% in the next 25 years (10). 
 
It is of interest that those who have suffered stroke have a higher risk of recurrent stroke 
than of myocardial infarction (MI), whereas the opposite applies for those who have 
suffered MI. Data from large scale observational studies suggest that nearly 80% of 
recurrent vascular events in those with previous stroke are stroke and that only 20% are MI 
(22).  In the Cardiovascular Health Study, the stroke rate was double that of MI in those 
whose index event was stroke (23), whereas in the CAPRIE study it was 7 times higher 
(24). Approximately 25% of strokes are recurrent events (25) and approximately 25% of 
stroke patients will suffer recurrence within 5 years. The risk of recurrence may be highest 
early, with approximately 4% suffering recurrence within one month and 12% at one year 
(26).  Thereafter, the risk of recurrence after one year has been estimated at 4-5% per 
annum (27) and while risk may be highest early, the majority of recurrent strokes do of 
course occur after one year (28). 
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It is important also to consider the incidence of transient ischaemic attack (TIA). While 
many now regard stroke and TIA as one condition, they are currently managed in a 
different fashion in the UK and beyond. A TIA is an episode of temporary and focal 
neurological symptoms caused by cerebral artery occlusion, with symptom resolution in 
less than 24 hours (29). Patients with a recent transient ischaemic attack (TIA) or minor 
stroke require rapid investigation and treatment initiation to minimize the risk of future 
vascular events, and in particular, the early risk of stroke.  Between 15 and 30% of patients 
with stroke give a history of preceding TIA (30) and the seven day risk of stroke following 
TIA may exceed 30% in high risk groups (31) and risk is highest in the first 48 hours (32).  
These patients represent a group at extremely high risk of stroke and accordingly, 
guidelines recommend that patients are assessed and investigated within 1 week (33;34) 
and that fast track or rapid access neurovascular clinics are established (35).  
 
Data from the Oxford Community Stroke Project suggested a crude annual incidence of 
TIA of 35 per 100,000 population per year in a southern English population, with a slightly 
higher age and sex standardized rate. Other studies have revealed age and sex standardized 
rates of 68 and 83 per 100,000 per year (36;37) and more recent data from Oxfordshire 
showed a higher incidence than previously (38), perhaps reflecting better recognition of 
TIA. 
 
Summary of the Burden of Stroke 
Stroke is clearly a common disorder with dire consequences for the patient and for society 
and will increase in prevalence over the coming years. Following stroke, many suffer a 
further stroke, and recurrent strokes account for approximately 25% of the total. 
Considerable scope therefore exists to improve both primary and secondary stroke 
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prevention.  TIA is also common and represents a high risk condition which must be 
addressed as an emergency. Those with TIA represent an excellent group in which to study 
new treatments and care strategies given their high risk of events.  
 
1.02 Treatment of Acute Stroke 
 
1.02.1 Therapeutic Targets 
Infarct volume increases in the first few hours after onset of ischaemic stroke, with the 
ischaemic penumbra gradually being subsumed into the area of infarction. The penumbra is 
the region of brain where blood supply is significantly reduced but energy metabolism is 
maintained because of collateral flow (39). Its viability depends on the severity and 
duration of ischaemia and, if blood flow is swiftly restored, some penumbral tissue may be 
saved. However, during the time lag to reperfusion, a physiological cascade occurs which 
places penumbral tissue at further risk. Cellular metabolism becomes anaerobic leading to 
acidosis and sodium-potassium transporters become dysfunctional causing a rise in 
intracellular osmolarity and cytotoxic oedema. Intracellular calcium increases and 
ultimately the process becomes self-perpetuating with further rises in intracellular calcium, 
possibly because of release of intracellular glutamate (40). Increased calcium concentration 
within cells enhances injury through activation of lipase, protease and free radical 
generation. Blood brain barrier integrity is reduced (41) and if breached, blood components 
can enter the interstitial space causing vasogenic oedema and increasing the risk of 
haemorrhagic transformation of infarcted tissue. Furthermore, even if reperfusion occurs, 
the penumbra is vulnerable to the effects of reperfusion injury (42) as further free radical 
formation and release of harmful neurotransmitters may be provoked.  It has been estimated 
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that up to 2 million neurons are lost each minute from stroke onset from this area every 
minute that treatment is delayed (43). 
 
In the context of intracerebral haemorrhage, it has recently been recognised that early 
haemorrhage growth occurs in a significant number of patients (44;45). In a study of 103 
patients, all of whom presented within three hours of onset and underwent serial brain 
imaging with x-ray computed tomography (CT), substantial haemorrhage growth occurred 
in 28% of patients (45). Haemorrhage growth was defined as a 33% increase in volume, 
occurred particularly within the first hour, and was associated with clinical deterioration. 
Haemorrhage growth may be increased in those with hypertension although data do conflict 
(46;47). 
 
Thus, for both ischaemic and haemorrhagic stroke there are therapeutic targets, which are 
likely to exist only in the early hours after stroke. This of course necessitates rapid 
assessment and investigation. However, the National Sentinel audit (5) (of England and 
Wales) found that only 30% of those suspected stroke patients who were deemed to require 
urgent brain imaging (within 30 minutes) received a scan on the same day. Also, many 
ambulance services do not treat potential stroke patients as the highest category of 
emergency. Reducing delays to assessment and imaging to increase the numbers presenting 
within the first hours after onset of stroke is therefore crucial and will have a significant 
impact on patient outcomes. Such delays are multi-factorial and will require comprehensive 
strategies to increase public awareness and improve ambulance, emergency medicine and 
radiology services, whilst ensuring all patients have equity of access to stroke unit care. 
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1.02.2 Current Management Strategies 
Once a patient has arrived at hospital and received a diagnosis of acute stroke, management 
serves a dual purpose; to reduce the high risk of recurrent stroke and to reduce the burden 
of disability in established stroke. Secondary preventative measures continue to improve 
and will be outlined later. Acute treatment of stroke involves control of physiological 
variables, strategies to reperfuse the ischaemic area, measures to reduce growth of primary 
intracerebral haemorrhage (haemostatic therapy, currently unproven), protection of the 
vulnerable, yet salvageable, ischaemic penumbra (neuroprotectant therapy, currently 
unproven) and surgery. All patients should be cared for in a dedicated acute stroke unit, 
which in itself saves lives and significantly improves functional outcomes (48). By 
definition, a stroke unit is an area and environment of organised and multidisciplinary care 
which ensures access to specialist medical, nursing and allied staff and treatment. 
 
All patients with suspected acute stroke or TIA should undergo emergency brain imaging to 
help confirm the diagnosis, distinguish infarct from haemorrhage and to identify important 
differential diagnoses such as tumour.  The choice of brain imaging modality lies between 
computed tomography (CT) and magnetic resonance imaging (MRI). An urgent brain scan 
enables rapid differentiation of ischaemic from haemorrhagic stroke and there is no 
rationale for waiting to image patients – it delays treatment initiation and is the least cost 
effective approach (49). A non-contrast CT brain is the most widely available test and has 
excellent sensitivity for identification of haemorrhage early after onset, while MRI has 
similar sensitivity for identification of haemorrhage and significantly greater sensitivity for 
detection of ischaemia (50).  Newer CT and MRI based techniques are available which 
have the potential to increase both diagnostic sensitivity and specificity and increase the 
numbers of patients receiving treatments such as thrombolysis (51).  
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1.02.3 Control of Physiological Variables 
Arterial hypertension occurs in as many as 80% of patients following acute stroke (52). It is 
associated with a poor outcome (53) but it may represent a protective response - falls in 
blood pressure may lead to infarct extension because of impaired cerebrovascular 
autoregulation following acute stroke (54). There is some evidence that a U-shaped 
relationship exists with arterial hypotension also being associated with a poor outcome (52). 
Such uncertainty also surrounds intracerebral haemorrhage where hypertension may 
contribute to haemorrhage growth. Current guidelines suggest lowering blood pressure in 
the presence of hypertensive encephalopathy, aortic dissection, severe cardiac failure and if 
blood pressure is extremely high on repeated measurement (>220 mmHg systolic or > 120 
mmHg diastolic blood pressure) (55). This leaves a great deal of uncertainty in the majority 
of patients and it is unclear whether prior antihypertensive therapy should be discontinued 
in the acute phase and at what thresholds of blood pressure we should intervene and the 
treatment targets that we should aim for.  Fortunately, several large clinical trials are now 
underway and should address these issues (Controlling Hypertension and Hypotension 
Immediately Post-Stroke Trial [CHHIPS trial] (56), Continue or Stop post-Stroke 
Antihypertensives Collaborative Study [COSSACS] (57) and Efficacy of Nitric Oxide in 
Stroke Trial [ENOS trial] (58)).  
 
Elevated blood glucose is common in the acute phase following ischaemic stroke (59) and 
is associated with a poor outcome (60), regardless of the presence of pre-existing diabetes. 
In a recent systematic review of non-diabetic patients, stress hyperglycaemia defined as 
blood glucose of greater than 6 or 7.1 mmol/l was strongly predictive of increased hospital 
mortality (RR 3.28, 95% CI 2.32-4.64) and poor functional outcome (RR 1.41, 95% CI 
1.16-1.73) (59). This may be because elevated blood glucose increases brain lactate 
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production, which is associated with increased infarct size (61), may reduce the efficacy of 
thrombolytic therapy (62;63) and may increase the risk of haemorrhagic transformation of 
infarcted tissue.  However, whether routine lowering of hyperglycaemia with insulin 
improves outcome after acute stroke is as yet unproven.  The recent GIST-UK (Glucose 
Insulin in Stroke) trial (64) enrolled 933 patients and found no evidence of benefit for 
insulin therapy in terms of mortality (OR 1.14, 95% CI 0.86 to 1.51) or secondary 
outcomes. Significantly lower levels of both blood pressure and glucose levels were seen 
following treatment although it is likely the trial was underpowered and further randomized 
controlled trials are required. At present, current guidelines suggest insulin titration in those 
with serum glucose of > 10 mmol/l (55). 
 
Fever has also been associated with a poor outcome following acute stroke (65), possibly 
because of a detrimental effect on intracerebral metabolism, increased free radical 
production (66) or changes in blood brain barrier function (67). Guidelines suggest the use 
of fanning and paracetamol if temperature rises above 37.5°C and that this should prompt a 
search for infection (55). It is again unclear whether this improves clinical outcome but 
trials are in progress to evaluate this (68). 
 
1.02.4 Reperfusion Strategies for Acute Ischaemic Stroke 
Intravenous Thrombolytic Therapy 
Thrombolytic therapy with tissue plasminogen activator (rt-PA) is the only licensed 
treatment for acute ischaemic stroke in Europe where it must be administered within three 
hours of symptom onset. First evidence of efficacy was published in 1995 and license was 
granted for use in the United States of America in 1997. In Europe, however, a conditional 
license was first granted in 2002 and uptake has remained disappointingly slow. 
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Approximately two thirds of otherwise eligible patients miss out on treatment because of 
delay in presentation and/or early misdiagnosis (69). The United Kingdom performs 
particularly badly and currently holds 15th place in the European league table of 
thrombolysis use; only around 0.2% of stroke patients were treated in 2005 and access to 
treatment across the nation is patchy (70). 
 
Intravenous thrombolytic therapy is clearly beneficial as shown in a recent pooled meta-
analysis of the major thrombolysis studies (71). The analysis considered 2775 patients 
treated within six hours of ictus. The odds of favourable outcome (defined as no disability) 
were 2.8 (95% CI 1.8-9.5) for treatment within 90 minutes and 1.6 (95% CI 1.1-2.2) for 
treatment between 91 and 180 minutes. Benefit was still apparent for patients treated 
between 181 and 270 minutes (odds ratio 1.4, 95% CI 1.1-1.9). The rate of significant 
intracerebral haemorrhage was 5.9% in those treated with rt-PA compared to 1.1% in those 
treated with placebo. However, only a small number of these were of clinical significance, 
and this risk of haemorrhage is already accounted for in the calculation of odds of 
favourable outcome. Thus, the chance of being free of handicap after stroke is increased 
nearly 3 fold by thrombolytic treatment provided it is administered within 90 minutes of 
onset. Smaller but still significant benefits are seen up to 4.5 hours. The number needed to 
treat (NNT) to achieve an excellent outcome (and avert one case of death or dependency) 
following treatment is approximately 7 (71) while the NNT to achieve a reduction in 
disability is approximately 3 (72). The number needed to harm is 30 and these figures 
compare favourably to other interventions such as thrombolysis for acute MI. 
 
A rigorous audit of outcomes in several thousand European patients (The Safe 
Implementation of Thrombolysis in Stroke-Monitoring Study (73)) treated within license 
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and in routine clinical practice has confirmed that safety is at least as good as in clinical 
trials, with low rates of symptomatic significant haemorrhage. Efficacy also appears to be 
similar (table 1.1). The risk of haemorrhage should not deter use of thrombolytic therapy 
but precautions must be taken to minimise its risk. The factors associated with an increased 
risk of haemorrhage are increasing age, extensive early infarct change on brain imaging, 
diabetes mellitus (DM), elevated blood glucose, DM and a history of previous stroke, and a 
low platelet count (74). Those with higher baseline stroke severity may also have a higher 
risk of haemorrhage but equally, may derive greatest benefit from treatment. Exclusion 
criteria are similar to those for thrombolysis in myocardial infarction, although patients 
with a blood pressure of >180/110 mmHg, or those who require treatment to attain a 
satisfactory blood pressure, are generally not treated. There are also concerns regarding its 
use in those with DM and a history of previous stroke. Mild systemic bleeding can also 










Trials 17.3% 49% N/A 8.6% 
SITS-
MOST 
11.3% 54.8% 1.7% 7.3% 
Placebo 18.4% 30.2% N/A 1.9% 
* Bleed large enough to cause symptoms and accompanying neurological 
deterioration. † Any bleed with any alteration in neurological status regardless of 
severity. 
Table 1.1. Summary of outcomes in thrombolysis studies and the SITS register 
 
Very recent data show that intravenous thrombolytic therapy delivered within 3 to 4.5 hours 
of onset but otherwise within the terms of the license is also effective and has a similar 
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safety profile to treatment within 3 hours of onset. This was tested in a recent randomized, 
placebo controlled double blind trial, the ECASS III study (76). It included 821 participants 
with presumed ischaemic stroke and revealed an increase in the odds of an excellent 
outcome (OR 1.34, 1.02 to 1.76, p=0.04). The rate of symptomatic intracerebral 
haemorrhage was 2.4 % in the treatment and 0.2% in the placebo group (p=0.008). 
 
Intra-arterial Thrombolysis / Mechanical Reperfusion 
These therapies are not widely available in the UK. Intra-arterial thrombolysis involves 
direct catheterisation of an occluded artery and local administration of thrombolytic agents 
(rt-PA or urokinase (not available in UK)). This appears to be an effective therapy for 
confirmed middle cerebral artery (MCA) or basilar artery occlusion. For example, in the 
PROACT II (Prolyse in Acute Cerebral Thromboembolism) trial (77), where treatment was 
initiated within 6 hours of onset, reperfusion rates in those with confirmed MCA occlusion 
were significantly higher following intra-arterial thrombolysis with urokinase and 
intravenous heparin (66% compared to 18% in heparin treated controls, p<0.001).  Clinical 
outcomes were also significantly improved with more patients living independently at day 
90 (40% compared to 25% of controls, p=0.043, relative risk reduction 58%).  
 
Basilar artery occlusion carries a grave prognosis with a high mortality rate – perhaps in 
excess of 70%. While randomised controlled trial evidence are lacking, several case series 
have been published which suggest reduced mortality rate following intra-arterial 
thrombolysis (78;79). However, a recent systematic analysis suggested reperfusion rates 
and clinical outcomes were similar with both intra-arterial and intravenous treatment 
emphasising the need for administration of either form of thrombolysis in this devastating 
condition (79). 
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Catheter based techniques may allow lower systemic doses of thrombolytic agents to be 
used but also the use of mechanical clot disruption and retrieval. The later approach would 
be a particular advantage in those with a significant haemorrhage risk or in those unsuitable 
for intravenous rt-PA.  As yet, no randomized data confirm efficacy of mechanical 
embolectomy. However, in a study of 151 patients with ischaemic stroke and any treatable 
intracranial or extracranial artery occlusion who were deemed unsuitable for rt-PA (80;81) 
presenting within 8 hours of onset, a high rate of vascular recanalisation was seen (46% 
compared to 18% in a historical control sample). Those who exhibit recanalisaton also have 
better outcomes than would be expected for their baseline stroke severity (81). These 
strategies therefore represent a real alternative for those with major stroke who are 
unsuitable for rt-PA but the limited availability and need for specialist neuro-radiology staff 
may hinder introduction of these techniques into routine practice. 
 
Trials are ongoing to assess efficacy of thrombolytic therapy in ischaemic stroke up-to 6 
hours after onset of symptoms (82) and to establish whether newer imaging techniques can 
better guide thrombolytic therapy and perhaps allow treatment up to 9 hours after onset in 
selected patients.  Results of small phase 2 studies of this later approach have been 
conflicting (83-85), although it remains a promising strategy. 
 
1.02.5 Aspirin Treatment 
Patients with ischaemic stroke should be treated with aspirin.  The effect size is modest but 
important; a combined analysis of the CAST (86) and IST (87) revealed 9 fewer deaths or 
fatal strokes for every for every 1000 patients treated with aspirin in the acute phase (88). If 
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patients receive thrombolytic treatment, it is generally advised that aspirin should be 
deferred for 24 hours. 
 
1.02.6 Anticoagulant Therapy 
Early anticoagulation has not been shown to yield benefit early after stroke. In a meta-
analysis of 22 trials, anticoagulation within 24-48 hours after ischaemic stroke onset led to 
a reduction in early recurrent stroke (OR 0.76, 95% CI 0.65 to 0.88) which was offset by an 
increase (of similar magnitude) in the number of symptomatic intracranial haemorrhages 
(OR 2.52, 95% CI 1.92 to 3.3) (89). Very early treatment with unfractionated heparin has 
been linked with better functional outcome and lower early recurrence rate (90;91) but 
again at the cost of increased haemorrhagic complications. Early anticoagulation is 
therefore not recommended as a treatment for acute ischaemic stroke (55) although is 
recommended by some for those with atrial fibrillation (92).  
 
1.02.7 Neuroprotectant Strategies 
Neuroprotectant drugs aim to save ischaemic brain tissue by damping down the potentially 
harmful molecular processes in the penumbra. This may prolong the life of the penumbra, 
maintain blood brain barrier integrity, reduce oedema and haemorrhagic transformation, 
and reduce reperfusion injury. Such strategies may also be of benefit in the peri-
haemorrhage region in intracerebral haemorrhage.  Unfortunately, no neuroprotectant 
strategy has yet been proven effective in phase III clinical trials or reached clinical practice, 
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1.02.8 Therapeutic Hypothermia 
Therapeutic hypothermia is arguably the most promising novel therapy for acute stroke (94). 
There are several mechanisms by which hypothermia may convey a neuroprotectant 
mechanism. It will decrease cellular metabolism (95), limit cytotoxic and excitatory 
cascades, reduce free radical formation and suppress blood brain barrier breakdown (96). 
Mechanisms of cooling include surface cooling which, while able to attain reductions in 
temperature (97), has disadvantages of patient discomfort and may necessitate sedation and 
paralysis. The preferable, yet more invasive approach, is to use intravascular cooling via a 
central venous heat exchange catheter and infusion of cold saline (98). It also allows greater 
control over rewarming, which may be associated with increases in intracranial pressure if 
performed rapidly (99). 
 
A wealth of data show therapeutic hypothermia is effective in animal models of cerebral 
ischaemia, particularly with transient ischaemia where cooling was initiated within one 
hour (100-102) Therefore, like thrombolytic therapy, it is likely that therapeutic 
hypothermia will only prove effective if initiated early after onset and in patients with 
reperfusion (either spontaneous or iatrogenic).  
 
Evidence of efficacy in humans is lacking, although a recent case report (103) and some 
human feasibility studies (104) provide prima facie evidence of efficacy. Further research is 
required. 
 
1.02.9 Specific Treatment for Intracerebral Haemorrhage 
Supportive treatment is indicated as for all types of stroke. Approximately 15% of cases of 
intracerebral haemorrhage are associated with warfarin. These patients have a higher risk of 
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death and disability (105) and require rapid reversal of anticoagulation (106).  No specific 
licensed treatment exists for the majority with spontaneous intracerebral haemorrhage.  
Recombinant activated factor VII (rFVIIa) is a licensed treatment for bleeding in 
haemophiliacs who are resistant to factor VIII replacement and is a powerful initiator of 
haemostasis even in patients with normal coagulation. It is also utilized in the setting of 
major haemorrhage (107) and peri-operative bleeding (108). Adminstration early after 
stroke limits early haemorrhage growth (109;110) but has not been proven to improve 
clinical outcome (110).  Initial data in this regard were highly encouraging when, in a study 
of 399 patients (109), mortality was reduced in the treatment group and the odds of 
improvement in disability in survivors was nearly doubled. Unfortunately a larger phase III 
trial did not confirm these benefits (110). This lack of efficacy may relate to randomization 
imbalances in terms of poor prognostic factors such as intraventricular haemorrhage rate 
(111;112) and this does remain a promising strategy. A minimal increase in risk of 
thromboembolic events was seen in these studies. 
 
1.02.10   Surgical Treatment of Acute Stroke 
Complete MCA infarction is associated with brain oedema, increased intracranial pressure 
and a risk of transtentorial herniation and death. Medical therapy does little to improve 
mortality rates, which may be as high as 80% (113). Decompressive hemicraniectomy has 
recently been shown to be effective in this scenario in a pooled analysis of 3 recent 
European trials (114), both in terms of improved mortality and improved functional 
outcome. Compared to best medical treatment, numbers needed to treat to prevent death, 
severe disability or moderate disability are 2; 2 and 4 respectively. However, in these 
studies, participants were relatively young (mean age 43, maximal age 60) and important 
questions remain concerning optimal timing of treatment and patient selection. Further, 
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while this is a viable treatment for the most feared subtype of stroke, this treatment is 
thankfully only relevant for a minority of stroke patients. 
 
Surgery is also a potentially effective therapy for ICH. The recently completed STICH trial 
(115) enrolled 1033 patients with ICH and no benefit was seen from early surgery (OR 0.89, 
95% CI 0.66 to 1.19 for favorable outcome). Pre-specified subgroup analysis suggested 
there may be benefit in lobar ICH located less than 1 cm from the brain surface and a 
further randomized trial is underway to test this hypothesis (116). 
 
Summary of Acute Treatments 
Despite the clear and significant burden of acute stroke, there are depressingly few effective 
treatments. For ischaemic stroke, the only proven effective interventions are stroke unit 
care, aspirin and reperfusion therapy with intravenous thrombolytic therapy and intra-
arterial thrombolysis in a small subset of patients with proximal middle cerebral artery 
occlusion. No specific licensed treatment exists for ICH (except for stroke unit care). There 
are promising therapies in development but this lack of available treatment, the increasing 
number of strokes due to the ageing population and the burgeoning burden of stroke in the 
developing world makes optimal and cheap preventative therapy vitally important. 
 
1.03 Preventative Treatments for Stroke 
 
Preventative therapies can be considered as either primary (where the individual may be at 
risk of but has no established cardiovascular disease) or secondary (where the individual 
has established cardiovascular disease). Current preventative strategies include anti-platelet 
therapy and lipid lowering therapy to prevent ischaemic stroke, anticoagulant therapy to 
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prevent cardioembolic stroke and blood pressure reduction to prevent all stroke subtypes. It 
is also recommended that patients undergo screening for and treatment of prevalent 
diabetes mellitus, smoking cessation therapy and lifestyle modification (if required). Many 
of these strategies will also reduce risk of other cardiovascular events such as MI. 
 
1.03.1 Anti-platelet Strategies 
Aspirin is the only licensed strategy for the primary prevention of stroke. There are four 
licensed strategies for anti-platelet therapy to prevent recurrent stroke in the UK. These are 
aspirin, clopidogrel, dipyridamole and the combination of aspirin and extended release 
dipyridamole.  A summary of the mechanism of action, licensed indication and dosage for 
each of these drugs is shown in table 1.2. Aspirin (acetylsalicylic acid) prevents platelet 
aggregation by irreversible inhibition of cyclooxygenase-1 (COX-1).  COX-1 is a 
constitutive enzyme present in most body cells and is irreversibly acetylatylated by aspirin, 
thereby reducing production of prostaglandins and of thromboxane A2 by platelets.  
Platelets, given their lack of nuclei, are unable to synthesise additional cyclo-oxygenase 
meaning the inhibitory effect of aspirin on thromboxane production will last for the lifespan 
of the platelet. Thromboxane A2 has prothrombotic properties and stimulates platelet 
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Licensed Indications Drug Mechanism of Action Dose* 









A Inhibition of 
cyclooxygenase-1 
75mg  Y Y Y --- Risk of 
PUD 
D Inhibition of platelet re-
uptake of adenosine and 




--- Y --- --- Headache 
GI Upset 
C Inhibition of the 
adenosine triphosphate 
receptor 
75 mg --- Y Y Y GI Upset 
A = aspirin. C = clopidogrel. D = Extended release dipyridamole. * = recommended 
dose in Scotland. PP = primary prevention of stroke and myocardial infarction. SP = 
secondary prevention. CVD = cerebrovascular disease. CHD = coronary heart 
disease. PVD = peripheral vascular disease. PUD = peptic ulcer disease. GI = 
gastrointestinal upset. 
Table 1.2. Anti-platelet drugs available for prevention of stroke and cardiovascular 
disease in the UK. 
 
Several trials have shown aspirin to be effective in reducing the risk of a first 
cardiovascular event (117-121) in apparently healthy men and men and women with 
adverse cardiovascular risk. Meta-analysis of these trials (122), including over 55000 
patients, of whom 11446 were women, showed a 32% relative risk reduction in risk of first 
MI (RRR 0.68, 95% CI 0.59 to 0.79) and a 15% reduction in risk of any important vascular 
event (RRR 0.85, 95% CI 0.73 to 0.93). However, no reduction in incidence of non-fatal 
stroke was seen (RRR 1.06, 95% CI 0.87 to 1.29). Subgroup analyses in the individual 
trials suggested benefit in females although it did not reach statistical significance in one 
(119;121). The recent Women’s Health Study involved 39876 initially healthy women aged 
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> 45 years and evaluated 100 mg aspirin versus placebo (123). No reduction in major 
cardiovascular events, death or MI was seen, although incidence of stroke was reduced (RR 
0.83, 95% CI 0.69 to 0.99). A recent sex specific meta-analysis of primary prevention trials 
(124) including 95456 individuals (51342 women) confirmed a differing effect of aspirin 
between the sexes. It suggested that in women, cardiovascular events and stroke rates (OR 
0.83, 95% CI 0.7 to 0.97) were reduced by aspirin treatment but there was no reduction in 
rate of MI while in men, MI was reduced but there was no reduction in rate of stroke (OR 
1.13, 95% CI 0.96 to 1.33). Current local guidelines recommend that individuals whose 10 
year cardiovascular risk exceeds 20% and those with diabetes who are aged over 40 years 
are given 75 mg of aspirin. However, even this can be questioned given recent data from 
the POPADAD study where no benefit was seen following aspirin use in 1276 individuals 
with diabetes (125). There is no clear evidence to support any alternative anti-platelet 
strategy in the primary prevention setting.  
 
Aspirin is the most commonly prescribed anti-platelet agent for secondary prevention after 
stroke and prevents up to a fifth of recurrent strokes (126). Most studies suggest an 
approximate relative risk reduction of 15% in comparison with placebo (86;127;128) for 
both recurrent stroke and composite vascular endpoints. For example, in the UK-TIA study 
(127), 2435 subjects were enrolled and aspirin treatment (either 300mg or 1200 mg per 
day) led to a 15% RRR in a composite endpoint of vascular death, nonfatal MI and nonfatal 
stroke).  It is also effective in reducing death and recurrence in the immediate period after 
stroke (86;87).  
 
At the time of writing, aspirin monotherapy has been compared with placebo, dipyridamole, 
clopidogrel, the combination of aspirin and clopidogrel, the combination of aspirin and 
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extended released dipyridamole and with ticlopidine (as well as other drugs that are in 
development or not commonly used). Clopidogrel monotherapy has also been compared to 
the combination of aspirin and clopidogrel and to the combination of aspirin and 
dipyridamole. 
 
Ticlopidine is a member of the thienopyridine family and is an ADP receptor inhibitor. It is 
superior to placebo following stroke in terms of a composite endpoint of stroke, MI or 
vascular death (129) while studies have suggested marginal superiority (130) over or 
equivalence (131) to aspirin. It is rarely used and is not licensed in the UK because of a risk 
of severe neutropaenia and thrombotic thrombocytopenia. 
 
The CAPRIE trial (24) compared clopidogrel monotherapy to aspirin in 19195 patients 
with symptomatic cardiovascular disease (recent stroke, MI or symptomatic peripheral 
vascular disease). Overall, clopidogrel use linked with a small but statistically significant 
reduction in the rate of the primary composite endpoint of ischaemic stroke, MI or vascular 
death (5.32% with clopidogrel compared to 5.83% with aspirin, p=0.043). This small 8.7% 
RRR appeared predominantly driven by an effect in those with PVD (RRR 23.8%, 
p=0.0028) while in the stroke and MI subgroups, no difference was seen (RRR 7.3%, 95% 
CI -5.7 to 18.7% in those with recent stroke). 
 
Dipyridamole monotherapy is superior to placebo in terms of recurrent stroke prevention, 
but not in prevention of myocardial infarction or vascular death and may have similar 
efficacy to aspirin but again without proven benefit in prevention of MI (132;133).  This 
similar efficacy is at the cost of a significantly increased trial drop out rate because of side 
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effects such as headache. Aspirin and dipyridamole in combination have also been shown 
to be superior to placebo (134). 
 
The recent MATCH (135) and CHARISMA trials (136) showed that, in the secondary 
prevention of stroke, dual therapy with clopidogrel and aspirin is no better than either alone.  
The MATCH trial included 7599 with recent stroke or TIA and additional risk factors for 
recurrence and compared clopidogrel with the combination of aspirin and clopidogrel. The 
combination did not reduce the occurrence of a composite endpoint of ischaemic stroke, MI 
and vascular death (15.7% vs 16.7%, RRR 6.4%, p=0.244) but did lead to a two-fold 
increase in life-threatening bleeding episodes (2.6% vs 1.3%, p<0.0001).  The CHARISMA 
trial compared aspirin and clopidogrel therapy versus aspirin alone amongst 15,603 patients, 
the majority of whom had established cardiovascular disease. In 27% of patients the trial 
entry criterion was previous cerebrovascular disease. Clopidogrel was no more effective 
than placebo in aspirin treated patients in the entire cohort (occurrence of primary 
composite endpoint of 6.8% with combination compared to 7.3%, RRR 7%, p=0.22). In the 
secondary prevention cohort there was a significant reduction in the primary endpoint 
(6.9% vs 7.9%, RRR 12%, p=0.046). Trends toward benefit were apparent in those who 
entered the trial on account of stroke, and all-cause stroke appeared lower in the population 
as a whole. However, benefits only bordered on statistical significance before adjustment 
for multiple comparisons and bleeding complications were again increased nearly two-fold 
in with combination therapy (2.1% vs 1.3%, RR 1.62, p<0.001).  Among those with 
multiple risk factors but no established disease, the primary endpoint was non-significantly 
increased on those on dual therapy (RR 1.2, 95% CI 0.91 to 1.59).   
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The CARESS trial compared dual anti-platelet therapy with aspirin and clopidogrel with 
aspirin in patients with recently symptomatic > 50% carotid stenosis and microembolic 
signals (MES). The study was randomized, double blind and the primary endpoint was the 
proportion of patients who were MES positive at seven days and the secondary endpoint 
included recurrent stroke or TIA. The primary endpoint was significantly reduced in those 
who received both aspirin and clopidogrel (43.8% compared to 72.7%, RRR 39.8%, 95% 
CI 13.8 to 50%). There was a strong trend towards a reduction in rate of stroke or TIA 
although numbers were small (4 recurrent strokes and 7 TIAs in the monotherapy group 
compared to 4 TIAs with dual therapy). These promising results suggest that those with 
large vessel atherosclerosis and recent stroke may benefit – in the same way as those with 
recently symptomatic large vessel coronary disease – from early dual anti-platelet therapy 
(137).   
 
The recent ESPRIT trial (138) involved 2763 patients with recent stroke or TIA and 
revealed, during a mean follow-up of 3.5 years, that the combination of aspirin and slow-
release dipyridamole afford a 20% relative risk reduction (HR 0.8, 95% CI 0.66 to 0.98, 
ARR 1% per year) in the rate of vascular death or non-fatal stroke or MI compared to 
aspirin alone. The surprising lack (and indeed reduction) of increased bleeding 
complications is curious and further claims of anti-inflammatory and non-platelet mediated 
benefits of dipyridamole have emerged (139). The results of ESPRIT confirm those of 
ESPS 2 (132) and have consolidated the position of aspirin and dipyridamole combination 
therapy as preferable to aspirin alone in the secondary prevention of stroke.   
 
The recent PRoFESS study compared aspirin and dipyridamole with clopidogrel and 
included 20332 patients with recent stroke (140). The primary endpoint was recurrent 
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stroke and there was no difference between the treatment groups (9% following aspirin and 
dipyridamole vs 8.8% following clopidogrel, HR 1.01, 95% CI 0.92 to 1.11). Unlike in 
ESPRIT and ESPS-2, the combination of aspirin and dipyridamole led to an increase in rate 
of major haemorrhagic events including haemorrhagic stroke in comparison to its 
comparator which offset the slight reduction in ischaemic stroke. 
 
Thus, aspirin, clopidogrel and dipyridamole monotherapy appear to provide similar efficacy 
in the secondary prevention of stroke, although clopidogrel may be slightly superior. The 
combination of aspirin and clopidogrel poses unacceptable risks for little gain, except 
perhaps in certain high risk subgroups. Aspirin and extended release dipyridamole has been 
shown to be superior to aspirin in two studies but recent data suggest this strategy offers 
similar yield to clopidogrel monotherapy, which is better tolerated.  In certain high risk 
groups aspirin and clopidogrel combination therapy may be indicated but further study is 
required to confirm efficacy and establish optimal treatment duration.  At present therefore, 
a reasonable strategy would be to employ aspirin and dipyridamole combination therapy as 
first line and, where patients are intolerant to dipyridamole to consider either aspirin or 
preferably clopidogrel monotherapy. For the primary prevention of stroke, aspirin appears 
to be of benefit but perhaps only in women, whereas in men, most evidence suggests a 
reduction in risk of MI. 
  
1.03.2 Anticoagulant Therapy (non-Cardioembolic Stroke) 
The WARSS study enrolled 2206 patients with recent (within 30 days) ischaemic stroke 
without evidence of cardioembolic source. It compared aspirin 325 mg with warfarin with a 
target INR of 1.4 to 2.8 (141). There were no significant differences between the groups in 
terms of efficacy or bleeding risk. The WASID trial (142) compared warfarin and aspirin in 
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those with recent stroke and documented 50 to 99% intracranial stenosis (who had no 
evidence of significant carotid or cardio-embolic disease) and revealed no benefit from 
warfarin in terms of stroke recurrence which was similar in both groups (HR 1.04, 95% CI 
0.73 to 1.48). However, there was significantly worse protection from cardiac events and 
increased haemorrhage rate and increased mortality. The SPIRIT trial was also terminated 
early because of increased bleeding risk, although did involve a high target INR (3 to 4.5) 
(143). It included 1316 participants with minor stroke or TIA. The ESPRIT trial (144) 
compared aspirin with warfarin (target INR 2 – 3) in 1038 individuals with recent 
ischaemic stroke. There was no difference in rate of the primary outcome between 
treatment groups although ischaemic events were lower following warfarin (HR 0.73, 95% 
CI 0.52 to 1.01) but major haemorrhage rate was higher (HR 2.56, 95% CI 1.48 to 4.43). 
Anticoagulation is therefore not recommended for prevention of stroke in those with non-
cardioembolic stroke (55).   
 
1.03.3 Statin / Cholesterol Lowering Therapy 
The link between serum cholesterol levels and coronary artery disease is well established 
and the evidence that cholesterol lowering therapy with HMG-CoA reductase inhibitors 
(statins) reduces coronary morbidity and mortality in those with and without established 
CHD is unequivocal (145). Debate however continues concerning the association between 
serum cholesterol levels and stroke. Such a link would seem likely given the strong link 
between it and CHD, while the heterogeneity of stroke causes and epidemiological 
evidence that lower serum cholesterol may link with increased risk of intracerebral 
haemorrhage suggests such a link cannot be assumed (146;147). However, statin therapy is 
now an accepted strategy following ischaemic stroke (55).  Further, in a large meta-analysis 
of over 90000 patients (mostly with manifest CHD) who were enrolled in statin trials, statin 
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treatment significantly reduced the risk of incident stroke (OR 0.79, 95% CI 0.73-0.85) 
(148). Each 10% reduction in LDL cholesterol appears to afford a 15.6% RRR of stroke 
(95% CI 6.7% to 23.6%). Further compelling evidence arose following the Heart Protection 
Study which enrolled over 20000 patients with CHD or risk factors and compared 
simvastatin 40 mg with placebo (149). Simvastatin reduced the risk of first stroke by 25% 
(95% CI 15% to 34%, p<0.0001). The ASCOT trial lipid lowering arm (ASCOT-LLA) 
(150), which included those with hypertension, revealed a similar magnitude of stroke risk 
reduction. Reduction in stroke risk did not accompany the modest reduction in serum 
cholesterol seen in the ALLHAT study (151) but, on balance,, the evidence shows that for 
those with and without CHD, statin therapy reduces both risk of MI, mortality and stroke 
risk.  Approximately 16% of patients in the HPS study had suffered previous stroke, just 
over half of whom had no documented CHD. In this group with stroke, statin therapy 
yielded no reduction in recurrent stroke (HR 0.98, 95% CI 0.79 to 1.22).   
 
Until very recently therefore, it was not clear whether statin therapy reduced the risk of 
recurrent stroke following an index cerebrovascular event.  The SPARCL trial (152) 
randomised 4731 patients to high dose (80 mg) atorvastatin or placebo. Treatment led to a 
16% relative risk reduction of recurrent stroke and to reductions in the rates of most other 
vascular complications. These results, subsequently confirmed in a meta-analysis (153), are 
in contrast to those from the HPS, and confirm that statin therapy can reduce risk of 
recurrent stroke. The effect was however less than would be expected in terms of secondary 
prevention of MI. 
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An important consideration is the epidemiological link between low serum cholesterol and 
incidence of haemorrhagic stroke, raising the important possibility that statin therapy may 
increase risk of ICH. Data from randomized controlled trials conflicts but the pivotal  
SPARCL trial (152) did show an increased risk of haemorrhagic stroke in those in the 
treatment arm (HR 1.67, 95% CI 1.09 to 2.56). When these data were combined with those 
from the HPS in a meta-analysis, risk remained elevated in those receiving statin treatment 
(HR 1.73, 95% CI 1.19 to 2.5) (152). However, the same meta-analysis revealed a 20% 
reduction in the risk of the more common recurrent ischaemic stroke (HR 0.8, 95% CI 0.7 
to 0.92) and a smaller but significant reduction in overall recurrent stroke burden (HR 0.88, 
95% CI 0.78 to 0.99). 
 
Thus, statin therapy is clearly indicated and recommended as a preventative strategy in 
those who have suffered ischaemic stroke or who have CHD (55;154). Whether statins 
should be given to those who have suffered ICH and have no other indication for their use 
is at the time of writing unclear. 
 
1.03.4 Blood Pressure Lowering Therapy 
Hypertension is the most significant risk factor for stroke and the relationship between 
increasing blood pressure and increasing stroke risk even extends to within the normal 
blood pressure range (155;156). Treatment of hypertension is of unequivocal benefit in 
reducing stroke risk in the primary prevention setting (157) and evidence suggests that 
newer antihypertensive agents, such as amlodipine and angiotensin receptor blockers 
(ARBs), offer greater protection than “older” atenolol and diuretic based regimens (158). In 
a recent meta-analysis (158), calcium channel antagonist (except verapamil), angiotensin 
converting enzyme inhibitor (ACEI) and ARB based therapy was superior to diuretic or ß-
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blocker therapy, affording 7% greater protection against stroke (OR 0.93 (95% CI 0.89-
0.98). This may however be due to the small differences in achieved blood pressure control 
rather than specific ancillary properties of any drug (159).  
 
Treatment of hypertension in those who have stroke has now also been shown to reduce 
recurrent stroke risk.  In a recent meta-analysis (158), odds of recurrent stroke were reduced 
by 24% (OR 0.76, 95% CI 0.63-0.92), but interestingly, the strongest evidence exists for 
diuretic based therapies, as opposed to ACE inhibitor or ß blocker based regimens (OR 0.63, 
95% CI 0.55 to 0.73 vs placebo compared to a non-significant 8% reduction in the odds on 
ACEI based therapy).  In the PROGRESS trial (160), which included 6105 patients with 
prior stroke, treatment with either perindopril or a combination of perindopril and 
indapamide led to a 26% RRR (95% CI 16 to 34%) in major vascular event rate and a 28% 
RRR (95% CI 17 to 38%) in risk of recurrent stroke during follow up. On sub-analysis, 
combination of perindopril and indapamide led to a 43% (95% CI 30 to 54%) RRR in risk 
of recurrent stroke compared to placebo, a 40% (95% CI 29 to 49%) RRR in the risk of 
major vascular events and a 12/5 mmHg blood pressure reduction. Perindopril monotherapy 
afforded only a 5/3 mmHg reduction in blood pressure and a non-significant 4% RRR in 
stroke risk.  Benefits were similar regardless of history of hypertension and the mean blood 
pressure at trial entry was 147/86 mmHg suggesting that those within the normal blood 
pressure range may also benefit from blood pressure reduction after stroke. 
 
The MOSES trial (161) suggested that an ARB based regimen using eprosartan was 
superior to the calcium channel antagonist nitrendipine. This data supported a new and 
popular hypotheses that drugs which increased angiotensin II production would, via 
increased activation of the AT2 receptor, increase neuronal resistance to anoxia via 
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recruitment of collateral vessels and thus provide protection to ischaemic brain (162).  
However, a number of issues surround interpretation of the MOSES trial including the 
inclusion of multiple events and the use of a comparatively low dose of nitrendipine 
(although blood pressure reduction was similar in both treatment arms).  Further against 
this hypothesis, the PRoFESS trial (163) showed no significant reduction in recurrent 
stroke, any recurrent vascular events or diabetes following telmisartan use. The trial 
involved 20332 patients with recent stroke and 2.5 years follow up. Benefit was not 
apparent despite a 3.8/2 mmHg reduction in blood pressure, although use of concomitant 
blood pressure lowering therapy was higher in the placebo group. 
 
Antihypertensive therapy is therefore recommended to both reduce risk of first and 
recurrent stroke and risk of other vascular events following ischaemic stroke, TIA and 
intra-parenchymal haemorrhage.  Therapy should be considered in all after stroke, although 
target blood pressure levels are not well defined.  Data support the use of diuretic treatment 
or a combination of diuretic and ACE inhibitor therapies in the secondary prevention 
setting and newer antihypertensive agents such as amlodipine or ACEI / ARB regimens in 
the primary prevention setting. 
 
1.03.5 Diabetes 
Diabetes is a risk factor for stroke (164-166) and is an increasingly prevalent condition 
found in as many 33% of patients with ischaemic stroke (167).  In data from Oxfordshire 
(168), diabetes was shown to be an independent risk factor for recurrent stroke (HR 1.85%, 
95% CI 1.18 to 2.9, p<0.01) and a similar relationship has been found in other analyses 
(169). 
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It is recommended that for the primary prevention of stroke that a lower blood pressure 
target is employed in those with diabetes (130/80 mmHg) and hypertension and this is 
effective in reducing stroke risk (170;171).  In the UKPDS (172), blood pressure control (to 
a mean of 144/82 mmHg) yielded a 44% RRR in risk of stroke and a smaller but similar 
reduction in a combined vascular endpoint.  Additive beneficial effects on progression to 
macroalbuminuria means that ACE inhibitor or ARB based regimens are recommended as 
first-line agents in those with diabetes (173).  
 
Glycaemic control is effective in reducing the risk of microvascular complications, in both 
type 1 and type 2 diabetes (174;175). These include diabetic retinopathy, nephropathy and 
neuropathy. Data concerning the impact of glycaemic control on risk of macrovascular 
complications including stroke are less convincing. Trends toward a reduction in 
cardiovascular event rates have been seen but this remains unproven (176;177).  
Furthermore, data from two recent randomised controlled trials were disappointing. The 
ADVANCE trial (178) included 11,140 patients and compared an intensive strategy of 
gliclazide ± other drugs with standard treatment and found a 10% reduction in incidence of 
microvascular or macrovascular disease during follow-up (HR 0.9, 95% CI 0.82 to 0.98, 
p=0.1). This was predominantly due to a reduction in rate of nephropathy with no 
difference in macrovascular event rate (HR 0.94, 95% CI 0.84 to 1.06, p=0.32).  The 
ACCORD trial (179) was of similar magnitude and included 10,251 patients. It compared 
efficacy of an intensive strategy intended to achieve a glycated haemoglobin level of below 
6% and a standard therapy strategy aiming for a level of 7 to 7.9%. The rate of primary 
outcome of non-fatal MI or stroke or cardiovascular death was similar between the groups 
(HR 0.9, 95% CI 0.78 to 1.04, p=0.16) but mortality was higher (HR 1.22, 95% CI 1.01 to 
1.46, p=0.04) leading to premature termination of the trial. Significant hypoglycaemia and 
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weight gain were also more common. Sub-analysis showed no suggestion of benefit with 
specific regard to stroke risk in either of these trials.  
 
Recent European guidelines suggest those with type 2 diabetes who do not require insulin 
and have suffered stroke be commenced on pioglitazone therapy (55).  However, this 
recommendation is based on data from subgroup analysis from the PROactive trial (180) 
which included 5238 patients with type 2 diabetes and known macrovascular disease and 
compared pioglitazone with placebo. In the cohort with previous stroke (≈500 in each 
group) there was a trend toward a reduction in major vascular events and death and a 
significant reduction in both fatal and non-fatal stroke (HR 0.53, 95% CI 0.34 to 0.85) and 
CV death, non-fatal MI and stroke (HR 0.72, 95% CI 0.52 to 1, p=0.0467) (181). 
 
1.03.6 Cardioembolic Stroke / Atrial Fibrillation 
Approximately 20% of strokes are cardioembolic with the majority of cases being due to 
atrial fibrillation.  Left ventricular mural thrombus and valvular heart disease are other 
important causes (182) with the majority of left ventricular mural thrombi being associated 
with acute myocardial infarction.  Atrial fibrillation is increasingly common and the 
incidence rises dramatically with age. It is estimated that its prevalence roughly doubles 
with each advancing decade from 0.5% at age 50-59 years to nearly 9% in the ninth decade 
of life (183). 
  
Presence of atrial fibrillation predicts both first stroke and recurrent stroke and those with 
concurrent increased age, diabetes, congestive cardiac failure, previous stroke and 
hypertension are at the highest risk. Concurrent increased left atrial size, spontaneous echo 
contrast and left ventricular dysfunction on echocardiography are also predictive factors 
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(184). Scoring algorithms are now commonly employed to help predict stroke risk and 
identify those with atrial fibrillation most likely to benefit from anticoagulant treatment. An 
example is the CHADS2 score (185) where the variables presence of recent congestive 
cardiac failure, hypertension, age > 75 years and diabetes mellitus are assigned 1 point and 
history of stroke or TIA two points. Those with a score of 2 or more (assuming no 
treatment) have a stroke risk of approximately 4% per annum rising to 8.5% per annum in 
those with a score of 4. The most widely used and studied anticoagulant is warfarin which 
inhibits synthesis of vitamin K dependent clotting factors. 
 
In the primary prevention setting, warfarin is hugely effective. Pooled analysis from the 
major placebo controlled trials reveals a highly beneficial RRR of 68% for ischaemic stroke 
(186) compared to placebo. In absolute terms, the stroke rate fell from 4.5% per annum to 
1.4% with warfarin treatment.  Maximum benefit requires the INR to be above 2 (187;188) 
and the recommended INR range is 2 to 3. 
 
Pooled analysis from large placebo controlled trials (189) also confirms that primary 
prevention with aspirin provides a reduction in stroke risk compared to placebo (RRR 21%, 
95% CI 0 to 38%). However, it is clearly an inferior strategy when compared to warfarin 
(190). Meta-analysis revealed a RR of 0.36 (95% CI 0.26 to 0.51) for those treated with 
warfarin compared to aspirin. Similar benefit is also seen in the elderly (191;192). 
 
In the secondary prevention of stroke, warfarin is also highly effective in those with atrial 
fibrillation. In the European Atrial Fibrillation Trial (188), the annual rate of stroke, MI, 
systemic embolism or vascular death was 8% with warfarin in comparison to 15% with 
placebo (HR 0.60, 95% CI 0.41 to 0.87). The timescale of initiation of anticoagulation in 
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this setting is unclear. It is clear that early unselected use of anticoagulation (with heparin) 
in those without cardioembolic stroke is ineffective (89-91) but whether it is of benefit in 
those with AF is unclear (92). In the European Atrial Fibrillation Trial (188), nearly one 
half of patients commenced anticoagulation within 14 days, although their neurological 
deficits were minor. Thus, it is generally recommended that anticoagulation be initiated 
within two weeks in those with AF and stroke, although delays of one week are commonly 
employed and guidelines suggest the decision regarding timing be individualised (55). Dual 
anti-platelet therapy with aspirin and clopidogrel was compared to warfarin in the ACTIVE 
W trial (193). This included 6706 patients and suggests that dual anti-platelet therapy offers 
inferior stroke protection at the cost of a similar burden of bleeding complications. 
 
Regarding safety and risk of haemorrhage, warfarin can be considered safe in comparison 
to aspirin, with a major bleeding rate of 1.3% compared to 1% on aspirin or placebo. 
 
There are a number of newer anticoagulant agents in development, many of which are now 
in phase 3 study. These include direct thrombin inhibitors (such as ximelagatran and 
dabigatran etexilate (194;195) and factor Xa inhibitors such as Rivaroxaban (196;197). The 
potential benefits of these drugs include a lack of requirement for dose adjustment and 
regular monitoring but as yet, none has been shown to be as safe or effective as warfarin for 
the prevention of stroke in those with atrial fibrillation. Ximelagatran was shown to be as 
efficacious as warfarin with a similarly low risk of bleeding complications in both primary 
and secondary prevention in two large trials (198). The drug was however removed from 
the market because of concerns over hepatic toxicity (199).  
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In the ACTIVE-A study, clopidogrel was compared to placebo in those with atrial 
fibrillation taking aspirin who were deemed unsuitable for anticoagulation (200).  The rate 
of vascular events was significantly lower in those treated with clopidogrel and aspirin (RR 
0.89, 95% CI 0.81 to 0.98) and in particular, the risk of stroke was reduced (RR 0.72, 95% 
CI 0.62 to 0.83). The risk of major haemorrhage was however increased with dual 
antiplatelet therapy (from 1.3% per year to 2% per year, RR 1.57, 95% CI 1.29 to 1.92). 
 
Thus, in summary, anticoagulation with warfarin is the treatment of choice for prevention 
of recurrent stroke in those with cardioembolic stroke. It is also the treatment of choice for 
primary prevention of stroke in those with atrial fibrillation whose risk of stroke exceeds 
the likely risk of haemorrhage. Risk stratification algorithms can be employed to aid this 
decision. In those deemed unsuitable for anticoagulation, aspirin is effective and therapy 
with aspirin and clopidogrel leads to significantly fewer strokes at the cost of increased 
haemorrhage risk. 
 
1.03.7 Carotid Artery Intervention 
Approximately 10-15% of ischaemic strokes are thought to be due to large artery 
atherosclerosis (201), most of which are associated with a stenosis of the ipsilateral 
extracranial carotid artery. This stenosis can be remedied by carotid endarterectomy (CEA), 
where, under local or general anaesthesia, the carotid artery is dissected free, opened and 
the atheromatous stenosis removed. Percutaneous placement of a stent via the femoral 
artery is an alternative approach. Large randomized controlled trials have shown superiority 
of carotid endarterectomy in comparison to medical therapy (202-204) in those who have 
symptomatic severe carotid stenosis. A pooled analysis of the major symptomatic stenosis 
trials (205) included data on over 6000 patients. In those with symptomatic severe (≥70%) 
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stenosis, surgery afforded a 16% absolute risk reduction (ARR) over 5 years and a smaller 
4.5% ARR (p=0.04) in those with moderate (50-69%) stenosis. Surgery slightly increased 
risk (by 2.2%) of stroke in those with less than 30% stenosis (p=0.05) but no effect on risk 
was seen in those with 30-49% stenosis or near occlusion. 
 
Further analysis from a pooled dataset of the largest trials shows that early surgery, despite 
its inherent increased risk, is associated with greater absolute and relative risk reduction 
than delayed surgery (206). In those with severe stenosis, surgery in those who were 
randomized to treatment within 2 weeks of symptoms afforded an ARR of 23% (95% CI 
13.6 to 32.4%) compared to only 7.4% (95% CI -3.3 to 18.1%) if randomized after 12 
weeks. In those with moderate stenosis randomized there was a 14.8% ARR (95% CI 6.2 to 
23.4%) following surgery if randomized within 2 weeks but no significant benefit if 
randomized thereafter. 
 
Thus, if treated early, benefit is also apparent for those with a symptomatic 50-69% stenosis. 
It is also possible to further refine the risk-benefit ratio. Of those with symptomatic 
moderate stenosis, men, those aged over 75, those with evidence of infarction and those 
with hemispheric (rather than retinal) symptoms appear to benefit most (207-210). Co-
morbidity must also be considered as this will increase peri-operative risk and thus 
adversely refine the risk benefit ratio. Peri-procedural risk is a key factor in determining 
benefit from carotid endarterectomy; the lower the absolute benefit from carotid 
endarterectomy (such as in younger female patients or asymptomatic disease), the lower the 
surgical complication rate requires to be to ensure benefit. It is generally accepted that this 
must be <6% for those with severe stenosis but < 3% in those with moderate stenosis (55) 
and those with asymptomatic disease. 
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Carotid artery stenting (CAS) has not yet been proven to be superior or even equivalent to 
carotid endarterectomy.  Several trials have been performed, 2 of which have been 
terminated early because of poor results in the stenting arm and 1 of which because of slow 
recruitment. The Wallstent trial (211) involved 219 patients with symptomatic stenosis and 
found a higher peri-procedural stroke rate and a higher rate of major stroke or death at 1 
year when compared to endarterectomy (12.1% vs 4.5% (p=0.049) and 3.7% vs 0.9% 
(p=0.204) respectively). It has since been criticized for allowing relatively inexperienced 
stent operators to participate – a criticism also levied at the recent EVA-3S study (212). 
 
EVA -3S included patients with at least 60% carotid stenosis and ipsilateral stroke within 
120 days. It was terminated prematurely after inclusion of 527 patients; the 30 day 
incidence of stroke or death was 3.9% following carotid endarterectomy and 9.6% after 
stenting (RR 2.5, 95% CI 1.2 to 5.1). When only disabling stroke or death were considered, 
it remained more common in the stenting group (3.4% vs 1.5%, RR 2.2, 95% CI 0.7 to 7.2) 
and outcomes were significantly worse at 6 months.  
 
A further recent trial (213) also failed to prove non-inferiority of carotid stenting. The 
SPACE trial included 1200 patients with severe symptomatic (within 6 months) carotid 
stenosis. Outcomes were similar. The rate of death or ipsilateral ischaemic stroke within 30 
days was 6.84% following stenting and 6.34% following endarterectomy (OR 1.09, 95% CI 
0.69 to 1.72). Despite these similar outcomes, the pre-specified non-inferiority margin was 
missed. The reasons for these differing results are not clear but in SPACE, interventional 
radiologists were required to show greater levels of experience than in EVA-3S before 
being included in the study. 
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Some trials have however showed similar outcomes following stenting. The CAVATAS 
trial enrolled 504 patients with symptomatic carotid disease and compared CEA with 
carotid angioplasty (only ¼ of patients received stents) (214). The trial also included 
participants with vertebrobasilar stenotic disease.  The 30 day risk of stroke or death was 
similar (9.9% with CEA and 10% with CAS) with no difference in recurrent stroke rate at 1 
year. The peri-surgical risk was however higher than that suggested as the maximum 
accepted level in consensus guidelines (55). CAVATAS does however provide important 
long-term follow up data in those who have undergone percutaneous carotid intervention 
and while restenosis appears more common in those who underwent angioplasty (215), it 
may not translate into worse clinical outcome and may not afflict those who also received 
stenting (216).  
 
In the SAPPHIRE trial (217), 334 patients deemed at high risk were randomized to either 
CEA or CAS with emboli detection. Patients either had at least 50% symptomatic stenosis 
or asymptomatic 80% stenosis. The endpoint was a composite of death, stroke or MI within 
30 days after the event or ipsilateral stroke between 31 days and 1 year. This was less 
frequent following stenting (12.2% vs 20.1%, absolute difference of 7.9%, 95% CI -0.7 to 
16.4%) and the non-inferiority criteria were met (p=0.004 for non-inferiority). The benefit 
was largely driven by a reduction in MI in those treated with CAS.  Importantly, the peri-
procedural rate of stroke, MI or death following CAS was only 4.8% in this study in 
comparison to the higher rates in other trials (212;213). The peri-procedural complication 
rate following endarterectomy was high at 9.9%. However, long-term follow up data are 
now available (218) and further support the authors initial assertions that, in this patient 
group, stenting can afford similar outcomes compared to CEA.  
 - 64 - 
 
At the time of writing, the Carotid Revascularization Endarterectomy vs Stenting Trial 
(CREST) (219) is ongoing and aims to recruit 2500 patients with symptomatic stenosis and 
will hopefully clarify the relative benefits or otherwise of carotid stenting. 
 
Carotid endarterectomy in the primary prevention setting (those with asymptomatic 
stenosis) has also been the subject of large randomized controlled trials (220-222). In 
general, these trials support benefit in those with at least moderate stenosis although the 
absolute benefit appears small and thus mandates a low peri-procedural complication rate to 
give benefit.  For example, in the most recent trial, the Asymptomatic Carotid surgery Trial 
(223), 3120 patients were randomized to either immediate endarterectomy or indefinite 
deferral of endarterectomy. The peri-operative rate of stroke or death was 3.1% following 
CEA. Even when these events were considered, the 5 year risk of stroke or death was lower 
following CEA (6.4% vs 11.8%, ARR 5.4%, 95% CI 3 to 7.8). Similar benefits were seen 
when only fatal events were considered. On subgroup analysis, benefit was not apparent in 
those aged over 75 years.  
 
1.03.8 Utility of Microembolic Signals 
As well as the parameters mentioned, there are further means of risk stratifying individuals 
with carotid disease. Asymptomatic microembolic signals (MES) can be detected using 
transcranial Doppler ultrasound scanning (TCD) (223). The prevalence of MES has varied 
in studies and they are thought to represent thrombi and platelet fibrin aggregates (224;225). 
They are found in those with carotid artery disease, and are more common in those with 
recent symptoms (226;227), in those with atrial fibrillation and they arise during cardiac 
and aortic surgery and can be found thereafter in those with cardiac valve prostheses, and in 
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particular those with metallic valves (228). In those with recently symptomatic carotid 
stenosis, they are typically seen in approximately 40% of individuals (227;229), although 
higher and lower prevalence has been seen. 
 
In those with carotid disease, their occurrence has been shown to be predictive of an 
increased stroke risk (226;227;230;231) in a series of small studies.  For example, in one 
study (226) of 64 asymptomatic individuals with unilateral 70% to 90% internal carotid 
artery stenosis, a microembolic rate of ≥2 per hour was associated with increased risk of 
suffering ischaemic stroke. However, only five strokes occurred, hence the uncertainty of 
size of the association (odds ratio 31, 95% CI 3 to 302, p=.005).  In a further study, 
microembolic signals at study entry were predictive of TIA and stroke risk in both 
symptomatic and asymptomatic patients with an adjusted combined odds ratio of 8.1, 
although again there was uncertainty regarding the actual magnitude of the association 
(95% CI, 1.58 to 41.5, p=0.01 (231;232).   
 
Microembolic signals (MES) are responsive to anti-platelet therapy; aspirin has some effect 
(233) but more marked effects are seen with addition of clopidogrel (234), with the platelet 
glycoprotein inhibitor tirofibran (235), and with S-Nitrosoglutathione (a nitric oxide donor) 
therapy (236).  The feasibility of using MES as a surrogate endpoint in clinical trials was 
recently studied (234).  As outlined earlier, the CARESS investigators showed that they 
could use MES to detect treatment differences between groups using much smaller numbers 
than trials with traditional clinical endpoints. 
 
Thus, in those with recent stroke or TIA and carotid artery stenosis, carotid endarterectomy 
should be performed if the stenosis is greater than 70% but not sub-totally occluded and if 
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the peri-procedural complication rate in that centre is lower than 6% (55). It should also be 
performed in some high risk individuals with moderate stenosis but not in stenosis of less 
than 50% and only if the predicted peri-procedural complication rate is acceptably low. If 
indicated, surgery should be performed as soon as possible and preferably within 2 weeks 
of symptoms. CAS is a viable alternative strategy, particularly if endarterectomy is not 
possible provided the peri-procedural complication rate is in the region of 4-6% (170). In 
those with asymptomatic disease, guidelines therefore suggest that those with high risk of 
stroke such as men with severe stenosis who have a life expectancy of > 5 years can be 
considered for surgery where the peri-operative risk is low at 3% or less (55). Further, 
presence of microembolic signals may help identify a particularly high risk group with 
carotid disease. 
 
1.03.9 Behavioural Risk Factors 
Smoking Cessation 
Cigarette smoking is an independent risk factor for both stroke and recurrent stroke (237).  
In a meta-analysis performed nearly 20 years ago (238), smoking linked with a doubling of 
risk of ischaemic stroke following adjustment for other risk factors.  There are no 
randomised controlled trials to evaluate the efficacy of smoking cessation therapy after 
stroke as it is generally regarded as an important strategy given compelling data from 
observational studies and the other health benefits associated with stopping.  Observational 
data suggest that stopping smoking affords a reduction in stroke risk and that risk returns to 
that of a non-smoker after 5 years (239).  Further, data show that rates of admission for 
acute coronary syndrome fell significantly after the smoking ban in Scotland (240), 
although no data are available to show effect on stroke risk. Guidelines currently suggest 
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that a combination of pharmacological and behavioural therapy is used, an approach for 
which there is some evidence (241;242).  
 
Excess Alcohol Intake 
The relationship between alcohol intake and stroke risk is complex, unproven and 
somewhat controversial. It is generally accepted that the relationship is J-shaped with heavy 
drinkers having an increased risk and likewise those who consume no alcohol (243). Those 
who consume small or moderate amounts of alcohol, have the lowest risk. In a recent meta-
analysis (244), those who consumed more than 5 drinks per day had a RR of 1.69 for stroke 
compared to non-drinkers while those who drink less than one or one to two drinks per day 
had a RR of 0.8 and 0.72 respectively.  The relationship probably holds with regard to the 
risk of recurrent stroke (245).  Guidelines suggest that those who are heavy drinkers should 
be advised to eliminate or reduce their consumption of alcohol. 
 
Weight Reduction / Physical Exercise 
Obesity is also a risk factor for stroke and (246), while it is linked to several major risk 
factors such as blood pressure, presence of diabetes and cholesterol level (247-249), the 
relationship appears independent (248).  The relationship between risk and centri-pedal 
obesity (measured by the waist-hip ratio) may be the strongest with risk tripling in the 
highest quartile of the distribution (250). As yet, no data exist to suggest benefit from 
weight reduction in obese individuals with stroke but given the benefits on metabolic 
parameters such as lipid levels and blood pressure, guidelines suggest weight management 
is encouraged through lifestyle measures (154). Pharmacotherapy to aid weight reduction is 
a growing area and several agents are undergoing phase III clinical trials at the time of 
writing, some of which include clinical cardiovascular endpoints. 
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Moderate intensity physical exercise is also encouraged for those who area able and links 
with improvement in cardiovascular risk parameters (154). No evidence exists to confirm 
clear benefit on stroke risk but in those who have suffered stroke, exercise can improve 
mobility and fitness (251). 
 
There are thus a number of effective preventative therapies for both the primary and 
secondary prevention of stroke.  Strategies include anti-platelet therapy and lipid lowering 
therapy to prevent ischaemic stroke, anticoagulant therapy to prevent cardioembolic 
ischaemic stroke and blood pressure reduction, treatment of prevalent diabetes, lifestyle 
therapy and behavioural modification to prevent all stroke subtypes.  
 
Summary 
It is difficult to accurately predict the impact of currently available therapies but it is clear 
from recent randomised controlled trials and epidemiological data that first and recurrent 
stroke remain common and that they will become increasingly so. Using the recent 
PRoFESS trial as an example, approximately 9% of patient suffered recurrent stroke 
despite high uptake of preventative therapies. It is therefore clear that both the optimal and 
rapid use of current strategies and the development of novel therapies are required to ensure 
best possible stroke prevention. 
 
This programme of research and thesis aimed to make improvements in several of these 
areas, with emphasis on improving access to care (chapter 2), improving use of current 
therapies (chapter 3) and the development of new preventative strategies (chapter 4).  











A RECOGNITION TOOL FOR TRANSIENT ISCHAEMIC 
ATTACK 
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Development of a Recognition Tool for Transient Ischaemic Attack 
 
2.01 Difficulties in Delivering Effective Therapies 
 
Those with TIA represent a high risk group whose risk of stroke is highest in the first 48 
hours (32). UK guidelines therefore recommend that patients with suspected TIA are 
assessed as soon as possible (and at least within 1 week) (33;34) in fast track or rapid 
access neurovascular clinics (35). However, at the time of writing the sad reality is that TIA 
is poorly managed in the UK and guideline recommendations are not widely met. Recent 
reports from the UK National Audit Office and the House of Commons Public Accounts 
Committee (5) found that approximately half of patients with suspected TIA were seen 
within 14 days, 58% had a scan outside an effective time window and the majority waited 
12 weeks or more for a carotid ultrasound scan. This must be improved as more rapid 
management is effective in reducing stroke risk (252).  It may even be that current 
guidelines are not stringent enough and that assessment on the day of the event should be 
the aim. The recent EXPRESS study provides compelling evidence (252) that urgent (same 
day) assessment of those with TIA dramatically reduces risk of early stroke. This was a 
very well conducted observational study, where outcomes in an initial standard 
management phase were compared to those of an urgent same day appointment system. The 
risk of early stroke in the early phase was 10.2% compared to 2.1% in the later phase. 
There are two important points worth mentioning. Firstly, even the initial phase represents 
a significantly more acute and advanced system than exists in most of the UK. Secondly, 
the main difference between the study phases was the time lag to therapy initiation; 
treatment protocols were similar (although anti-platelet therapy was more aggressive in the 
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later phase), the geographical area was identical and the background incidence of stroke 
and TIA was similar throughout.    
 
Such clinics should therefore be the aim but will increase pressure on scare clinical and 
radiology resources, require more frequent availability of specialist staff and are costly to 
implement and run and a number of barriers preclude their effective introduction.  Current 
delays to assessment include delay to presentation by the patient, delay to referral to the 
TIA service by a General Practitioner (G.P), delays to TIA clinic appointments, delay to 
appropriate investigations and a time lag to initiation of appropriate treatment, including 
both medical therapy and therapy for carotid artery stenosis.  Public awareness campaigns 
to improve patient recognition of stroke symptoms are underway, as are programmes to 
improve knowledge of TIA assessment and management among G.Ps. Several strategies 
could be employed to improve hospital TIA services. The number of rapid access out-
patient clinics could be increased and access to imaging services could be improved. For 
example, stroke services could be supported to develop their own imaging services. 
 
All of these strategies will prove costly and it is likely that improvements and streamlining 
of current systems will be most readily achieved. 
 
2.01.1 Strategies to Improve Care of Those with TIA – Rapid Diagnosis 
An obvious target for improvement is to reduce the number of non-cerebrovascular 
referrals to TIA clinics, thereby freeing up existing clinic time.  Difficulties in accurate 
diagnosis of patients with suspected TIA are well documented (253-255); inter-observer 
agreement has been shown to be as low as 50% (256), and between 31 and 62% of patients 
referred with suspected TIA are deemed to have a non-cerebrovascular diagnosis by a 
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stroke specialist (255;257-259).  This is also a significant problem in Glasgow (257) where 
a recent analysis of referrals over a one year period revealed that just under 50% had an 
alternative diagnosis. Such a large number will make it more difficult for services to meet 
their aim of rapid assessment of those with TIA. 
 
Improvements in the diagnostic accuracy during assessment of suspected TIA by non-
specialists (G.Ps for example) could be achieved if simple diagnostic algorithms were 
available.  Stroke assessment tools have been developed to aid in the rapid and accurate 
identification of those with stroke and to ensure appropriate ambulance dispatch of the 
patient. Most have been designed for use by paramedical staff and include the Los Angeles 
Pre hospital Stroke Screen (LAPSS) (260), the Cincinnati Pre hospital Stroke Scale (CPSS) 
(261), a combination of the two, the Melbourne Ambulance Stroke Screen (MASS) (262) 
and the Face Arm Speech Test (FAST) (263).  The CPSS and the FAST involve a screen 
for clinical signs commonly seen in stroke, while the LAPSS and MASS encompass both 
components of the history which make stroke less likely and clinical signs commonly seen 
in stroke.  If all the history items are absent and the patient has appropriate signs, stroke is 
deemed to be present.  Use of these scales leads to reasonable diagnostic accuracy - 80% 
diagnostic accuracy for the LAPSS, 84% for the CPSS and 86% for the MASS (262) with 
similar rates likely with FAST (263).  A further study showed that paramedic diagnostic 
accuracy using the LAPSS improved after a period of training (264).  The commonest 
stroke mimics with these tools are cardiac events, seizures, hypoglycaemia, subdural 
haematoma and fracture.  Missed strokes (10% of 73 using the MASS for example) usually 
occurred because of presence of a history item or where a visual field defect was the only 
clinical sign (not scored in scale).  The more recently developed ROSIER scale (265) 
extends the concept of the stroke assessment tool from the field into the emergency room 
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and is intended for use by emergency room staff. The clinical skill possessed by emergency 
room physicians, in comparison to paramedical staff, applied in an environment more 
conducive to thorough assessment should allow the use of more complex assessments and 
thereby yield better diagnostic accuracy. The main differences between ROSIER and the 
paramedic stroke scales are a specific question regarding syncope (which should increase 
specificity) and an examination to identify visual field defects (which should increase 
sensitivity).  Early use of ROSIER has yielded promising results: sensitivity was 93% 
during the prospective validation phase, comparing favourably with the paramedic stroke 
recognition instruments. Specificity was broadly similar to previous scales, although fewer 
stroke mimics were referred during the validation phase of the study, suggesting that 
specificity may improve as experience grows.  
 
Nearly all (6/7) of the missed stroke patients during testing of ROSIER had mild symptoms 
with an NIHSS score of <3, whom the authors would not have considered for thrombolytic 
treatment. This does, however, highlight a potential weakness of the ROSIER scale and 
also, posterior circulation stroke was more likely to be missed.  The authors state that the 
inclusion of assessment of eye movements into the ROSIER scale would have led to 
detection of 2 more strokes and increased sensitivity further to 95% and this merits further 
consideration. 
 
Lessons from these scales and a recent systematic review of the predictive value of various 
symptoms and clinical signs encountered when evaluating suspected stroke patients (266) 
helps identify those variables likely to be of use in an assessment algorithm for suspected 
TIA.  It is clear that unilateral weakness, in particular of the arm and face, and a language 
disorder strongly suggest that a stroke or TIA has occurred, while the absence of such signs 
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and the presence of loss of consciousness or seizure activity point toward an alternative 
diagnosis.  Diplopia, vertigo and sensory loss, while consistent with stroke or TIA, are of 
less value in making a clear clinical diagnosis but may contribute. As yet however, there 
are no such diagnostic algorithms in use for suspected TIA, although clinical prediction 
tools have been developed to aid risk stratification following confirmed TIA. An example is 
the “ABCD” scoring tool and its refinement “ABCD2”, both of which were developed and 
validated in cohorts with confirmed TIA. Using only clinical parameters, the 
ABCD/ABCD2 scores describe ordinal hierarchical scales from 0 – 6/7 (table 2.1). Those 
with the highest scores have significantly increased risk of early stroke (31;32). 
 
A Age ≥ 60 years 1 point 
B Blood pressure ≥ 140/90 mmHg 1 point 
C Clinical features Unilateral weakness 2 points 
  Speech impairment without weakness 1 point 
D Duration ≥ 60 minutes 2 points 
  10-59 minutes 1 point 
D Diabetes Presence of Diabetes Mellitus 1 point 
Table 2.1. ABCD2 Scoring Criteria. When using the ABCD score, no point is added 
for prevalent Diabetes Mellitus. 
 
There remain some controversies regarding widespread use of these tools. Attempts to 
validate these systems in independent populations have been generally (32), but not 
universally successful (267) and some groups have questioned the utility of a score that 
does not incorporate significant carotid disease or other potential cardio-embolic source 
(268). Most importantly, in the original and subsequent ABCD validation studies, 
presentation with true TIA was assumed. This renders suitability of the tool by referring 
practitioners (or using information from them) on all those referred to TIA services 
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unsupported; TIA assessment services consistently see a high rate of non-cerebrovascular 
pathologies (257). Further, given that the majority of studies testing the properties of the 
ABCD system did not utilise brain imaging to support ischaemic brain damage and the 
known difficulties with diagnosis, it is possible the cohorts described included a substantial 
proportion of patients without a true TIA. It could be argued the very low rate of early 
stroke in those with a low ABCD score (32) supports this assertion and that part of the 
utility of these tools is to distinguish true TIA from other more benign pathologies. 
Regardless, the utility of these scores could be seen to justify attempts to develop better and 
more encompassing diagnostic tools. 
 
Thus, data from the field of acute stroke and from risk stratification instruments for 
confirmed TIA suggest that development of an algorithm or clinical scoring system for 
diagnosis of TIA should be possible. If it were, and the number of patients referred with 
alternate diagnoses was reduced, this could reduce burden on services and improve care for 
those with genuine TIA.  
 
2.02 Chapter Aim / Hypothesis 
The hypothesis was that a diagnostic algorithm and clinical scoring system could be 
developed to aid accurate diagnosis of TIA and minor stroke in the community, that its use 
would reduce the numbers referred with non-cerebrovascular diagnoses and that this would 
reduce clinic waiting times and facilitate rapid assessment. The aim was to develop and 
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2.03 Methods 
 
The algorithm was developed using data contained in the West Glasgow Stroke Registry 
and was tested on an independent prospective data set from the same source. The impact of 
the projected reduction in non-cerebrovascular referral rate was then assessed using real 
data on referral rates and clinic availability during the prospective validation study. 
 
The West Glasgow Stroke Registry 
The Western Infirmary serves a catchment population of approximately 225,000 people and 
receives approximately 500-600 outpatient referrals per year (predominantly (>95%) from 
GPs).  The fast track TIA clinic is held twice weekly. Baseline demographic data, a history 
of presenting complaint, relevant examination findings and diagnosis and management 
plans are prospectively recorded at the time of clinic review. All patients are discussed with 
a Consultant Stroke Physician (with at least 10 years experience). Data are entered into an 
electronic database (the West Glasgow Stroke Registry) which currently includes all 
patients who attended the Fast Track clinic between March 1992 and January 2005. At a 
follow up visit, data regarding investigation results, final diagnosis and treatment plans are 
gathered.   
 
Development of the Diagnostic Tool 
The diagnosis (“cerebrovascular” versus “non-cerebrovascular”) as determined at clinic 
visit was used as the reference standard in the study. This included patients with TIA and 
those with minor stroke symptoms lasting 24 hours who had not been referred to the in-
patient service. Variables felt likely to be useful in the diagnosis of TIA, including those 
thought to be suggestive of an alternative diagnosis (table 2.2) were identified in advance.  
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Included variables were symptoms used in stroke diagnostic algorithms and those 
previously shown to predict a stroke diagnosis (261-263;265;266).  Logistic regression 




Analyses were performed using S Plus version 6.2. First, univariate analysis was used to 
identify variables predictive of diagnosis. Logistic regression models were used to identify 
independently discriminatory variables.  Stepwise selection procedures were employed to 
identify significant explanatory variables using Akaike’s Information Criterion (269). In a 
forward stepwise selection procedure, the initial model involves no explanatory variables 
and the most significant variable of all the explanatory variables is added to the model at 
each step until all significant variables are included. In backward selection, the initial 
model involves all possible explanatory variables and at each step the least significant 
variable is omitted from the model until the final model selected involved only significant 
variables. Two way interaction variables were also considered. The interactions considered 
were all feasible two way interactions within each subcategory of predictive variables (as 
shown in table 2.2). The final model was internally validated using three-fold cross 
validation.  During three-fold cross-validation, the data were split into three groups of equal 
size and the model was fitted to the data of two of the groups to predict the class of the 
remaining group. This was repeated for all group combinations and for two further random 
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Variables that showed discriminatory power were considered for inclusion in a clinical 
scoring system. Non-weighted (where explanatory variables were assigned a value of 1), 
weighted and rounded weighted scoring systems (based upon the regression co-efficient) 
were then developed. Receiver operating characteristic curves were used to determine 
optimal cut-off scores; and sensitivity, specificity and positive and negative predictive 
values were calculated.  Following this two ‘costs of misclassification’ models were 
developed to reflect the presumed greater importance of failing to identify cerebrovascular 





Predictive of Non 
Cerebrovascular 
Diagnosis 
Smoker Unilateral Face Weakness * Headache * 
Hypertension * Unilateral Arm Weakness * Seizure * 
Diabetes Mellitus * Unilateral Leg Weakness * Loss of Consciousness * 
Hyperlipidaemia * Unilateral Face Sensory 
Disturbance * 
Atrial Fibrillation Unilateral Arm Sensory 
Disturbance * 
History of Stroke or TIA * Unilateral Leg Sensory 
Disturbance * 
Other Vascular Disease * Sudden True Vertigo  
Diplopia * 
Sudden True Ataxia * 
Language Disorder * 




Table 2.2.  Pre-identified Variables Felt Likely to be Predictive of Clinic Diagnosis.  
* = variables predictive on univariate analysis, all p<0.001. 
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events compared to incorrectly labelling mimics.  A cost of 2:1 is considered when it is 
assumed that the cost of misclassifying a cerebrovascular patient as non-cerebrovascular is 
twice as much as the cost of misclassifying in the opposite direction. Similarly, a cost of 
3:1 is where the cost of misclassifying a cerebrovascular patient as non-cerebrovascular is 
deemed to be three times as great. Essentially it is a penalty assigned for making a mistake, 
taking into account that a failure to treat a life-threatening condition is more serious than 
undertaking unnecessary but generally safe investigations. By raising or lowering the cost 
of a misclassification, decisions are biased in different directions, as if there were more or 
fewer cases in a given class. These ratios were arbitrarily chosen. The Hosmer-Le Cessie 
test (270) was used to evaluate fit of the model. 
 
A formal power calculation was not performed for the multivariable logistic regression 
models; this is notoriously complex. However, the data includes a large number of 
outcomes for each variable included (35 for the least common variable (seizure) with others 
in the hundreds). Further, the small standard errors, small p values and large sample size 
give further evidence that power was sufficient for the plan to proceed to multivariate 
modeling. 
 
Prospective Validation of the Diagnostic Tool 
Data on all referrals to the Fast Track TIA clinic were gathered during the period October 
2005 to June 2006. The clinical scoring system scores were not used to aid clinical 
diagnosis and were later calculated by independent observers who were not involved with 
the patients care or development of the scoring system. 
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Assessment of the Impact of the Tool 
Delays to clinic appointment during the prospective validation phase were calculated 
(expressed as median and inter-quartile range).  The effect of the projected reduction in 
non-cerebrovascular referral rates was then established via a model based upon the actual 
number of referrals and clinic availability during the study period.  During early modeling 
it was predicted that the scoring system would reduce the number of non-cerebrovascular 
referrals by approximately 50% or 25% with the unadjusted weighted system and 2:1 costs 
model respectively. The median delay to clinic appointment was then recalculated first with 
every second then every fourth non-cerebrovascular patient being removed.  
 
The advice of a Multi-centre Research Ethics Committee was sought and formal ethics 




Development of the Scoring System 
The development cohort included 3230 patients. Mean age was 65 years (SD 12.8).  Other 
baseline characteristics are shown in table 2.3.  Sufficient data were available for 3216 
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Variables predictive of diagnosis on univariate analysis are shown in table 2.2. Three risk 
factors (history of stroke or TIA, hypertension and diabetes) and 17 clinical features were 
significantly predictive of clinician diagnosis on logistic regression analysis. The predictive 
clinical features were headache, vomiting, loss of consciousness, seizure (all predictive of 
non-cerebrovascular diagnosis), age, duration of symptoms, visual loss, diplopia, ataxia, 
speech disorder, dysphasia, unilateral arm or leg weakness, unilateral facial weakness, 
unilateral sensory disturbance, other pattern of weakness and other pattern of sensory 
disturbance (predictive of a cerebrovascular diagnosis).  During stepwise selection, 8 
variables were rejected from the model leaving twelve explanatory variables. These were 
history of stroke or TIA, headache, diplopia, loss of consciousness, seizure, age, duration of 
symptoms, speech disorder, unilateral leg weakness, unilateral upper motor neuron (UMN) 
facial weakness, unilateral lower motor neuron (LMN) facial weakness and other weakness. 
No interaction terms remained in the model. 
 




Age 65 years (SD 12.8) 65 years (SD 15.7) 
Smoker 1893 (58.6%) 84 (35.45%) 
Hypertension 1484 (45.96%) 111 (46.84%) 
Diabetes 261 (8.08%) 29 (12.24%) 
Hypercholesterolaemia 637 (19.73%) 56 (23.63%) 
Atrial Fibrillation 161 (4.99%) 18 (7.59%) 
Previous Stroke or TIA 937 (29.02%) 55 (22.36%) 
Other Vascular Disease 879 (27.22%) 60 (25.32%) 
Table 2.3 – Baseline Characteristics of Samples Used to Develop The Scoring 
System. 
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Three variables were removed as it was felt they would not be useful in the scoring system; 
LMN facial weakness was removed as there were few cases and each occurrence was 
associated with a diagnosis of Bell’s palsy (a rare occurrence in the TIA clinic). UMN 
facial weakness was then renamed unilateral facial weakness.  Duration of symptoms was 
removed. This was recorded as < 1 hour, 1-24 hours, 1-3 days or > 3 days in the database 
and it was felt none of these boundaries was sensitive enough to influence decision making; 
many TIAs last less than 1 hour, while on the other hand, those lasting longer convey 
greater risk (31;32).  “Other weakness” was also removed. This was essentially defined as 
non unilateral weakness, so was already being accounted for in the model and it was felt 
this may lead to confusion during use of the score.  Unilateral leg weakness was included in 
the final model but unilateral arm weakness was not; this was because the vast majority of 
patients with unilateral arm weakness had unilateral leg weakness and vice versa meaning 
one of these variables was removed during stepwise regression. The variable unilateral leg 
weakness was therefore replaced by unilateral limb weakness.  This left 9 predictive 
variables: 6 positive indicators of cerebrovascular disease and 3 indicators of a non-
cerebrovascular diagnosis.  The final regression coefficients (when only these 9 variables 
were included and rounded to one decimal place) are shown in table 2.4 and all had p 
values of <0.001. Removal of the unsuitable variables did not affect the performance of the 
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Explanatory Variable Coefficient Standard Error 
History of Stroke (or TIA) 0.51 0.1 (3.5x10-7) 
Headache 0.46 0.11 (7.1x10-5) 
Diplopia 1.23 0.28 (2.7x10-6) 
Loss of Consciousness 1.06 0.21 (1.9x10-7) 
Seizure 1.58 0.43 (1.4x10-4) 
Speech Abnormalities 1.29 0.14 (<1x10-10) 
Unilateral Limb Weakness 1.72 0.10 (<1x10-10) 
UMN Facial Weakness 0.63 0.15 (9.5x10-8) 
Age 0.04 0.004 (<1x10-10) 
Table 2.4. – The final regression co-efficients for variables predictive of clinic 
diagnosis. UMN = upper motor neurone. 
 
The Weighted Scoring System 
The weighted scoring system is shown in table 2.5. Predictive variables were allocated the 
value of the regression coefficient for that variable if the variable was present or absent as 
outlined in the table. ROC curves identified a score of >6.1 as the optimal cut-off for 
prediction of cerebrovascular diagnosis (figure 2.1). This accurately identified 84% of 
cerebrovascular diagnoses and 60% of non-cerebrovascular diagnoses with a positive 
predictive value (PPV) of 82% and negative predictive value (NPV) of 62% (table 2.6). 
 
With the 2:1 cost ratio, an optimal cut-off score of > 5.4 was used (figure 2.2) and 97% of 
TIA and 24% of non-TIA patients were accurately identified with a positive predictive 
value of 73% and 78% (table 2.7). With a 3:1 cost ratio, an optimal cut-off score of > 5 was 
used and 98% of TIA and 15% of non-TIA patients were accurately identified. With a 5:1 
cost ratio, an optimal cut-off score of > 4 was used and 100% of TIA and 2% of non-TIA 
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patients were accurately identified. As these later two scores yielded only minor increases 
in sensitivity with significant falls in specificity, they were not considered further. 
 























Variable Score if Yes Score if No 
History of Stroke or TIA 0.5 0 
Headache 0 0.5 
Diplopia 1.2 0 
LOC / Pre-syncope 0 1.1 
Seizure 0 1.6 
Speech Abnormalities 1.3 0 
Unilateral Limb Weakness 1.7 0 
UMN Facial Weakness 0.6 0 
Age Multiply by 0.04 
To calculate the score, all values should be summed. If total score >6.1, classify as 
TIA. For “2:1 cost ratio,” if total score >5.4, classify as TIA. 
Table 2.5. – The Weighted TIA scoring system. All values reflect the regression 
coefficients seen. 
Figure 2.1. Receiver Operating Characteristic Curve for Weighted Scoring 
System 
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Predicted Diagnosis Clinic Diagnosis 
CVD Non-CVD 
Row Total 
CVD 1852 363 2215 
Non-CVD 397 604 1001 
Column Total 2249 967 3216 
Table 2.6.  2*2 Table for Weighted Scoring System During the Development Phase.  
Calculated sensitivity 84%, specificity 60%, PPV 82%, NPV 62%. 
 
Predicted Diagnosis Clinic Diagnosis 
CVD Non-CVD 
Row Total 
CVD 1852 363 2215 
Non-CVD 397 604 1001 
Column Total 2249 967 3216 
Table 2.7.  2*2 Table for Weighted Scoring System with 2:1 Cost Adjustment During 




Figure 2.2. Receiver Operating Characteristic Curve for Weighted Scoring System 
With 2:1 Cost Ratio 
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The Un-weighted Scoring System 
The un-weighted scoring system is shown in table 2.8. Predictive variables were allocated a 
value of one to be added if variable was present or absent as outlined in the table. ROC 
curves identified a score of >5.5 as the optimal cut-off for prediction of cerebrovascular 
diagnosis (figure 2.3). This accurately identified 82% of cerebrovascular diagnoses and 
60% of non-cerebrovascular diagnoses with a positive predictive value of 82% and NPV of 
60% (table 2.9). 
 
With the adjustment to reflect the greater seriousness of missing true cerebrovascular 
patients (the 2:1 cost ratio), an optimal cut-off score of > 4.5 was used (figure 2.4) and 98% 
of TIA and 18% of non-TIA patients were accurately identified (table 2.9).  
 
Variable Score if Yes Score if No 
History of Stroke or TIA 1 0 
Headache 0 1 
Diplopia 1 0 
LOC / Pre-syncope 0 1 
Seizure 0 1 
Speech Abnormalities 1 0 
Unilateral Limb Weakness 1 0 
UMN Facial Weakness 1 0 
Age Multiply by 0.03 
To calculate the score, all values should be summed. If total score >5.5, classify as 
TIA. For “2:1 cost ratio,” if total score >4.5, classify as TIA. 
Table 2.8. – The Un-weighted TIA scoring system. 
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Figure 2.3. Receiver Operating Characteristic Curve for Un-weighted Scoring 
System 
Figure 2.4. Receiver Operating Characteristic Curve for Un-weighted Scoring 
System With 2:1 Cost Ratio. 
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Predicted Diagnosis Clinic Diagnosis 
CVD Non-CVD 
Row Total 
CVD 1822 393 2215 
Non-CVD 401 600 1001 
Column Total 2223 993 3216 
Table 2.9.  2*2 Table for Un-Weighted Scoring System During the Development Phase.  
Calculated sensitivity 82%, specificity 60%, PPV 82%, NPV 60%. Using the 2:1 Cost 
Adjustment, calculated sensitivity 98% and specificity 18%. 
 
The Rounded Scoring System 
The rounded weighted scoring system is shown in table 2.10. Predictive variables were 
allocated a value of one to be added if variable was present or absent as outlined in the table. 
ROC curves identified a score of >6.6 as the optimal cut-off for prediction of 
cerebrovascular diagnosis (figure 2.5). This accurately identified 85% of cerebrovascular 
diagnoses and 55% of non-cerebrovascular diagnoses with a positive predictive value of 
81% and NPV of 63% (table 2.11). 
 
With the 2:1 cost ratio, an optimal cut-off score of > 5.7 was used (figure 2.5) and 97% of 
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Variable Score if Yes Score if No 
History of Stroke or TIA 0.5 0 
Headache 0 0.5 
Diplopia 1 0 
LOC / Pre-syncope 0 2 
Seizure 0 1.5 
Speech Abnormalities 1 0 
Unilateral Limb Weakness 2 0 
UMN Facial Weakness 0.5 0 
Age Multiply by 0.04 
To calculate the score, all values should be summed. If total score >6.6, classify as 
TIA. For “2:1 cost ratio,” if total score >5.7, classify as TIA. 
Table 2.10. – The Rounded TIA scoring system. All values reflect the regression 
coefficients seen rounded to the nearest half integer. 
 
 























Figure 2.5. Receiver Operating Characteristic Curve for Rounded Weighted Scoring 
System. 
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Predicted Diagnosis Clinic Diagnosis 
CVD Non-CVD 
Row Total 
CVD 1891 324 2215 
Non-CVD 450 551 1001 
Column Total 2223 993 3216 
Table 2.11.  2*2 Table for the Rounded Weighted Scoring System During the 
Development Phase.  Calculated sensitivity 85%, specificity 55%, PPV 81%, NPV 63%. 
Using the 2:1 Cost Adjustment, calculated sensitivity 97% and specificity 23%. 
 
The Prospective Validation Set 
237 patients were included of whom 143 (60.3%) had a diagnosis of TIA or minor stroke.  
Further baseline characteristics are shown in table 2.3.  
 
The weighted scoring system correctly identified 85% of patients with a cerebrovascular 
diagnosis and 54% of those with a non-cerebrovascular diagnosis with a PPV of 74% and a 
NPV of 70%.  Using the 2:1 misclassification score, 93% of patients with a cerebrovascular 
diagnosis and 34% of those with a non-cerebrovascular diagnosis were correctly identified 
Figure 2.6. Receiver Operating Characteristic Curve for Rounded Weighted 
Scoring System with 2:1 Cost Ratio. 
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with a PPV of 68% and NPV of 76% (table 2.12). With the 2:1 cost adjustment, the 
rounded weighted scoring system gave a sensitivity of 93% and a specificity of 37% with a 
PPV of 69% and NPV of 78% (table 2.13). Also with the 2:1 cost adjustment, the un-
weighted scoring system gave a sensitivity of 94% and a specificity of 26% with a PPV of 
66% and NPV of 73% (table 2.14). The confidence intervals for all parameters greatly 
overlap those found during the development phase suggesting similar performance of the 
model in each data set. 
 
Predicted Diagnosis Clinic Diagnosis 
CVD Non-CVD 
Row Total 
CVD 133 10 143 
Non-CVD 62 32 94 
Column Total 195 42 237 
Table 2.12.  2*2 Table for the Weighted Scoring System with 2:1 Cost Adjustment 
During the Prospective Validation Phase.  Calculated sensitivity 93%, specificity 34%, 
PPV 68%, NPV 76%. 
 
 
Predicted Diagnosis Clinic Diagnosis 
CVD Non-CVD 
Row Total 
CVD 133 10 143 
Non-CVD 59 35 94 
Column Total 192 45 237 
Table 2.13.  2*2 Table for the Rounded Weighted Scoring System with 2:1 Cost 
Adjustment During the Prospective Validation Phase.  Calculated sensitivity 93%, 
specificity 37%, PPV 69%, NPV 78%. 
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Predicted Diagnosis Clinic Diagnosis 
CVD Non-CVD 
Row Total 
CVD 134 9 143 
Non-CVD 70 24 94 
Column Total 195 42 237 
Table 2.14.  2*2 Table for the Un-Weighted Scoring System with 2:1 Cost Adjustment 
During the Prospective Validation Phase.  Calculated sensitivity 94%, specificity 26%, 
PPV 66%, NPV 73%. 
 
It was felt that the 2:1 cost adjustment models performed best and that the weighted and 
rounded weighted scoring systems performed equally well but were better than the un-
weighted system. Given that the scores would require formal calculation because age was 
used as a continuous variable, the weighted scoring system with 2:1 cost adjustment was 
chosen as the final model (table 2.5, figure 2.2) as it most closely represents the data and an 
on-line tool was developed to allow automated calculation of the score 
(http://www.stams.strath.ac.uk/~karenl/tia/). The Hosmer-Le Cessie test gave a p value of 
0.02 for fit of the final chosen model. 
 
Impact on Clinic Waiting Times 
During the period of the prospective validation set the median waiting time from referral 
date to clinic attendance was 15 days (IQR 8-23).  Removal of every fourth and every 
second non-cerebrovascular patient had potential to reduce the median waiting time to 8 
and 7 days respectively. The proportion of those seen within 7 days (and thus within the 
minimum standard of current guidelines) was 21.6%. This increased to 42.9 and 50% 
respectively following omission of every fourth and every second non-cerebrovascular 
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patient representing a 21.3 and 28.4% increase in those assessed within the framework of 





The results of this study show that a clinical scoring system could be utilized to reduce the 
number of non-cerebrovascular referrals to a fast track TIA service.  A scoring system that 
employs a 2:1 cost of misclassification adjustment would have little adverse impact on 
recognition rates of bona fide TIA and could reduce the number of non-cerebrovascular 
referrals by a clinically meaningful amount. 
 
TIA is poorly managed in many countries, including in the UK as the above data from the 
UK National Audit Office and the House of Commons Public Accounts Committee (5) 
clearly show.  UK consensus guidelines suggest that patients with suspected TIA are 
assessed and investigated within 1 week (33;34) while European guidelines appropriately 
suggest assessment “without delay” (55). Fulfilling these aims will be costly and will 
present challenges. For example, the clinic at the Western Infirmary was established (and 
was able) to assess patients within days but experienced a progressive increase in non-
 Current Clinic 
Performance 
25% ↓ in Non-TIA 
Referral Rate 
50% ↓ in Non-TIA  
Referral Rate 
Median Delay to 
Clinic  
15 8 7 
Assessed Within 7 
Days 
21.6% 42.9% 50% 
Table 2.15. Projected Improvements in Delays to Clinic Presentation 
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cerebrovascular referrals to approximately 50% (257). This “overloaded” the system, such 
that the median delay to clinic assessment in the prospective validation period of this study 
was an unsatisfactory 15 days.   Reducing the number of non-cerebrovascular referrals is 
feasible and will free up existing resources and facilitate urgent assessment of those with 
TIA.  
 
However, accurate identification of stroke and TIA patients is notoriously difficult 
(255;256) and a variety of conditions, such as seizure, migraine or systemic upset can 
mimic TIA (266). Assessment algorithms exist but are rarely employed out with the clinical 
trial setting (271;272) and in practical terms represent little more than descriptions of a 
typical TIA which give little practical guidance to aid decision making by non-specialists.  
A recent systematic review of the predictive value of various symptoms and clinical signs 
(266) and the available stroke assessment tools (260-263;265) show that symptoms such as 
unilateral weakness and a language disorder suggest that stroke has occurred, while loss of 
consciousness or seizure activity point toward an alternative diagnosis.  Diplopia, vertigo 
and sensory loss are also, but more weakly, consistent with stroke.  In this study, similar 
variables were unsurprisingly found to be predictive of TIA. 
 
Unilateral limb weakness, unilateral facial weakness, speech disorder, diplopia, history of 
stroke or TIA and increasing age were predictive of TIA. There are obvious deficiencies of 
a scoring system involving only these variables.  Patients with amaurosis fugax, sensory 
lacunar and some posterior circulation events would be missed.  It is unrealistic, given the 
heterogeneity of TIA symptoms, to expect that a clinical scoring system could detect all 
types of event. Amaurosis fugax for example has an entirely different set of differential 
diagnoses than other types of TIA.  It is imperative that such systems are introduced in 
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conjunction with improved user education, with clear direction as to their limitations and 
clear advice that clinician concern and acumen override the score. 
 
The recently developed ABCD and ABCD2 scores are risk stratification instruments that 
deserve comment (31;32).  They seem able to identify those with a high risk of stroke early 
after TIA but were developed on data from patients with a confirmed diagnosis of TIA and 
are thus unproven as diagnostic instruments. They would also suffer similar, or perhaps 
greater, weaknesses as the score developed in this study in terms of failure to detect 
amaurosis fugax, sensory lacunar and posterior circulation events. A recent analysis from 
our unit suggests this may be the case (273)  but whether this score would add further to the 
increasingly used ABCD scores is unclear and under investigation. 
 
There are limitations to this study. The clinic diagnosis, rather than final diagnosis (such as 
that supported by brain imaging) was used as the reference standard. Essentially therefore 
this study has assessed whether a scoring system can distinguish those whom a specialist 
feels require further investigation for cerebrovascular disease from those who do not. This 
is an appropriate aim for a diagnostic tool, in particular one to aid the clinical diagnosis of 
TIA.  However, levels of inter-observer agreement in the unit from which the study data 
arises have not been assessed but hopefully the standardized review process, the large 
number of subjects and limited number of experienced observers used will limit these. 
Further, only three patients with suspected stroke had a final diagnosis which differed from 
the original clinic diagnosis during the prospective validation phase. Although it was 
reassuringly consistent with the development sample, the prospective validation sample 
was small and cannot replace external validation. 
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The Hosmer-Le Cessie test yielded a p value of 0.02 suggesting the favoured model is not a 
good fit to the data (p-values of greater than 0.05 suggest a good fit). The fit of the model 
could perhaps have been improved by selecting different weights for the scores involved in 
the system or by selecting a different cut-off point for the model but this would render the 
tool less clinically useful; a greater importance was assigned to sensitivity in order to 
ensure the maximum number of true TIA cases would be referred for specialist assessment. 
 
This tool could be used by colleagues in primary care.  However, it was developed using 
data generated during assessment by stroke specialists.  It is not certain that GPs would 
reach the same conclusions regarding what constitutes a particular symptom, for example, 
pre-syncope or unilateral limb weakness.  A sensitivity of 85%, as seen with the weighted 
scoring system, represents a failure rate of TIA detection too great for safe use in clinical 
practice.  The 2:1 misclassification scoring system yielded a sensitivity of 97% and 
specificity of 24% during the development phase and 93% and 34% during the prospective 
validation phase.  This reduction in non-cerebrovascular referral rate was shown to be 
clinically meaningful; it would greatly reduce delay to assessment in this service. The 
weighted system performed best, although the non-weighted system would be easiest to use 
in clinical practice. The rounded weighted system may appear easiest to use but age is 
incorporated as a continuous variable so formal calculation would be required so it was 
opted to use the weighted system which most accurately reflects the data as the final model. 
This makes the score seem cumbersome and perhaps too difficult to use but many centers 
are moving toward an electronic referral process which would allow scores to be calculated 
automatically from information given, without the need for manual calculation. An 
example of this can be found at http://www.stams.strath.ac.uk/~karenl/tia/. This allows 
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maximum information and discriminatory ability to be retained, and in particular to avoid 
dichotomizing continuous variables such as age. 
 
The false negatives or “missed TIAs” are of interest.  In the prospective validation phase 
there were 10 patients with a presumed cerebrovascular diagnosis who were not identified 
by the 2:1 costs scoring system.  Of these, three were felt at final clinic review not to have 
had a TIA or minor stroke and only one of the remainder had brain imaging supportive of 
ischaemia in the relevant territory. This patient presented with a pure hemianopic visual 
disturbance. Two had possible transient ataxia, one had a transient language disorder and 
the remainder pure sensory symptoms.  These patients should still be identified if the score 
was used in conjunction with basic clinical acumen; use of the score itself will improve 
knowledge of presentation of stroke and TIA and may thus increase detection of TIA at the 




This study suggests that a reduction in the rate of referral of non-cerebrovascular diagnoses could 
significantly improve performance of TIA services and that a simple clinical scoring system could be 
used to achieve this.  Further work to evaluate use of the score in clinical practice is ongoing. 
Independent external validation and perhaps comparison to the ABCD scores would be of use. 











ASPIRIN RESISTANCE AND RISK OF 
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Aspirin Resistance and Risk of Cerebrovascular Events  
 
3.01 Potential Significance of Aspirin Resistance 
As outlined in the introduction, aspirin based anti-platelet strategies are the most commonly 
prescribed and are likely to remain so. However, regardless of the chosen anti-platelet 
strategy, it is clear that the effect is modest and recurrent event rates remain high. Methods 
to identify the most suitable regimen for individual patients are attractive as recent data 
suggest that intra-individual response to anti-platelet agents differs. 
 
It is increasingly recognised that some have a degree of “aspirin resistance.”  A recently 
published meta-analysis revealed a prevalence of 28% (274) but included studies covering a 
variety of patient groups and study methodologies. In the context of patients with a history 
of acute stroke, a “resistance” rate of 25.5% (and 8.1% to 1300mg aspirin per day) has been 
quoted (275).  Recent meta-analyses have also shown resistant patients to have a near four 
fold increase in risk of suffering a vascular event compared (274;276) with aspirin 
responders. For example, across 20 studies of 2930 individuals, 810 (28%) were classified 
as aspirin resistant and 39% of these suffered a cardiovascular event during follow-up, 
compared to only 16% of those who were aspirin sensitive (OR 3.85, 95% CI 3.08 to 4.8). 
The OR for a new cerebrovascular event in those with aspirin resistance was 3.78 (95% CI 
1.25 to 11.41); the wide confidence intervals reflect the small number of studies and 
subjects included. A high rate of aspirin resistance has been seen in those with stroke 
recurrence despite aspirin (277) and an increase in total vascular events (278) has been seen 
in aspirin non-responders with documented cerebrovascular disease.  A recent study 
showed a far higher rate of aspirin resistance in those who suffered a repeat stroke during 
follow up in comparison to those who did not (OR 14.25, 95% CI 8.5 to 23.7) (279). It 
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seems therefore that lack of response to aspirin may link to increased stroke risk in both the 
primary and secondary preventative setting. 
 
However, it is important to recognize that a variety of issues beset research in this field; as 
yet no consensus exists concerning the definition of aspirin resistance or its mechanism and 
no evidence exists to suggest that its presence should guide therapy. 
 
3.01.1 Definition of Aspirin Resistance / Measuring Platelet Function 
Aspirin resistance can be defined either clinically (vascular events in patients taking aspirin, 
perhaps better termed treatment failure) or in terms of laboratory measures (such as failure 
to inhibit platelet aggregation or thromboxane A2 production).  The available laboratory 
measures are numerous. 
 
The platelet count is not affected by anti-platelet therapy so is unsuitable as a means of 
assessing aspirin responsiveness.  Likewise, the bleeding time, while it is affected by 
aspirin (280;281) and can show differences between action of anti-platelets (281), is not 
well-suited to widespread clinical use as it involves a skin incision and is unlikely to be 
well tolerated by patients. 
 
The level of response to aspirin therapy can be determined by measuring the extent by 
which aspirin inhibits platelet production of thromboxane A2.  Thromboxane A2 is 
metabolised to various stable thromboxane B2 products which can be detected in the plasma 
or urine as simple and inexpensive indicators of platelet activity.  Thromboxane A2 is 
metabolised to thromboxane B2 (detectable in plasma), and 11-dehydrothromboxane B2 
(detectable in urine).  These metabolites can be measured by ELISA techniques and have 
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been used in studies of aspirin resistance which have shown an association between 
resistance and increased cardiovascular event rate (282). There are important issues 
concerning specificity of these techniques. For example, urinary 11-dehydrothromboxane 
B2 levels reflect thromboxane production, which by in large will be inhibited by aspirin but 
extra-platelet sources of thromboxane A2 exist and may arise in those with recently 
symptomatic cardiovascular disease (283) and thus lead to overestimates of resistance 
levels. 
 
There are a number of other means of measuring thromboxane-dependent platelet function.  
Light or optical aggregation techniques have traditionally been used and measure the 
increase in light transmittance through platelet suspensions when platelets are aggregated 
by an agonist such as thromboxane A2, adenosine diphosphate or collagen.  This requires 
the preparation of a suspension of platelet-rich plasma and while often considered the gold 
standard, is time consuming. Other drawbacks include the potential for artificial activation 
of platelets during centrifugation. Electrical impedance aggregometry (284) is a similar 
technique which measures changes in electrical impedance between two electrodes when 
platelets are aggregated by an agonist.  Conveniently, this method can be performed on 
whole blood samples and obviates some of the drawbacks of optical aggregometry. 
However, the accuracy and reproducibility of both techniques is somewhat poor due to the 
impact on aggregation of factors such as age, sex and race.  Furthermore, in-vitro 
techniques for measuring platelet function do not reflect the complex in-vivo interactions of 
platelets with other circulating blood elements. 
 
Semi-automated cartridge based analysers are now available and have the advantage of 
being simple and quick to use and can be performed on whole blood samples.  Two 
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commonly used systems are the PFA-100 system (Dade Behring, Leiderbach, Germany) 
and the RPFA system (Verify Now, Accumetrics). The PFA-100 (285) device measures 
platelet function under controlled shear stress.  A citrated blood mix is placed in an analyser 
and is vacuum aspirated through a capillary system with a membrane coated with platelet 
agonists (collagen and epinephrine or adenosine diphosphate cartridges are available). 
Provided levels of von Willebrand factor and platelet glycoprotein receptors are sufficient, 
platelets will attach and aggregate upon contact with the membrane. Platelet adhesion, 
activation and aggregation is then expressed as the ‘closure time’ – the time taken for a 
platelet plug to form and occlude the analyser aperture.  Only the collagen and epinephrine 
assay is sensitive to the action of aspirin.  The device has been shown to be more sensitive 
than traditional optical aggregation techniques (286) and labels a higher proportion of 
individuals as resistant (274).  The maximum time measured is 300 seconds, after which the 
closure time is given as >300 seconds.  The RPFA system utilizes a slightly different 
method and is a form of whole blood aggregometry.  A citrated blood mix and ‘aspirin 
assay’ are placed into an analyser and platelet induced aggregation is measured as an 
increase in light transmittance.  The aspirin assay contains fibrinogen coated beads and 
arachidonic acid. Arachidonic acid causes platelet aggregation and binding to the 
fibrinogen beads follows causing platelet agglutination. The extent of this is proportional to 
the changes in light transmission and results are expressed as the number of aspirin 
response units and percentage inhibition of platelets by aspirin.  The RPFA system can also 
give measures of clopidogrel and platelet-glycoprotein inhibitor responsiveness if different 
assays are used. Anecdotally, results on use of the PFA-100 device are also user dependent 
and a learned effect exists. Specific data are limited, although many laboratories report that 
reproducibility of results and the number of errors reduces with experience. 
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Thromboelastography can also be performed using a point of care device (TEG, 
Haemoscope Corp, Niles, IL, USA). The TEG system measures a variety of variables as 
blood is induced to clot under low shear stress conditions. The pattern of changes in visco-
elastic properties of blood mirror those of clot formation and allow assessment of the 
kinetics of clot formation and growth and strength and stability of the clot. A coagulation 
profile is then displayed and while this is most commonly used to evaluate clot formation 
during cardiopulmonary bypass, it can be used to assess response to anti-platelet therapy. A 
recent development is the TEG Platelet Mapping assay (Haemoscope Corp, Niles, IL, 
USA) which eliminates the contribution of thrombin and fibrin to clot strength (via addition 
of heparin, reptilase and factor XIIIa) and thus allows the impact of platelet pathways to be 
studied by the addition of relevant agonists (287). Addition of arachidonic acid allows 
measurement of thromboxane A2 mediated platelet aggregation. 
 
Flow cytometry techniques may also be used to determine levels of platelet inhibition by 
aspirin.  Surface expression of numerous platelet activation markers such as P-selectin 
(288) and activated glycoprotein IIb/IIIa receptors (289) on platelet membranes can be 
induced and measured as indicators of aspirin activity.  However, these techniques require 
expensive equipment, are not widely available and are time-consuming. 
 
There are thus a variety of techniques to assess aspirin responsiveness and there are 
advantages and drawbacks with each. Most available methods are limited by the need for 
local analysis; whether whole blood or plasma based techniques, transportation to central 
laboratories, a standard feature in most clinical trials, is not possible as transportation of 
samples will increase likelihood of false results. The cartridge based analysers are attractive 
because they could function as point of care devices but have limitations in that they do 
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they do not directly measure platelet thromboxane A2 production and agreement between 
them has previously been shown to be poor (290).  On the other hand, there is attraction to 
measuring platelet function as a whole rather than one means of platelet activation. Further, 
it is important to note that approaches that more directly measure thromboxane A2 
production have other drawbacks, such as influence from extra-platelet or COX mediated 
production. 
  
3.01.2 Mechanism of Aspirin Resistance 
The mechanism of aspirin resistance is likely to be multi-factorial, or at least may be 
different in different individuals. It is also true that the presence of apparent aspirin 
resistance in the laboratory setting may signify increased platelet activation which reflects 
more severe atherosclerosis; aspirin resistance may therefore simply be a marker of more 
severe disease which could explain the apparent link with increased cardiovascular events.  
Putative mechanisms however include lack of patient adherence, insufficient dosing, 
reduced absorption, non COX-1 mediated thromboxane A2 synthesis, increased activity of 
alternate platelet activation pathways and interference of aspirin action by other drugs.  
 
Poor compliance is perhaps the most important factor to consider. A flaw of existing work 
is that many studies have not reliably assessed recent aspirin ingestion and patient 
compliance (which may itself be a factor in some of these events (291)). If a patient has not 
taken aspirin, they will appear aspirin resistant and changing an anti-platelet regimen from 
aspirin to a newer anti-platelet may be unnecessary and costly. Approximately 10-40% of 
patients do not take prescribed anti-platelet tablets in the secondary prevention setting (292-
296) and this could confound aspirin resistance work. It is now possible to measure aspirin 
(or its salicylate metabolites) in urine using high performance liquid chromatography 
 - 105 - 
techniques, thus allowing objective determination of compliance. This has not been 
adequately performed in studies to date and it is possible that rates of resistance reported in 
the literature reflect a proportion of participants with poor therapy compliance. 
 
Aspirin is hydrolysed to inactive salicylate in the gut through the actions of esterases which 
may reduce its bioavailability and effect (297;298).  It is reported that use of proton pump 
inhibitors can increase mucosal hydrolysis of aspirin (299) which could cause apparent 
resistance but this is by no means proven (300). It is well known that concurrent intake of 
certain non-steroidal anti-inflammatory drugs (such as ibuprofen and naproxen) can 
interfere with the anti-platelet effect of aspirin by preventing aspirin binding to COX-1 
(301) and thus prevent a reduction in inhibition of thromboxane production.  Interestingly, 
use of ibuprofen alongside aspirin has been shown to link with increased mortality during 
follow-up in comparison to aspirin alone and aspirin with diclofenac (302). 
 
Thromboxane A2 may be produced from non-platelet sources, in particular in pro-
inflammatory states where COX-2 activity is increased in monocytes and macrophages and 
can yield thromboxane A2 production. This may be relevant in atherosclerosis which is an 
inflammatory condition (303) and may explain why those with recurrent events or more 
severe atherosclerosis appear more likely to be aspirin resistant. Renal production of 
thromboxane may also contribute to platelet activation and several cardiovascular risk 
factors can increase thromboxane synthesis via alternate pathways such as via isoprostane 
production (304).  Likewise, other pathways of platelet activation exist and include direct 
stimulation of platelet glycoprotein receptors and platelet shear stress and will be less likely 
to respond to aspirin; perhaps in this scenario alternative drugs such as clopidogrel will 
prove of use (305). 
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Genetic polymorphisms may impact on the inter-individual variation in response to aspirin. 
A variety of candidate genes have been suggested (306). Polymorphisms in the COX 
enzymes, platelet receptors and factor XIII have all been postulated as potential 
mechanisms (307). However, the overall contribution of genetic variation to aspirin 
resistance has not yet been clearly determined and in a recent systematic review, only the 
PIA1/A2 polymorphism in the GPIIIa platelet receptor linked with aspirin resistance (OR 
2.36, 95% CI 1.24 to 4.49) (308). 
 
Summary 
Thus, aspirin resistance appears to link with increased risk of cardiovascular events in those 
who take it. However, no firm evidence exists to suggest that routine screening for aspirin 
resistance and subsequent tailored anti-platelet regimens will improve outcome.  Also, the 
size of the effect of aspirin resistance is unclear; confidence intervals around available 
estimates are wide and, given that aspirin prevents approximately 1/5 of recurrent strokes, it 
seems unlikely that resistance would lead to a three or four fold increase in event rate 
unless resistance reflected, at least in part more severe disease. 
 
There is also no consensus concerning its definition, disagreement as to the best means of 
measuring it and no clear answer as to its cause. These questions are likely to remain until 
large scale prospective clinical trials are conducted or until aspirin resistance is associated 
with a robust and easy to study surrogate marker. A link with asymptomatic microemboli in 
patients with carotid disease for example would prove useful in stimulating and allowing 
further study; they are a high risk group, MES are easy to measure and are anti-platelet 
therapy responsive. 
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3.02 Chapter Aims / Hypothesis 
 
First, as recommended, a brief study was performed to establish the local reference range 
for normal platelet function using the PFA-100 device (study one). The chapter hypothesis 
was that aspirin resistance would be associated with the presence of microembolic signals 
in aspirin treated patients with carotid disease and that the prevalence of aspirin resistance 
in those who had proven recent aspirin ingestion would be lower than the rates reported in 
previous literature. The aim was thus to compare the rate of aspirin resistance in those with 
and without MES (study two) and to quantify the prevalence of aspirin resistance in those 
with cerebrovascular disease whilst addressing concerns surrounding patient compliance 
(study three).  
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3.03 Study One - Development of a Local Normal Range for Use of the PFA-100 
Device 
 
It is recommended by the manufacturer and expert guidelines that each institution clarifies 
its own reference range using healthy controls and establishes a control group for further 
quality control analyses prior to interpretation of results when using the PFA-100 device.  
The aim of this study was to establish this range. 
 
3.03.1 Study One Methods 
 
Forty healthy volunteers were recruited. The study was performed in the University 
Division of Cardiovascular and Medical Sciences at the Western Infirmary, Glasgow and 
was approved by West Medical Research ethics committee.  Inclusion criteria for this study 
were presumed normal platelet function and age > 18 years. Exclusion criteria were any 
anti-platelet or anti-coagulant use (within past 1 month), known haematological disorder or 
family history of haematological disorder and recent non-steroidal anti-inflammatory drug 
ingestion (within past 2 days).  
 
Approximately 7 mls of blood was drawn using a 21 G needle.  With the PFA-100 device, a 
citrated blood mix is placed into the analyser and platelet adhesion, activation and 
aggregation is expressed as the ‘closure time’ – the time taken for a platelet plug to form 
and occlude the analyser aperture after exposure to platelet agonists.  Epinephrine and 
collagen cartridges are used and are pre-warmed to room temperature.   Those with a 
closure time of between 110-160 seconds were considered for inclusion in a donor control 
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group and had testing performed in duplicate; if the repeat result was within a range of 
±15% of the first sample, they were asked to be part of the control group. 
The normal range was then expressed as the 95 % reference range of closure times in 
seconds. When performing quality control measurements, a closure time within the 
reference range was deemed satisfactory.  The coefficient of variation of closure times has 
been reported as 10% in the literature (309). 
 
3.03.2 Study One Results  
 
In total 40 participants were recruited between May 2005 and October 2008. All were 
healthy with no past medical history, no family or personal history of haematological 
disorders and were taking no regular medications. The majority (24, 60%) were female. 
Only 37 individuals were included in the analyses. Of those who were excluded, one 
subsequently admitted to taking warfarin, one suffered factor V Leiden deficiency (both 
these individuals had abnormal results) and in one further case, no result could be obtained. 
 
The mean closure time was 134 seconds (standard deviation 22.8). The range of values was 
95 to 182 seconds and the 95% reference range was 89.4 to 178.9 seconds. Individual test 
results are shown in figure 3.1. Ten individuals had testing performed in duplicate and the 
mean coefficient of variation was 7.5%. A closure time below the upper limit of the 95% 
reference range in the context of recent aspirin ingestion was used to define aspirin 
resistance (rounded up to a closure time < 179 seconds for analyses). 
 





3.03.3 Study One Discussion 
 
The definition of aspirin resistance used here is consistent with that used in other studies 
(277;286;309-324) (table 3.1).  It is important to note the length of time taken to complete 
this study and develop the local reference range – this was done alongside other studies 
rather than before which is in retrospect the optimal approach. However, this did not affect 










Figure 3.1 Distribution of Closure Times in 37 Healthy Volunteers Not Taking 
Regular Medication 
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Authors Reference Definition of Aspirin Resistance 
Jilma et al (309) < 193 seconds 
Kundu et al (310) < 193 seconds 
Christiaens et al (311;315) < 186 seconds 
Cohen et al (312) <192 seconds 
Pamukcu et al (321) < 186 seconds 
Narvaez et al (314) < 173 seconds 
Gum et al (286) < 193 seconds 
Grundmann et al (277) < 165 seconds 
Wong et al (316) < 158 seconds 
Coma-Canella et al  (317) <161 seconds 
Fateh-Moghadam et al (320) < 165 seconds 
Andersen et al (318) < 193 seconds 
Lordkipanidze et al (319) < 193 seconds 
Di Chiara et al (322) < 193 seconds 
Gurbel et al (323) < 193 seconds 
Angiolillo et al (324) < 193 seconds 
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3.04 Study Two - Microembolic Signals and Aspirin Resistance in Patients with 
Carotid Stenosis 
 
The study hypothesis was that aspirin resistance would be associated with the presence of 
microembolic signals in aspirin treated patients with carotid disease. An observational 
cohort study was perfomed to test this. 
 
3.04.1 Study Two Methods 
 
The study was performed in the University Division of Cardiovascular and Medical 
Sciences at the Western Infirmary, Glasgow. The study was approved by the local research 
ethics committee.  
 
Patients aged > 18 years taking current aspirin therapy and who had significant carotid 
artery disease (defined as at least a moderate internal carotid artery (ICA) stenosis or 
symptomatic ulcerating plaque disease) were included. Those taking clopidogrel, 
dipyridamole or anti-coagulant therapy and who had poor compliance with aspirin therapy 
were excluded. Further exclusion criteria included absence of a bony temporal window on 
TCD imaging, atrial fibrillation or other cardiac source of embolism (defined as valvular 
heart disease, recent myocardial infarction or known patent foramen ovale) and 
thrombolytic therapy within the past 2 weeks.  Compliance was assessed by questioning 
and, where the participant was an in-patient, from drug prescription charts and discussion 
with nursing staff. The presence of a temporal window for TCD imaging was assessed 
during carotid Doppler scanning as part of routine clinical care. Carotid ultrasound imaging 
utilised an Acuson Aspen 128 with a 5-Mhz linear transducer (Acuson, Mountain View, 
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CA, USA). In the Doppler laboratory, a moderate ICA stenosis is defined as being present 
if peak systolic velocity (PSV) is >1.5 m/s and a severe stenosis if PSV is >2 m/s. 
 
Participants were identified during out-patient attendance at the hospital Fast Track TIA 
service or during an in-patient stay in the Acute Stroke Unit. All gave full written informed 
consent to participate unless hemiplegia or visual disturbance precluded writing, where 
witnessed oral consent was accepted. 
 
Study Assessments 
Patients were reviewed at baseline where TCD monitoring for MES and blood testing for 
platelet function analyses were performed.  Those who still met the eligibility criteria had 
repeat TCD monitoring and platelet function analysis performed as near to 7 days as 
possible. The purpose of this was to evaluate whether aspirin resistance was a stable 
phenomenon. At day 30, all patients were contacted by telephone or seen at clinic (or 
reviewed on the ward if still an in-patient) to screen for any signs of recurrent TIA or stroke 
using a standardised set of clinical questions. This marked the end of their involvement in 
the study.  Where patients could not be contacted by telephone, this information was 
gathered at the next scheduled clinic review. 
 
TCD recordings were made from the middle cerebral artery ipsilateral to the stenosis using 
a TCD 100M device (Spencer Technologies, Seattle, WA, USA) in–line with consensus 
guidelines (325). Recordings lasted one hour and were made by sonographers with 
extensive experience in TCD techniques.  Where there was bilateral carotid disease, 
simultaneous bilateral TCD recordings were made.  Recordings were monitored on-line by 
the sonographer and potential MES were also automatically identified using the emboli 
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detection function. All recorded potential MES were reviewed and independently verified 
by the sonographer and one of the study investigators. Both were blinded to the aspirin 
responsiveness status. The presence of MES was defined as ≥1 MES on TCD scanning. 
 
Approximately 12 mls of blood was drawn using a vacutainer system and a 21 G needle 
into 3.8% citrate blood tubes. Well validated point of care cartridge based platelet analysers 
(PFA-100, Dade-Behring, Miami, FL (310;326) and Verify Now, Accumetrics (327;328)) 
were used to assess platelet function.  Samples were analysed at between 30 minutes and 4 
hours of being taken.  The PFA-100 device was used as described above. The coefficient of 
variation when using the PFA-100 device is typically 10% (309) and as described above, 
similar was seen in study one.  With the Verify Now device, a citrated blood mix and 
‘aspirin assay’ which contains fibrinogen coated beads and platelet agonists, are placed into 
the analyser and platelet induced aggregation is measured as an increase in light 
transmittance.  Results are expressed as the number of aspirin response units. The 
coefficient of variation when using the RPFA device is reported to range from 2.6 to 4.5% 
(information contained in Verify Now ASA product information sheet). 
 
Both devices are simple to use and give results within 10 minutes.  Using the PFA-100 
analyser, aspirin resistance was defined as a closure time below the in-house upper limit of 
the normal range for healthy non-aspirin treated individuals (<179s, as obtained in study 
one of this chapter).  Using the Verify Now system, aspirin resistance is defined as the 
presence of >550 aspirin reaction units (329). Participants were deemed to be aspirin 
resistance if found to be so on either test.  Platelet function tests were performed blinded to 
results of TCD imaging and MES status. 
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Statistical Analysis 
The primary endpoint was the proportion of aspirin resistant patients in the MES and non-
MES group.  This was assessed using Fishers exact test. Pre-specified secondary endpoints 
were the number of aspirin resistant patients in the MES and non-MES group according to 
each individual test, agreement between the first and second visit aspirin resistance status, 
agreement between the two platelet function tests and the rate of stroke or TIA according to 
aspirin status.  Agreement between tests was assessed using attribute agreement analysis 
and described with kappa statistics. It was estimated that the prevalence of aspirin 
resistance would be 30% (274;275) in the whole study group and that the rate would be 
higher at approximately 40% in those with MES (277) (similar to the rate in patients with 
recurrent stroke in other studies) compared to a lower rate of approximately 10% in those 
without MES (277;278). A sample size of 31 patients in each group would allow detection 
of such a 30% difference in the rate of aspirin resistance between the MES and non-MES 
group with 80% power and a significance of 0.05.  It was estimated that at least 40% of 
screened patients would have MES (223;229;234) but in order to ensure blinding to MES 
status could be maintained, it was planned to recruit the first 62 eligible patients. 
 
P values of <0.05 were deemed to denote statistical significance and standard definitions of 
degree of agreement based on kappa statistics were used (330).  
 
3.04.2 Study Two Results  
 
Sixty-two patients between June 2006 and January 2008.  All had baseline MES and aspirin 
responsiveness status recorded.  In total, 37 patients (59.7%) remained eligible and had the 
day 7 visit performed.  Of those who did not, twelve had undergone carotid endarterectomy, 
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one was commenced on clopidogrel, two went for scheduled cardiac surgery, two were 
moved to an off-site rehabilitation facility and could not attend, four did not attend and four 
withdrew consent for the second visit stating it was too soon after discharge. 
 
The mean age was 69.7 (± 11.8) years. The majority (53 patients, 85.5%) had symptomatic 
carotid disease and a severe stenosis (50 patients, 80%). Half (31 patients) were in-patients 
in the acute stroke unit; the remainder were out-patients attending the department. Of those 
who were symptomatic, 21 (39.6%) were evaluated within 48 hours of onset, 9 (17%) 
within 7 days, 12 (22.6%) within one month and 11 (20.8%) within 6 months. Further 
baseline demographic details, including stroke subtype, drug therapy, risk factor burden, 
renal function and platelet levels are shown table 3.2. 
 
Baseline aspirin responsiveness and platelet function data are shown in table 3.3.  In total, 
16 patients (25.8%) exhibited evidence of aspirin resistance on one or more test. Of these 
patients, 13 (21%) were resistant on PFA-100 testing, 8 (12.9%) were resistant on RPFA 
testing and 5 (8.1%) were resistant on both. Sixteen (25.8%) had evidence of MES, with a 
range of 1-39 signals during monitoring. Only one patient (who was aspirin resistant on all 
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Variable Value 
Age 69.7 (11.8) 
No Stroke Symptoms 
Total Anterior Circulation Stroke 
Partial  Anterior Circulation Stroke 
Lacunar Stroke 
Posterior Circulation Stroke 







Symptomatic Carotid Disease 53 (85.5%) 
< 50% stenosis / plaque disease only 
>50% stenosis 




Smoker 20 (32.3%) 
Ischaemic Heart Disease 14 (22.6%) 
Diabetes Mellitus 9 (14.5%) 
Hyperlipidaemia 19 (30.7%) 
Hypertension 31 (50%) 
ACE I or ARB Therapy 24 (38.7%) 
Diuretic Therapy 23 (37.1%) 
Statin Therapy 43 (69.4%) 
Baseline Platelet Count 255.3 (101.7) *109/L 
Table 3.2 – Study Two Baseline Demographic Variables. Expressed as n (%) for 
categorical variables and mean (SD) for continuous variables. ACE I = ACE inhibitor, 
ARB = Angiotensin Receptor Blocker. 
 
MES and Aspirin Responsiveness Status 
Aspirin resistance on at least one test was present in 8/16 (50%) of those with 
microembolic signals and in 8/46 (17.4%) of those without MES (p=0.018 on Fisher’s 
exact test). 
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PFA-100 CEPI-CT 254.2 (72.6) seconds 
Aspirin Resistance on PFA-100 13 (21%) 
RPFA 442.3 (90.3) ARU 
Aspirin Resistance on RPFA 8 (12.9%) 
Aspirin Resistance on Both Tests 5 (8.1%) 
Aspirin Resistance on ≥ 1 Test 16 (25.8%) 
Presence of MES 16 (25.8%) 
Number of MES (when present) 1-39 (range) 
Table 3.3 – Study Two Baseline Platelet Function Analysis Results 
PFA-100 = Platelet Function Analyser 100. RPFA = Rapid Platelet Function Analyser. 
ARU = Aspirin Responsive Units. MES = microembolic signals. Values expressed as n 
(%) for categorical variables and mean (SD) for continuous variables unless stated. 
 
Aspirin resistance was present in 5 (31.3%) of those with MES on PFA-100 testing 
compared to 8 (17.4%) without (p=0.29 on Fisher’s exact test). On RPFA testing, aspirin 
resistance was present in 5 (31.3%) of those with MES and 3 (6.5%) of those without 
(p=0.02 on Fisher’s exact test). 
 
Agreement between Platelet Function Tests 
Agreement between the aspirin responsiveness status measured by the different platelet 
function tests and at the two study visits is shown in table 3.4. At the baseline visit, 
agreement between the two tests was moderate (ĸ=0.40). A scatter plot of the individual 
patient data is shown in figure 3.2. At the second study visit, agreement between the tests 
was also moderate (ĸ=0.41). Agreement between aspirin responsiveness status at the first 
and second visit was moderate on PFA-100 (ĸ=0.53) testing, moderate on RPFA testing 
(ĸ=0.44) but was fair for presence of resistance on one or more test (ĸ=0.36). At the second 
study visit, 11 (29.7%) of patients exhibited evidence of aspirin resistance on one or more 
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test. All of these were resistant on PFA-100 testing and 4 (10.8%) were also resistant on 
RPFA testing. 
 
Visit 1 (PFA-100 vs RPFA) ĸ= 0.4 P<0.001 
Visit 2 (PFA-100 vs RPFA) ĸ= 0.41 p=0.006 
Aspirin Resistance on ≥ 1 Test (Visit 1 vs 
Visit 2) 
ĸ= 0.36 p=0.014 
PFA-100 (Visit 1 vs Visit 2) ĸ= 0.53 P<0.001 
RPFA (Visit 1 vs Visit 2) ĸ= 0.44 p=0.004 
Table 3.4. Measures of Agreement Between Tests and Study Visits in Study Two. 
PFA-100 = Platelet Function Analyser 100. RPFA = Rapid Platelet Function Analyser. 






Figure 3.2. Scatterplot of PFA-100 Measured versus RPFA Measured Aspirin 
Responsiveness in Study Two. Each data point represents one individual. Values 
to the right of the vertical reference line represent resistance on RPFA testing 
while values below the horizontal reference line represent resistance on PFA-100 
testing. ARU = Aspirin responsiveness units. 
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3.04.3 Study Two Discussion 
 
Data from this study show that aspirin resistance is more common in those with significant 
carotid disease and MES compared to those with equivalent carotid disease and no MES. 
This ties increased prevalence of aspirin resistance to a readily measurable and robust 
marker of stroke risk. Importantly, the utility of MES exceeds their predictive value 
regarding future stroke risk; their presence and their response to treatment can be used to 
identify differences between anti-platelet strategies with small numbers (234). The findings 
from this study provide a useful model for further work which should aim to establish 
whether screening for aspirin responsiveness and subsequent changes to therapy reduces 
the rate of MES and stroke risk in those with carotid disease. For example, this strategy 
could be compared to other regimens such as unselected use of aspirin and clopidogrel 
(234). 
 
Aspirin remains the most widely prescribed anti-platelet agent after stroke and attempts to 
better target its use, especially in high risk groups, are valid. Resistance to aspirin effect has 
received much attention over the recent years and does appear to be associated with an 
increased risk of cardiovascular events (274;276). However, several issues beset the field: 
as yet no consensus exists concerning the definition of aspirin resistance or its mechanism 
and no evidence exists to suggest that its presence should guide therapy. The size of recent 
anti-platelet trials (140) suggests that clarifying these issues with clinical endpoint studies 
may be costly and impractical. A link between aspirin resistance and a readily measurable 
surrogate marker of stroke risk would therefore be useful to establish as it would allow 
(with relative ease) further study of tailored anti-platelet strategies. 
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Aspirin resistance can be defined either clinically (vascular events in patients taking aspirin, 
perhaps better termed treatment failure) or in terms of laboratory measures (such as failure 
to inhibit platelet aggregation or thromboxane A2 production).  Given the lack of consensus 
concerning the optimal definition two simple point of care analysers were used to assess 
aspirin responsiveness in this study. A wide definition of aspirin resistance (the presence of 
normal platelet function on one or more test) was also used; it was hoped that the simplicity 
of these methods will allow further research to proceed whilst ensuring any findings can be 
readily translated into routine clinical practice – the same could not be said for the more 
time consuming and cumbersome techniques of flow cytometry or traditional methods of 
platelet aggregometry. There are however drawbacks to the tests used: neither is truly 
specific to the effect of aspirin therapy nor do they do directly measure platelet 
thromboxane A2 production; and agreement between them has previously been shown to be 
poor (290).  Attempts were made to limit the lack of specificity for aspirin action by 
ensuring those taking alternative anti-thrombotic / anticoagulant therapy or those with a 
known haematological disorder were excluded. Also, as mentioned, it is important to note 
that approaches that directly measure thromboxane A2 production have other drawbacks: 
extra-platelet sources of thromboxane A2 may arise in those with recently symptomatic 
cardiovascular disease (283) and thus lead to false overestimates of resistance levels. 
  
The PFA-100 has been shown to be more sensitive than traditional optical aggregation 
techniques (286) and labels a higher proportion of individuals as resistant (274).  Similar 
supportive trends were seen in this study: 13 (21%) were resistant on PFA-100 testing 
compared to only 8 (12.9%) on RPFA testing. Interestingly, resistance on RPFA testing 
appeared more closely linked to presence of MES than resistance on PFA-100 testing, 
although the numbers resistant on each technique were small and a firm conclusion as to 
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whether RPFA testing detects clinically more relevant aspirin resistance cannot be drawn.  
The prevalence of resistance using the combined definition in this study was 25.8% which 
is consistent with that seen in meta-analyses (274) and studies post stroke (275). 
 
Only moderate agreement between the methods used to define resistance and between 
aspirin responsiveness status at the first and second visits in this study. While the 
agreement seen between the different platelet function tests is superior to that seen in other 
studies (290) in the post stroke period, it remains too low to allow a patient to be deemed 
resistant on the results of a single test and the 95% CI for the estimate of agreement in this 
study overlaps with previous work (290). Until the optimal technique of measuring 
resistance is clarified, it is likely that a battery of tests should be used.  Other authors have 
suggested that aspirin resistance may have a temporal component (331) and although the 
rates of aspirin resistance were similar at the first and second visits here, agreement 
between visits was only moderate suggesting that the resistance status of some individuals 
changed. There are several potential explanations for this: compliance may have differed 
between visits in some individuals, as may the degree of platelet activation which can 
change following acute cardiovascular events (283). Importantly, it is unlikely that 
compliance has influenced the main results of this study; all patients verbally confirmed 
compliance and half were in-patients who had compliance objectively confirmed from 
hospital prescription charts and discussion with nursing staff. 
 
Patients who were taking dipyridamole were excluded. The trial commenced before the 
ESPRIT trial (138) revealed incremental reduction in recurrent stroke with combined 
aspirin and dipyridamole therapy. Whether more widespread dipyridamole use will reduce 
early stroke risk or the likelihood of MES in those who are aspirin resistant is unclear. 
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Available data suggest its addition does not alter the response to aspirin treatment measured 
by either the PFA-100 or RPFA (332) and it may be that the association seen would hold.  
Two patients toward the end of the study were commenced on dipyridamole prior to their 
second visit and neither had a change in their MES or aspirin resistance status. 
 
Only one patient in this study suffered a recurrent event, which, given the baseline risk of 
the group, appears low. This patient was aspirin resistant but no useful information can be 
drawn from this observation. The low recurrent stroke risk may in part reflect the number 
who proceeded to rapid carotid endarterectomy (7 of those with MES, 16 patients in total, 
12 of whom within one week of entering the study) or had aggressive anti-platelet therapy 
(3 with MES received aspirin and clopidogrel).  
 
A lower rate of MES than had been anticipated was seen. It was estimated that a rate of 
40% (223) would arise in the study group as a whole but MES were seen in only 25.8% 
(16) patients. Given that some patients in the study (9, 14.5%) had asymptomatic carotid 
disease, this probably is a representative figure. Furthermore, recent data (333) suggest that 
prevalence of MES falls with time after stroke (from 49% at 24 hours to 29% at 48 hours, 
although this was not a specific evaluation of subjects with carotid disease), and only ≈ 
40% of patients were recruited and assessed within 48 hours of symptoms.  
 
In conclusion, increased prevalence of aspirin resistance is linked to the presence of MES 
in patients with carotid disease. This provides a useful model to further study the benefits of 
guided anti-platelet strategies and further work should establish whether screening for 
aspirin responsiveness and subsequent adjustment to anti-platelet therapy reduces the rate 
of MES and stroke risk in those with carotid disease.  
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3.05 Study Three - Aspirin Resistance and Cerebrovascular Events; the Importance 
of Participant Compliance with Aspirin 
 
The study hypothesis was that the aspirin resistance would remain a common phenomenon, 
even after compliance was adequately assessed but that the rate would be lower than the 
rates previously reported in the literature. A prospective case-controlled study was 
performed to test this. 
  
3.05.1 Study Three Methods 
 
The study was performed in the University Division of Cardiovascular and Medical 
Sciences at the Western Infirmary, Glasgow. The study was approved by the West Medical 
Research Ethics Committee. The study incorporated an analysis of all participants and a 




Cases were aged > 18 years taking current aspirin therapy who had a clinical diagnosis of 
ischaemic stroke or transient ischaemic attack. It was required that recruitment and platelet 
function analysis be performed within 24 hours of onset of symptoms and that participants 
would be in theory able to submit a urine sample. Those with known poor compliance with 
aspirin therapy, those taking clopidogrel or anti-coagulant therapy or who had received 
thrombolytic therapy within the past 2 weeks and those with brain imaging which identified 
intracerebral haemorrhage were excluded. Compliance was assessed by questioning. 
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Cases were identified on admission to the Acute Stroke Unit at the Western Infirmary 
Hospital. Where possible, all gave full written informed consent to participate unless 
hemiplegia or visual disturbance precluded writing, where witnessed oral consent was 
accepted. Where potential participants were unable to consent, assent from the nearest 
relative or welfare guardian was accepted. Ethical approval was given for this as exclusion 
of those unable to consent because of their stroke would bias the study sample. It is 
important these patients are included as it is at least as relevant to establish the role of 
aspirin resistance in larger, more severe strokes. 
 
Controls 
Controls comprised individuals aged over 18 years of age taking current aspirin therapy for 
at least one year who had never suffered a cardiovascular event on aspirin. Those with 
known poor compliance with aspirin therapy, those taking clopidogrel or anti-coagulant 
therapy or who had received thrombolytic therapy within the past 2 weeks were excluded. 
Compliance was assessed by questioning. All gave full written informed consent. 
 
Controls were mostly identified during out-patient attendance at cardiovascular risk factor 
clinics at the Western Infirmary. 
 
Study Assessments 
Cases were reviewed at baseline and at 7 days or on discharge from depending on what was 
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Baseline Assessment 
Demographic and diagnostic data were gathered. A blood sample was drawn (ca 10 mls) 
for platelet function analyses and attempts were made to obtain a urine sample for 
measurement of aspirin metabolites.   
 
Measurement of Platelet Function and Aspirin Responsiveness 
The same well validated cartridge based platelet analysers (PFA-100, Dade-Behring, Miami, 
FL (310;326) and Verify Now, Accumetrics (327;328)) were used as outlined above in 
study two. The definitions of as aspirin resistance were also the same as outlined previously 
(closure time of < 179 with the PFA-100 device and the presence of >550 “aspirin reaction 
units” when using the Verify Now TM system). Investigators were blinded as to levels of 
urinary aspirin metabolites when performing platelet function analysis (results were not 
available at the time of platelet function analysis). 
 
3.05.1.1 Measurement of Aspirin Metabolites (Detection of Urinary Salicylates) 
Where able, participants submitted a single urine sample (the next urine sample following 
recruitment). High performance liquid chromatography analysis was performed. All tests 
were performed at Divisional Labs at the Western Infirmary Hospital.  Other methods such 
as the method of Trinder (the principle of the test is a direct colour reaction on urine - a 
violet colour indicates the presence of salicylates) are available but relatively insensitive 
techniques (334); studies have revealed urinary concentrations in excess of the limit of 
detection for the Trinder method (20mg salicylate/L urine) 10 hours after a single 600 mg 
dose (335) but it is unclear whether this threshold will be reliably reached after a single 75 
mg aspirin dose, and for what period thereafter. 
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High performance liquid chromatography (HPLC) assays have been developed to identify 
aspirin and its salicylate metabolites in both plasma and urine (336-341).  HPLC involves a 
column which holds material (the stationary phase), a pump to inject and move the mobile 
phase, which acts as a carrier for the analysis sample, through the column and a detector 
which shows the retention times of the molecules. The retention times, or the time taken to 
elute from the column, depend upon the chemical interactions between the stationary phase 
and the mobile phase, and thus the properties of the analysis sample.  The stronger the 
interaction with the stationary phase, the longer the retention time.  There a variety of types 
of HPLC analysis but the most widely employed is reverse-phase HPLC, which utilizes a 
non-polar stationary phase and compounds are separated on the basis of hydrophilicity and 
lipophilicity.  There are also different types of mobile phase and the environment of the 
mobile phase can be manipulated to ensure better separation of the sample. Detector 
systems can also vary and can be based, for example, upon measurement of the refractive 
index, the ability of samples to absorb ultra-violet light, or a variety of other techniques. 
 
HPLC techniques are highly sensitive; detection of concentrations as low as 0.1 mg/l of 
aspirin metabolites are possible with some assays (339). Such methods have been used in 
many studies of aspirin pharmacokinetics and of salicylate levels in healthy volunteers and 
data suggest that salicylates can be detected several hours, and perhaps days, after low dose 
aspirin ingestion (summarized below). 
 
Aspirin and Measurable Metabolites 
Acetylsalicylic acid is hydrolyzed in the stomach and in blood to salicylic acid and acetic 
acid (342). Both acetylsalicylic acid and salicylic acid are rapidly absorbed. Several studies 
suggest that plasma concentrations of acetylsalicylic acid peak within one hour of ingestion 
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(339;343;344) and that the elimination half life is approximately 20 to 40 minutes. Levels 
of approximately 1000 ng/ml are often seen (343). Plasma salicylate levels peak somewhat 
later at approximately 1 to 2 hours, are generally higher, and also have a longer elimination 
half-life of approximately 2 to 4.5 hours. Several studies confirm that salicylates can be 
detected in the plasma several, and up to 10 hours (339;345), after single oral dose 
ingestion. Following daily dosing of low dose aspirin, time – concentration curves suggest 
levels of acetylsalicylic acid and salicylic acid remain detectable for longer with high (near 
peak) levels of salicylic acid seen for approximately 6 hours after ingestion (343) on HPLC 
analysis. How long they remain detectable thereafter is unclear. 
 
Salicylates are predominantly excreted by the kidneys, mostly following hepatic 
conjugation, as salicyluric acid (75%), free salicylate (10%), salicylic phenol (10%), acyl 
glucuronides (5%) and gentisic acid (<1%) (346).  Studies suggest that the salicylate load 
from low dose aspirin is mostly excreted in the urine within 24 hours (340;343), although 
others suggest that only 10% is excreted within 10 hours after a single dose (335).  Levels 
of salicylic acid of over 30 µg/ml have been seen in urine 10 hours after ingestion of a 
600mg dose (335), while some more sensitive techniques allow detection of salicylates up 
to 48 hours after ingestion of a single 80 mg dose of aspirin (347). Otherwise, little data 
exist to suggest actual concentrations of salicylate metabolites in the urine in the hours after 
ingestion of low dose aspirin. 
 
Importantly, salicylates are found in both the plasma and urine of those who do not take 
aspirin or other salicylate drugs. For example, in one study using HPLC analysis, salicylic 
acid was detected in the plasma of all 76 subjects studied with higher levels in vegetarians 
(0.11 µmol/l (range 0.04 to 2.47) compared to 0.07 µmol/l (range 0.02 to 0.2)) in non-
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vegetarians (348). However, levels were significantly, and approximately 100 times higher, 
in those taking aspirin (10.03 µmol/l (range 0.23 to 25.4)). There was however some 
overlap with between vegetarians and those on aspirin; eight vegetarians had salicylic acid 
levels above the lowest level seen in aspirin treated patients. However, this level was 
surprisingly low and it is possible, or perhaps probable, that this individual was not 
compliant with aspirin therapy and that the vegetarian with very high levels had ingested 
some medicinal salicylate. In the urine, 24 hour excretion of salicyluric acid of 3.91 µmol 
per 24 hours (range 0.87 to 12.23) in non-vegetarians and 11.01 µmol per 24 hours in 
vegetarians (4.98 to 26.6) has been seen, compared to levels of 170.7 µmol per 24 hours 
(range 13.15 to 377.18) in those who have taken 75 mg of aspirin (349). Again there was 
some overlap between values seen in vegetarians and those on aspirin with a small number 
of vegetarians having levels above the lowest in the aspirin group. Interestingly, excretion 
of salicylic acid did not differ between vegetarian, non-vegetarians and those taking aspirin 
suggesting that salicyluric acid measurements are most meaningful.  Levels are also 
increased following consumption of cranberry juice (350).  In a further study using HPLC 
analysis (341), the median urinary concentration of salicylic acid was 0.56 µmol/L (range 
0.07-0.89 µmol/L), while that of salicyluric acid was 3.20 µmol/L (range 1.32-6.54 
µmol/L) in 10 individuals who did not take aspirin.  For salicyluric acid, a level of > 6.54 
µmol/L equates to > 1.3 µg/ml while for salicylic acid, a level of > 0.89 µmol/L equates to 
> 0.123 µg/ml. 
 
Thus, although salicylates are present in the plasma and urine of those who do not take 
aspirin, levels are significantly higher in those who take even low dose aspirin and remain 
detectable in both plasma and urine for several hours and may be detectable in the urine for 
up to 48 hours after a single 80 mg dose (347). This suggests that salicylate load due to 
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aspirin ingestion can readily be distinguished from that of the normal dietary intake, 
particularly in non-vegetarians, and that sensitive techniques that measure salicylate 
metabolites, and those in the urine in particular, can be used to confirm recent ingestion in 
those meant to be taking low dose aspirin. 
 
3.05.1.2 HPLC Analysis Used in This Study 
Urine concentrations of salicylic acid and salicyluric acid levels were determined using an 
established reverse-phase HPLC method (339).  The materials used included stock 
solutions (at a concentration of 1000 µg / ml) of salicylate and salicyluric acid in distilled 
H2O and 1.0M oxalic acid. The internal standard (IS) was 200ug m-hydroxybenzoic acid / 
ml distilled H2O. The mobile phase consisted of 25% H2O, 25% acetonitrile, and 50% 
phosphate buffer (0.2M pH 2.5). The solution was degassed by bubbling Helium through it 
for approximately 10 minutes.   
 
Standards comprised the stock solutions of salicylate and salicyluric acid. The standard 
curves for salicylate ranged from 3.125 to 25 µg / ml while those for salicyluric acid ranged 
from 25 to 200 µg / ml.  As salicylate and salicyluric acid are measured simultaneously, 
each prepared standard contained both metabolites at their chosen concentration. There 
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1 0 0 0 1000 
2 3.125 25 125 875 
3 6.25 50 250 750 
4 9.375 75 375 625 
5 12.5 100 500 500 
6 18.75 150 750 250 
7 25 200 1000 0 
Table 3.5. Prepared Standards Used in HPLC Analysis. SA = salicylic 
acid. SU = salicyluric acid. 
 
The urine sample for analysis was then prepared as outlined below; 
a) Pipette 200µl of urine for analysis into 5ml round-bottomed tube. 
b) Add 50µl internal standard (IS) and briefly vortex mix. 
c) Add 200µl 1M oxalic acid. 
d) Add 2ml hexane / diethyl ether mixture; ratio1:1. 
e) Mix on rotator for approximately 5 minutes. 
f) Centrifuge for 5 mins at 2000 rpm. 
g) Remove as much hexane / diethyl ether mixture as possible into clean 12ml tube. 
h) Evaporate to dryness in centrifugal evaporator at minimum temperature setting 
(approximately 15 minutes). 
i) Dissolve desiccant in 200µl Mobile Phase and briefly vortex mix. 
j) Carefully transfer as much volume as possible to HPLC vial and cap. 
 
The HPLC system consisted of a Shimadzu SCl-10A VP system controller, Shimadzu Lc-
10AT VP pumps, a Shimadzu SIL-10AD VP sample injector, a Shimadzu SPD-6A variable 
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wavelength UV detector and a computer with Jones JCL 6000 data acquisition software. 
The column used was a Phenomenex Synergi 4um Hydro-RP column (dimensions 15cm x 
4.6mm). The guard column is packed with Lichroprep RP-18, particle size 25-40um. The 
column and other system components are maintained at ambient temperature. 
 
HPLC conditions were a flow rate of 0.5 mls / min, a detector set at UV, λ 303 nm and 
absorbance 0.02 and the injection volume was 50 µl. Retention times were approx. 5.4 
minutes for IS, 6.9 minutes for salicyluric acid and 11.8 minutes for salicylic acid. 
 
Limits of detection were not pre-specified. Salicylate metabolites are endogenous 
compounds with levels above the likely limit of detection seen in many individuals. 
 
Definition of Evidence of Recent Aspirin Ingestion Used 
Little data exist to inform levels of salicyluric acid or salicylic acid at differing times after 
aspirin ingestion and in those not taking aspirin. In a small sample in the local laboratory, 
levels of 0 to 5.25 µg/ml of salicyluric acid have been seen, with most values < 5 µg/ml in 
those taking no aspirin. Levels of  > 5 µg/ml were seen 24 hours after single dose aspirin 
ingestion. Although direct comparisons are not possible, this threshold is broadly similar to 
that outlined by others (341) and a salicyluric acid of > 5 µg/ml was therefore used to 
define evidence of recent aspirin ingestion. These individuals were included in the urine 
sub-study. Given that it is also know that aspirin metabolites are predominantly cleared 
from the urine within 24 hours, evidence of no recent aspirin ingestion was defined as 
stated last dose of aspirin within 24 hours from submission of urine sample and a 
salicyluric acid level of < 5 µg/ml. Importantly, given that the platelet mediated effects of 
aspirin last longer than 24 hours, it is expected that some participants whose urine sample 
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was received after 24 hours would have evidence of aspirin mediated platelet dysfunction 
but a salicyluric acid level of < 5 µg/ml. 
 
Final Assessment - At the final assessment the final diagnosis and patient outcome were 
established for cases.  
 
Statistical Analysis 
It was planned to study 90 cases and 90 controls.  The primary endpoint was the proportion 
of individuals showing resistance to aspirin on any test. Secondary endpoints were defined 
as resistance to both tests, to the PFA-100 test and to the RPFA test. The rate of the primary 
(and secondary) endpoint(s) were compared between cases and controls.  It was estimated 
that the rate of aspirin resistance would be approximately 30% in the general population but 
that it would be higher, at approximately 40%, in cases (277;351) and lower in controls. It 
was estimated that approximately 20% in the control population would have no evidence of 
recent aspirin ingestion but there are little data to help estimate the rate in those with a 
vascular event.  Even after exclusion of these patients from the analyses (approximately 
20% of all subjects), 90 patients per group will allow detection of a ~ 20% difference in 
aspirin resistance rate between the two groups with 80% power and a significance of 0.05 
(for example 40% in cases vs 20% in controls).   
 
Differences between cases and controls were assessed by the Student's t test for means and 
the chi-square test for proportions or Fisher’s exact test. Agreement between the platelet 
function and salicylate detection testing was assessed using kappa statistics. A p value of 
<0.05 was used to determine statistical significance and standard definitions of degrees of 
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agreement were used. Analyses were performed separately for each of the two methods of 
determining aspirin responsiveness. Cases and controls were not matched on a 1:1 basis. 
 
3.05.2 Study Three Results 
 
Ninety cases were recruited between the 19th February 2007 and the 4th November 2008. 
Ninety controls were recruited from 29th June 2007 to 4th November 2008. Baseline 
characteristics are shown in table 3.6 and 3.7. There were several statistically significant 
differences between the groups. All participants verbally confirmed regular compliance 
with aspirin. 
 
All cases (for the exception of one) and all controls were prescribed 75 mg per day of 
aspirin.  Baseline levels of routine biochemistry and haematology indices including platelet 
count and coagulation parameters are shown in table 3.7. There were no significant 
differences. Coagulation screens were not routinely performed in controls and this 
comparison is thus based on a small number (n=7) of controls.  The time from stroke 
symptoms to blood sampling was 16 (IQR  4.5 to 22.5) hours in cases.  
 
Variable Cases Controls P Value  
Baseline Platelet Count 244.8 (8.1) 254.5 (14.1) 0.55 
Baseline Haemoglobin 13.4 (0.2) 13.7 (0.3) 0.39 
Baseline APTT 31.2 (0.5) 33.1 (1.9) 0.35 
Baseline PT 11.9 (0.16) 12.1 (0.6) 0.72 
Baseline Creatinine 96.8 (4.23) 97.7 (3.6) 0.99 
Table 3.6. Study Three Baseline levels of Blood Parameters in Cases and Controls. 
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Variable Cases Controls P Value 
Age 71.1 (10.5) 66.7 (11) 0.007 









Total Anterior Circulation Stroke 
Partial  Anterior Circulation Stroke 
Lacunar Stroke 

















NIHSS Score 5.6 (5.4) --- --- 
Smoker 27 (30%) 10 (11.1%) 0.001 
Ischaemic Heart Disease 25 (27.8%) 27 (30%) 0.74 
Previous CVA 24 (26.7%) 1 (1.1%) <0.001 
PVD 4 (4.4%) 4 (4.4%) 1 
Diabetes Mellitus 6 (6.67) 18 (20%) 0.015 
Hyperlipidaemia 22 (24.4%) 35 (38.9%) 0.054 
Hypertension 52 (57.8%) 80 (88.9%) <0.001 
Atrial Fibrillation 13 (14.4%) 3 (3.3%) 0.008 
Dipyridamole Therapy 13 (14.4%) 1 (1.1%) <0.001 
ACE I or ARB Therapy 45 (50%) 52 (57.8%) 0.37 
Diuretic Therapy 35 (38.9%) 51 (56.7%) 0.025 
Beta-blocker Therapy 32 (35.6%) 43 (47.7%) 0.13 
CCB Therapy 28 (31.1%) 41 (45.6%) 0.065 
Alpha-blocker Therapy 2 (2.2%) 20 (20.2%) <0.001 
Statin Therapy 66 (73.3%) 67 (74.4%) 1 
NSAID Therapy 2 (2.2%) 4 (4.4%) 0.682 
Table 3.7. Study Three Baseline Characteristics 
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Aspirin Responsiveness Status in Cases 
In total , 55 (61.1 %) had blood sampling for platelet function testing performed within 24 
hours of last stated aspirin ingestion. PFA-100 and RPFA tests were not successful in three 
individuals. In total, 30 cases (33.7 %) exhibited evidence of aspirin resistance on one or 
more test. Of these, 28 (32.1 %) were resistant on PFA-100 testing, 16 (18.4 %) were 
resistant on RPFA testing and 12 (14 %) were resistant on both (table 3.8).  
 
 Cases Controls P Value  95 % CI for 
Difference  
PFA-100 CEPI-CT 272 (142 to 300) 293 (205 to 300) 0.068 # 0.01 to 23.99 # 
Aspirin Resistance 
on PFA-100 * 
28 (32.1 %) 15 (18.1 %) 0.031 -27 to - 12.7 % 
RPFA 465 (396 to 530) 452 (399 to 481) 0.33 # -34.5 to 9.99# 
Aspirin Resistance 
on RPFA * 
16 (18.4 %) 12 (13.8 %) 0.54 -15.5 to 6.3 % 
Aspirin Resistance 
on Both Tests 
12 (14 %) 5 (5.9 %) 0.07 -16.9 to 1 % 
Aspirin Resistance 
on ≥ 1 Test 
30 (33.7 %) 21 (24.7 %) 0.19 -22.4 to 4.4 % 
Table 3.8. Study Three Platelet Function Analysis Results. * Only 87 participants had 
results available. P values and 95 % CI shown are for the difference between two 
proportions except for # where they are for the difference on Mann-Whitney testing.  
 
Aspirin Responsiveness in Controls 
All controls had blood sampling for platelet function testing performed within 24 hours of 
last stated aspirin ingestion. In total, 21 controls (24.7 %) who exhibited evidence of aspirin 
resistance on one or more test. Of these patients, 
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testing, 12 (13.8 %) were resistant on RPFA testing and 5 (5.9 %) were resistant on both 
(table 3.8). 
 
Comparison Between Cases and Controls 
The rate of aspirin resistance as defined by resistance on PFA-100 testing or resistance on 
both modalities was significantly higher in cases than control (table 3.8). There were also 
trends towards higher rates of resistance on RPFA testing and on resistance defined as 
resistance on at least one modality. 
 
The Urine Sub-study - Cases 
A urine sample was submitted by 66 cases (73.3%).  The mean concentrations of salicyluric 
acid and salicylic acid seen in the urine were 50.1 (SD 64.5) µg/ml and 1.2 (SD 2.56) µg/ml 
respectively. In total 40 (60.1 %) had levels of salicyluric acid above the pre-specified level 
used to define evidence of recent aspirin ingestion (> 5 µg/ml). 
 
The median time from drawing of blood to submission of the urine sample was 20 minutes 
(IQR 0 to 60 minutes). However, only 24 (36.6%) submitted their urine sample on the same 
day as their last aspirin dose, while 37 (54.6%) submitted their urine sample within 24 
hours of their last stated aspirin dose.  In total 12 of these (32.4 %) had no evidence of 
recent aspirin ingestion (sample submitted within 24 hours of last stated aspirin dose and 
levels of salicyluric acid of < 5 µg/ml).   
 
When considering only those with evidence of recent aspirin ingestion, 10 (26.3 %) were 
aspirin resistant on at least one platelet function test. Of these, 9 (23.7 %) were resistant on 
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PFA-100 testing, 5 (13.4 %) were resistant on RPFA testing and 4 (10.5 %) were resistant 
on both (table 3.9). 
 
Of those who submitted a urine sample within 24 hours of last ingestion and were aspirin 
resistant on at least one test, 5 of 10 (50 %) had salicyluric acid levels of < 5 µg/ml.  For 
PFA-100, RPFA testing or resistance on both tests, this figure was 5 of 9 (55.6 %), 4 of 6 
(66.7 %) and 4 of 5 (80 %) suggesting that poor compliance accounted for a significant 
number of the cases of resistance seen. 
 
 Cases (n=39) Controls (n=32) P Value 95 % CI for 
Difference 
PFA-100 CEPI-CT 283.5 (202.8 to 
300) 
276 (186 to 300) 0.89 # -8.01 to 14.98 # 
Aspirin Resistance 
on PFA-100 * 
9 (23.7 %) 6 (18.8 %) 0.77 -23.7 to 15.1 % 
RPFA 485 (404.5 to 
522.5) 
451 (395.3 to 
498.5) 
0.49 # -54.9 to 20 # 
Aspirin Resistance 
on RPFA * 
5 (13.5 %) 5 (15.6 %) 1 -14.6 to 18.8 % 
Aspirin Resistance 
on Both Tests 
4 (10.5 %)  3 (9.7 %) 1  -15.1 to 13.4 % 
Aspirin Resistance 
on ≥ 1 Test 
10 (26.3 %) 8 (25.5 %) 1 -21.3 to 20.3 % 
Table 3.9. Platelet Function Analysis Results in Those With Evidence of Recent 
Aspirin Ingestion. P values and 95 % CI shown are for the difference between two 
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The Urine Sub-study - Controls 
A urine sample was submitted by 37 controls (41.1%).  The mean concentrations of 
salicyluric acid and salicylic acid seen in the urine were 110.1 (SD 90.1) µg/ml and 1.6 (SD 
2.74) µg/ml respectively. In total 32 (86.5 %) had levels of salicyluric acid above the pre-
specified level used to define evidence of recent aspirin ingestion (> 5 µg/ml). 
 
All controls who submitted urine samples did so within the hour. All participants stated 
compliance with their aspirin up to the day of recruitment and thus all were assumed to 
have submitted their urine sample on the same day as their last aspirin dose. Thus, only 5 
individuals (13.5 %) had no evidence of recent aspirin ingestion (sample submitted within 
24 hours of last stated aspirin dose and levels of salicyluric acid of < 5 µg/ml).   
 
When considering only those with evidence of recent aspirin ingestion, 8 (25.8 %) were 
aspirin resistant on at least one platelet function test. Of these, 6 (18.8 %) were resistant on 
PFA-100 testing, 5 (15.6 %) were resistant on RPFA testing and 3 (9.7 %) were resistant on 
both (table 3.9). 
 
No individual with salicyluric acid levels of < 5 µg/ml had evidence of aspirin resistance. 
 
The Urine Sub-study - Comparison Between Cases and Controls 
The rate of aspirin resistance, regardless of definition used was similar in both cases and 
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Agreement Between Platelet Function Tests 
Agreement between the aspirin responsiveness status measured by the different platelet 
function tests is shown in table 5.6. Overall, agreement between the two tests was fair 
(ĸ=0.35).  On sub analysis agreement was also fair in both the case and control population 
(table 3.10). A scatter plot of the individual patient data is shown in figure 3.3. 
 
 Kappa P Value 
Cases (PFA-100 vs RPFA) 0.39 <0.001 
Controls (PFA-100 vs RPFA) 0.27 0.007 
Cases and Controls (PFA-100 vs RPFA) 0.35 <0.001 
Table 3.10. Measures of Agreement Between Platelet Function Tests in Study Three. 
PFA-100 = Platelet Function Analyser 100. RPFA = Rapid Platelet Function Analyser. 



























Figure 3.3. Scatterplot of PFA-100 Measured Aspirin Responsiveness versus 
RPFA Measured Aspirin Responsiveness in Study Three. Each data point 
represents one individual. Values to the right of the vertical reference line 
represent resistance on RPFA testing while values below the horizontal reference 
line represent resistance on PFA-100 testing. ARU = Aspirin responsiveness unit. 
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3.05.3 Study Three Discussion 
Data from this study revealed a prevalence of aspirin resistance of 34 % in cases with 
recent stroke or TIA compared to 25 % in controls where resistance on one or more test 
was used as evidence of resistance. This difference did not reach statistical significance 
although resistance defined by PFA-100 testing or resistance on both tests was significantly 
higher in cases with recent stroke or TIA. However, when only those with objectively 
confirmed evidence of recent aspirin resistance were considered, the prevalence of 
resistance was similar in both groups.  A high proportion of cases who were resistant to 
aspirin had no evidence of recent aspirin ingestion despite stating they regularly took 
aspirin, suggesting that compliance accounts for some of the apparent difference seen 
between cases and controls. 
 
The fact that aspirin resistance appeared higher in cases than controls would fit with recent 
data suggesting that aspirin resistance links with a higher rate of cardiovascular events 
(274;276). However, previous case control studies have not yielded such differences 
between groups (352-354), although this is the first such study to examine participants with 
stroke and is the largest case-control study to date. Although the rate of aspirin resistance 
was higher in cases than controls, both were compatible with previous figures given in the 
literature (276-278) and in particular with previous studies using similar techniques 
(318;355-361). Thus, aspirin resistance, regardless of the definition used, is a common 
finding. There were some significant differences between the case and control groups. For 
example cases were older which links with a higher prevalence of resistance (362) although 
fewer were female or diabetic which is also linked with increased resistance (286;363). 
These factors could confound this analysis as these are also risk factors for cerebrovascular 
disease. 
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The majority of studies have attempted to assess participant compliance, including 17 of the 
20 studies in a recent meta-analysis (274). However, as well as the three studies which 
made no mention of compliance assessment (277;321;364), 3 relied upon verbal 
confirmation of compliance (as done in this study) (359;365;366) and the remainder 
involved hospital in-patients or supervised ingestion of aspirin (278;355-357;360;367-373) 
at baseline. However, it is well know that verbal means of compliance assessment may not 
accurately reflect whether medication has actually been taken and an objective means of 
assessment is preferable (374) but few studies have employed such methods to date (354).  
 
The importance of participant compliance cannot be overestimated. Approximately 10-40% 
of patients do not take prescribed anti-platelet tablets in the secondary prevention setting 
(292-296). These individuals will be highly likely to appear aspirin resistant on testing. 
Poor compliance has also been shown to be a major cause of aspirin resistance in previous 
studies; for example, just over half (367;375) to all (291) of apparent aspirin resistance has 
previously been shown to be due to poor participant compliance with therapy. 
 
This study utilized direct measurement of aspirin metabolites in the urine as an objective 
means of ensuring recent aspirin ingestion in a secondary analysis. However, there are also 
difficulties with this approach; aspirin is rapidly metabolized and metabolites may be fully 
excreted in the urine at around 24 hours after a single dose, although this is less likely to 
occur in those on long term therapy. Further, salicylates are endogenous compounds, 
although levels are much higher then normal following aspirin ingestion. A cut-off level of 
salicyluric acid of 5 µg/ml was used in this study with higher levels used to confirm recent 
ingestion and lower levels used to suggest poor compliance provided the urine sample was 
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submitted within 24 hours of the last stated aspirin dose.  It is hoped, given that participants 
were approached and recruited during a single attendance at a clinic or on admission for an 
acute vascular event that their compliance status reflects their normal behaviour; they could 
not have expected to participate in the study before attendance.  The rate of non-compliance 
seen may be an overestimate as individuals who rapidly metabolise and excrete aspirin and 
its metabolites could have undetectable levels of salicyluric acid and salicylate before 24 
hours has elapsed since last aspirin ingestion. However, results were similar when analysis 
was restricted to those who claimed aspirin ingestion within 12 hours of submitting a urine 
sample and those who take aspirin regularly (as all claimed in this study) excrete 
metabolites for longer in the urine.   
 
Despite the fact that all individuals in this study claimed compliance (and would thus have 
been recruited to many previous studies published in the literature), approximately 1/3 of 
cases met the definition of poor compliance with aspirin therapy. This further suggests that 
verbal statements of compliance are not reliable and that more objective measures should 
be mandatory in studies of aspirin resistance.  For example, in this study, over half of cases 
who submitted a urine sample within 24 hours of last ingestion and were aspirin resistant 
had salicyluric acid levels of < 5 µg/ml.  This suggests that poor compliance was an 
important cause of aspirin resistance in this group.  However, even when this was 
considered, resistance remained common and as in other studies, was highest with the PFA-
100 device at approximately 20%. 
 
Again in this study agreement between tests was only fair. This is in-line with work from 
other authors and has been discussed in chapter four.  
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In conclusion, data from this study suggests that aspirin resistance is a common 
phenomenon that merits further study but that poor compliance may contribute in a 
substantial number of cases of apparent resistance suggesting that objective measures to 
account for compliance should be mandatory in future studies of aspirin resistance. 
 
Chapter Summary 
The studies in this chapter have shown that the rate of aspirin resistance is higher in those 
with cerebrovascular microembolic signals (MES) and carotid disease compared to those 
with equivalent carotid disease and no MES. Approximately a quarter had MES and those 
with MES had a resistance rate of 50% compared to 17.4% in those without (p=0.018 on 
Fishers exact test). This provides a link to a well established and robust surrogate marker of 
outcome and thus a useful model to further study the benefits of guided anti-platelet 
strategies. Aspirin resistance was present in 34% of those with recent stroke and in 18% of 
those with risk factors but no established disease in a case-controlled study. However, the 
role of poor compliance with therapy as a cause in a substantial number of individuals was 
established; it accounted for approximately half of those labelled resistant in the stroke 
group. Further, when only those with objective evidence of recent aspirin ingestion were 
considered, the prevalence of aspirin resistance was similar in both groups (at 26%) and it 
remained a common phenomenon. Objective measures to confirm compliance with aspirin 
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4.01 Potential Novel Therapies – Lowering Serum Uric Acid 
 
The role of serum uric acid in the development of cardiovascular disease has been the 
subject of controversy for many years. Many studies concerning the association between 
increasing serum uric acid level and event rate and mortality in a variety of cardiovascular 
disease states have been published.  However, the presence of a causal relationship is less 
clear and elevated levels of uric acid may reflect a separate underlying disease process, 
atherosclerosis itself, or increased xanthine oxidase activity; all of which may influence 
vascular risk.   
 
4.01.1 Biochemistry of uric acid in man 
Uric acid is a breakdown product of ingested and endogenously synthesised purines (figure 
4.1).  DNA and RNA are degraded into purine nucleotides and bases, which are then 
metabolized, via the action of xanthine oxidase, to xanthine and uric acid.  These later steps 
are irreversible and generate superoxide anions.  Uric acid undergoes no further metabolism 
in humans and is excreted by the kidneys and intestinal tract.  In the kidney, it is filtered 
and can be subsequently reabsorbed or further excreted in the proximal tubule, 
predominantly under the action of a urate transporter (URAT1) (376). 
 




Serum levels are governed by the balance of production and excretion.  Production can be 
increased by several mechanisms including rare enzymatic defects, states of high cell 
turnover and alcohol ingestion (partly because of purines contained in alcoholic drinks 
(377;378)).  However, the majority of cases of elevated serum uric acid result from 
impaired renal excretion, possibly because of inter individual differences in function of the 
URAT1 transporter. 
 
4.01.2 Uric Acid as a Cardiovascular Risk Factor 
This has been evaluated in a number of studies. Studies have typically utilised data from 
randomised control trials or epidemiological databases and expressed results as change in 















Figure 4.1. Uric Acid Metabolism in Man 
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Cardiovascular Risk States 
In patients with diabetes, serum uric acid levels above the median (295µmol/l) have been 
associated with near double an increased risk of stroke (HR 1.91, 95 % CI 1.24-2.94) (380), 
while increasing uric acid levels were associated with increased prevalence of peripheral 
arterial disease in both a Taiwanese (381) and Australian cohort (382) (OR 1.004, 95% CI 
1.001-1.008 and 1.03, 95% CI 1-1.06, per additional 0.1mmol/l in serum uric acid 
respectively). 
 
In patients with essential hypertension, serum urate in the highest quartile was associated 
with increased cardiovascular event rate (HR 1.73, 95% CI 1.01-3),   cardiovascular 
mortality and all cause mortality (HR 1.63, 95% CI 1.02-2.57) (383).  A similar positive 
association was seen in the SHEP trial, where serum uric acid in the highest quartile 
conveyed an increased risk of cardiovascular events (HR 1.32 95% CI 1.03-1.69) but not of 
all cause mortality or stroke (384). Other large studies have shown that small increments in 
serum uric acid are associated with increasing incidence of cardiovascular disease and with 
cardiovascular death (385;386).  These associations persist despite adequate adjustment for 
confounding factors and other risk factors.  However, in the Syst-Eur study of hypertensive 
patients, a trend but no association was seen with cardiovascular events or mortality (HR 
1.06, 95% CI 0.99-1.13 and HR 1.03, 95% CI 0.93-1.14 per 50µmol/L increment in serum 
urate respectively) (387).  While the event rate was similar to that in other studies, the 
proportion of females was far greater, meaning it is possible that a gender effect has 
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Cardiovascular Disease 
In patients with stroke, increasing serum uric acid levels have been associated with a 
reduced likelihood of a favourable outcome and an increased risk of recurrent vascular 
events (OR 0.78, 95% CI 0.67-0.91 and RR 1.27, 95% CI 1.18-1.36 per additional 
0.1mmol/l in serum uric acid respectively) (388).  This association was more prominent in 
diabetic patients (389).  Elevated levels of serum uric acid in the early stages after acute 
stroke have also been associated with early clinical deterioration (390).  In patients with 
angiographically defined coronary artery disease, serum uric acid in the highest quintile 
(391) and quartile (392) has been shown to be predictive of all cause mortality (HR 1.5, 
95% CI 1.02-2.1 and HR 1.23, 95% CI 1.11-1.36 respectively). Increasing levels of serum 
uric acid have also been shown to strongly predict mortality, need for cardiac transplant and 
in-hospital mortality in those with cardiac failure (393;394).  Conversely, it has been shown 
that increased serum uric acid in the acute phase following stroke is associated with a good 
outcome (395); a finding that is addressed later.  
 
Healthy Populations 
The NHANES study (396) did show an association with each 59.5 µmol/l increment in 
serum uric acid leading to increased risk of cardiovascular events (HR 1.09, 95% CI 1.02-
1.18 in men) and cardiac mortality (HR 1.17, 95% CI 1.06-1.28 in men).  A yet more 
significant association was seen in women. However, a large analysis from the Framingham 
Heart study cohort found no association with cardiovascular mortality after adjustment for 
diuretic therapy (397) and a similar lack of association has been reported in other large 
studies of healthy individuals (398-400).  Lower event rates in such healthy populations 
may explain this inconsistency; larger sample sizes are required and some may have lacked 
power to detect an independent association 
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For An Association 
Reference Population Change in Outcome Measure 
(380) DM HR 1.91 (1.24-2.94) (serum uric acid >295umol/l) for 
risk of stroke 
(389) DM / stroke HR 1.49 (1.21-1.84) a  for recurrent CV event 
(388) Acute stroke RR 1.27 (1.18-1.36) a for recurrent CV events   
(390) Acute stroke Serum uric acid ↑ in those with early clinical 
deterioration (p=0.001) 
(391) CAD HR 1.5 (1.02-2.1) b  for all cause mortality 
(392) CAD HR 1.23 (1.11-1.36)c  for all cause mortality 
(384) ↑ BP HR 1.32 (1.03-1.69)b, for CV events 
(401) ↑ BP HR 1.22 (1.11-1.35)d for development of CV disease 
(386) 
 
↑ BP HR 1.14 (1.02-1.27)e  for CV mortality,  
HR 1.34(1.14-1.57)e for fatal stroke 
(383) ↑ BP HR 1.73 (1.01-3) b for CV event rates 
Against An Association 
(395) Acute stroke OR 1.12, 95% CI 1-1.25 per additional mg/dl uric acid 
for good outcome 
(387) 
 
↑ BP HR 1.03 (0.93-1.14)e for CV mortality 
HR 1.06 (0.99-1.13)e  for all CV events 
Results expressed as ratio and 95% CI. DM = Diabetes Mellitus, PVD = Peripheral 
Vascular Disease, CV = Cardiovascular, CAD = angiographic coronary disease, a = 
per additional 0.1mmol/l in serum uric acid, b =  for highest vs lowest quintile / 
quartile, c,d = per additional 0.6 and 0.86mmol/l in serum uric acid respectively,  e = 
for each 50µmol/L increment in serum urate   
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Summary / Gaps in the Epidemiological Evidence 
Most large, well-conducted epidemiological studies support the hypothesis that elevated 
serum uric acid is a powerful predictor of increased vascular event rate and mortality in 
patients with hypertension, diabetes and in those with known cardiovascular disease (table 
4.1).  The results in healthy populations are less consistent.  Despite this, the relationship 
with stroke rate and mortality is less clear; most studies have not specifically evaluated 
stroke mortality or have been limited by relatively low stroke rates (383;396).  Where it has 
been evaluated, only one Chinese study has shown a strong association (386) while others 
have not (384;387).  An association has been seen with stroke risk in patients with diabetes 
(380) and in a large observational cohort of patients aged > 55 years of age, although the 
association was less prominent in hypertensive individuals (402). The impact of serum uric 
acid on outcome in the acute period after stroke is also unclear. In a study of 2498 patients 
with acute stroke, increasing serum UA levels were associated with a reduced likelihood of 
favourable outcome at 90 days (OR 0.78, 95% CI 0.67-0.91 per additional 0.1 mmol/L UA) 
and an increased risk of recurrent vascular events (388), which were more prominent in 
those with diabetes (389). Some have suggested increased risk of early clinical 
deterioration following ischaemic stroke (390). However, a further study reported 
conflicting results: in 800 patients with acute ischaemic stroke, increasing UA levels were 
associated with a good outcome (OR 1.12, 95% CI 1-1.25 per additional mg/dl UA) at 
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4.01.3 An Innocent By-stander? 
Against a Direct Causal Association  
It is argued that elevated serum uric acid in those with cardiovascular disease simply 
reflects the presence of other risk factors such as hypertension or diabetes, diuretic 
treatment, impaired renal function, atherosclerosis itself or increased oxidative stress. 
 
Worsening renal function is associated with increased serum uric acid levels and increased 
burden of cardiovascular disease.  Markers of oxidative stress are increased in patients with 
chronic renal disease and are predictive of increased cardiovascular mortality (403;404). 
Successful renal transplantation (405-407) improves such markers.  Therefore, the 
association may simply reflect impaired renal function and the associated oxidative stress 
and cardiovascular risk.  While most studies have adequately adjusted for renal impairment, 
it cannot be excluded that raised uric acid levels reflect or contribute to sub clinical levels 
of renal impairment which contribute to the association in as yet undefined ways. 
 
Even in those with normal renal function, higher levels of uric acid may reflect higher 
levels of xanthine oxidase activity and oxidative stress.  This would also explain why serum 
uric acid levels rise after an ischaemic insult as discussed below. The action of xanthine 
oxidase leads to generation of superoxide anions, and is one of the principle sources of 
reactive oxygen species (ROS) in the human vasculature (408;409).  The molecular effects 
and importance of ROS in cardiovascular disease has already been extensively reviewed 
(410-413). In summary, once formed, superoxide anions can inactivate nitric oxide, leading 
to formation of peroxynitrite, which is also a strong oxidant.  This inhibits endothelium-
dependent vasorelaxation, limits the favourable effects of nitric oxide on platelet 
aggregation and vascular smooth muscle proliferation and causes oxidation of DNA and 
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lipids; all factors integral to development of atherosclerosis (414).  Under normal 
circumstances ROS production is usually countered by antioxidant defence mechanisms, 
including the action of superoxide dismutase (SOD) (415). 
 
As well as this putative role in atherosclerosis development, ROS production increases 
acutely following cerebral or cardiac ischaemia and may contribute to the degree and extent 
of tissue damage (416-418).  This hypothesis is supported by animal models of ischaemic 
stroke where SOD knockout mice exhibit greater lesion volumes after temporary middle 
cerebral artery occlusion (419-421), whereas SOD over expressing mice exhibit reduced 
lesion volume (422).  Infusion of SOD and catalase have led to a reduction in stroke lesion 
volume in a murine stroke model (423).  Human studies have also shown that locally 
increased oxidative stress and reduced peripheral antioxidant activity are associated with 
increased stroke lesion volume and a greater neurological deficit (424;425).  Similar work 
in animal models of myocardial infarction has suggested oxidative stress is associated with 
increased development of heart failure (426;427).  It is also likely that oxidative stress 
predisposes to development of heart failure after acute myocardial infarction in humans 
(428;429).  Thus, increased uric acid levels may simply reflect increased xanthine oxidase 
activity which may directly contribute to the development of atherosclerotic disorders and 
predispose to more severe vascular events. 
 
There is evidence that uric acid has antioxidant activity and that levels may rise after an 
ischaemic insult.  This has led to an alternate hypothesis that elevated serum uric acid 
represents a physiological, and perhaps protective, response to the oxidative stress that 
characterises many vascular disease states (430;431).  In a rat model of cerebral ischaemia, 
brain uric acid levels increased (432;433) and in a transient ischaemia model, infusion of 
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uric acid led to a reduction of infarct volume and improved behavioural outcome (433). 
This is further supported by data from a rat model of traumatic brain injury and a mouse 
model of multiple sclerosis, where uric acid was found to reduce formation of peroxynitrite 
radicals (434;435). In healthy human volunteers, uric acid administration has been shown to 
increase serum antioxidant capacity (436).  In a study of 800 patients with ischaemic stroke, 
admission serum uric acid was higher in those with a good outcome and increasing levels 
associated with a good outcome (OR 1.12, 95% CI 1-1.25 per additional mg/dl uric acid) 
(395).  This finding is in direct contrast to those of other studies (388-390).   
 
While these findings warrant consideration, the potential antioxidant properties of uric acid 
in vitro or in vivo should not be over-interpreted. Increased local tissue levels in animal 
models of ischaemia and brain injury may simply reflect the levels of oxidative stress and 
xanthine oxidase activity, and not an innate protective response.  The substance itself may 
well have antioxidant properties but its generation and associated superoxide anion 
production may be of much greater significance and detriment.  Even the intriguing 
findings that uric acid infusion may be protective in animal models of brain ischaemia do 
not imply that uric acid lowering strategies, and particularly those involving xanthine 
oxidase inhibition, could not have favourable effects in vivo. 
 
For a Causal Association 
Data from animal and in-vitro studies do raise the possibility of a direct causal mechanism 
for uric acid in cardiovascular disease which provides further support for the convincing 
epidemiological associations.  Monosodium urate crystals have been shown to stimulate 
release of the platelet constituents serotonin, ATP and ADP (437), while uric acid has been 
shown to stimulate rat vascular smooth muscle production in vitro (438).  Uric acid may 
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also increase oxygenation of LDL (439) and may have a causative role in the development 




4.01.4 Pharmacological intervention to Lower Uric Acid 
Several drugs are known to lower uric acid.  These either increase uric acid excretion 
(urosuric drugs), block the final step in uric acid production via xanthine oxidase inhibition 






















  O2 
Serum Uric 
Acid 
Figure 4.2 Potential Mechanisms by Which Elevated Serum Uric Acid is 
Related to Cardiovascular Disease and Potential Methods of Risk 
Reduction. Drugs and sites of action are shown in italic font, 
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probenecid and sulfinpyrazone, while fenofibrate (a fibrate) (443) and losartan (an 
angiotensin II antagonist) (444;445) also have urosuric activity.  Rasburicase is a 
recombinant urate-oxidase enzyme which converts uric acid to allantoin.  It is used in 
association with some anti-cancer treatments and is unsuitable for repeated dosing.  There 
are two commercially available xanthine oxidase inhibitors, allopurinol and oxypurinol.  
Allopurinol is rapidly metabolised to oxypurinol, which is an analogue of xanthine and 
preferentially binds to xanthine oxidase thereby inhibiting its activity (446).  Because of its 
action on both uric acid levels and xanthine oxidase activity, allopurinol is a logical drug to 
study in trials of cardiovascular risk reduction (figure 4.2).   
 
Allopurinol is generally well tolerated with few side effects.  Its major indication is in the 
prophylaxis of gout (447).  Side-effects typically comprise gastro-intestinal upset and 
rashes.  A rash develops in approximately 2 percent of patients and typically subsides after 
treatment is discontinued.  More serious side effects, such as generalised hypersensitivity, 
occur in less than 1 in 1000 cases and include exfoliative dermatitis, often with vasculitis, 
fever, liver dysfunction, eosinophilia, and acute interstitial nephritis (448).  The rate of 
adverse reaction is highest in patients with renal dysfunction and rashes are more common 
with concurrent amoxicillin therapy (449;450).  There is a known interaction with 
azathioprine and 6-mercaptopurine therapy and some rare reports of cytopenia. This side-
effect profile is comparable to that of commonly used secondary preventative agents such 
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4.01.5 Uric Acid Lowering Drugs and Cardiovascular Risk 
Three drugs known to reduce cardiovascular mortality have been shown to reduce serum 
uric acid.  This may explain some of their beneficial effect but changes in other risk factors 
such as renal function and blood pressure may explain both the beneficial effects and 
changes in uric acid levels. 
 
Fenofibrate is a fibric acid derivative known to reduce total and LDL cholesterol by 
approximately 15% with a similar increase in HDL cholesterol and with larger reductions 
in triglyceride levels (454).  Fibrates reduce incidence of cardiac events in dyslipidaemic 
patients (455) and in those with coronary disease (456).  These benefits may be greatest in 
type two diabetics (457) where they have been shown to reduce atherosclerosis progression 
(458) and total vascular events (459).  Fenofibrate reduces serum uric acid levels (via 
increased renal excretion) by as much as 46% in healthy volunteers, hypertensive and 
diabetic patients and those with gout on specific urate lowering therapy (460-462).  This 
may provide adjunctive efficacy in the treatment of gout when combined with allopurinol 
(463;464) and may contribute to the reduced vascular risk associated with fibrate therapy.  
This effect is not seen with other fibrates (465) and its mechanism is elusive although 
unlikely to be mediated by improvements in renal function (466). 
 
Losartan is an angiotensin II receptor antagonist which is superior to atenolol in the 
prevention of cardiovascular events when given to hypertensive patients with left 
ventricular hypertrophy (467).  Losartan is known to increase renal uric acid excretion 
(468) (by as much as 30%), thereby causing significant reductions in serum uric acid (469).  
This mediated via effects on the urate/anion transport mechanism in the renal proximal 
tubule (470). This is not a class effect; other angiotensin II antagonists have little or no 
 - 158 - 
effect on serum uric acid excretion (471).  Up to 29% of the 13% relative risk reduction 
seen with losartan use in the LIFE study has been attributed to its effect on serum uric acid 
(472).  Serum uric acid increased with both atenolol and losartan use in the LIFE study, but 
the increase was significantly less with losartan.  Whether this does underpin much of the 
benefit of losartan and whether it can attenuate the possibly detrimental effects of diuretics 
on uric acid requires further clarification.  Although the effect was independent of measures 
of renal function, treatment with ACE blockade or angiotensin II antagonists do reduce 
levels of oxidative stress (473) which could itself account for this added benefit. 
 
Statin therapy has also been shown to lower serum uric acid.  In the GREACE study, 
atorvastatin was associated with a fall in serum uric acid (by 8.2%), whereas serum uric 
acid increased in those patients allocated to the placebo group (by 3.3%).  After extensive 
adjustment of several risk factors including change in renal function, each 60µmol/l 
reduction in serum uric acid was associated with a reduction in vascular event rates (HR 
0.76, 95% CI 0.62-0.89) (474).   A fall in serum uric acid has been mirrored in other studies 
of statin therapy (149;475) but typically in association with improvements in serum 
creatinine.  Atorvastatin however, has repeatedly been shown to lower uric acid (by 6.4%) 
in other studies (476) even after adjustment for renal function, possibly because of 
decreased uric acid production (477).  As yet, this has not been adequately studied and 
cannot be assumed to explain some of atorvastatin’s effects, although it may represent a 
further beneficial effect. 
 
Specific Intervention to Lower Serum Uric Acid and Xanthine Oxidase Inhibition 
The effect of xanthine oxidase inhibition on measures of endothelial and cardiovascular 
function has also been tested in a number of small studies, performed in the context of 
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diabetes, hypercholesterolaemia, hypertension, elevated 10 year cardiovascular risk, sleep 
apnoea, angiographically confirmed cardiovascular disease, stroke and heart failure.  A 
recent systematic review performed by myself has identified 22 such studies (478-498). A 
summary of the findings is given below and in table 4.2. 
 
Study design has varied using either oral or intravenous xanthine oxidase inhibition with 
differing treatment duration. For example, seven studies (478;480;486-488;493;495) 
utilised a single dose of allopurinol or oxypurinol. In other studies duration of therapy was 
one week (480), two weeks (491;492;498), one month (481;483;484;490;494;497), six 
weeks (489), two months (479), three months (482;496) and six months (485).  Some 
studies were open label (478;480;486-488;493;496), others employed a cross over design 
(479-482;490;494;495;498) and the remainder were randomised controlled trials (483-
485;489;491;492;497).  
 
The populations studied have varied. There have been nine studies in heart failure or 
cardiomyopathy (478-486), two in those with established cardiac disease (487;488), three 
in those with diabetes (490-492), one in those with stroke (489), two in those with 
hypercholesterolaemia (493;494), one in those with the metabolic syndrome (497), one in 
smokers (495), one in those with hyperuricaemia and elevated Framingham risk score (496) 
and one in those with sleep apnoea (498).  
 
The endpoints assessed also varied. Six studies reported changes in forearm blood flow 
responses following acetylcholine infusion (480;483;490;493-495) with similar measures 
of limb blood flow responses assessed in a further four studies (480;496-498). Three 
studies assessed changes in blood markers of oxidative stress (491;492) and inflammatory 
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activity (489) while further studies evaluated change in BNP levels (482), exercise 
tolerance (482;484) and myocardial efficiency, contractility and function (486) 
(478;484;488). Others reported effects on heart rate variability parameters (479), coronary 
vasoconstrictor activity (487) and in one study, a clinical endpoint of change in clinical 
status in those with chronic heart failure was assessed (485).  
 
Improvements in endothelial function following allopurinol have been shown in patients 
with type II diabetes and mild hypertension (490).  Endothelial function, expressed as 
percentage change in ratio of infused forearm blood flow (FBF) compared to non-infused 
arm FBF in response to intra-arterial acetylcholine infusion, was found to return to near 
normal following one month of 300mg allopurinol treatment.  No effect was seen on 
control patients. Using similar methods, a single oral dose of allopurinol was found to 
improve peripheral endothelial function towards normal in smokers but had no effect in the 
non-smoking control group (495).  The rapidity of the improvement strongly suggests that 
xanthine oxidase is a key contributor to the endothelial dysfunction seen in smokers.  
Further study in those with diabetes has suggested improvement in markers of oxidative 
stress (491;492).  
 
Improvement in forearm endothelial function has also been seen in patients with 
hypercholesterolaemia following intra-arterial administration of oxypurinol (493) but this 
was not replicated in a similar but smaller study of 4 weeks oral allopurinol treatment (494).  
It is possible this later study was underpowered; the power calculation was based upon the 
effect size seen following 3 months of simvastatin treatment (499).  The anticipated 
treatment effect was larger than that seen in other studies of allopurinol use, while the effect 
seen in this study at one month, was more similar and approximately half this.  
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Forearm blood flow responses, expressed as ischaemia induced change in brachial artery 
diameter, were also improved by a three month course of allopurinol in a group of patients 
with elevated 10 year cardiovascular risk (496) and hyperuricaemia.  A recent study in 
patients with stable coronary artery disease (487) showed that intravenous administration of 
oxypurinol improved both peripheral endothelial function and coronary endothelial 
function (expressed as the coronary vasoconstrictor response to acetylcholine and changes 
in coronary blood flow) in those with impaired baseline function. A similar study showed 
an improvement in left ventricular function in those with IHD (488). 
 
Intra-coronary infusion of oxypurinol has been shown to reduce myocardial oxygen 
consumption, probably via preserved nitric oxide bioactivity, and to significantly increase 
myocardial efficiency measurements in those with heart failure (478). In a further study a 
single intravenous infusion (486) and a one month course of 600 mg allopurinol (484) 
improved left ventricular ejection fraction. Further, both an intravenous infusion (480), a 
one month 300 mg oral course (481) and a six month 600 mg oral course (483) of 
allopurinol have been shown to improve a variety of measures of peripheral endothelial 
function in patients with heart failure.  Recent work has shown that B-type natriuretic 
peptide concentrations are reduced by a three month course of oral allopurinol (482) but no 
improvements in exercise tolerance were demonstrated, while in previous study no change 
in heart rate variability parameters was seen (479). 
 
Results from the largest study to date were disappointing. In the OPT-CHF trial (485), 405 
participants with heart failure were randomised to receive either oxypurinol 600 mg or 
placebo for 6 months. The primary endpoint was defined as a change in clinical status 
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based upon changes in a variety of parameters; mortality, heart failure related 
hospitalisations, need for therapy escalation, New York Heart Association functional class 
and Patient Global Heart Failure Clinical Status. There was no difference in the proportion 
of patients who improved or worsened between treatment groups (43.3% improved with 
allopurinol compared to 45%) with placebo while 32% and 35.6%) remained the same and 
24.6% and 19.3% worsened (p = 0.42)). However, post-hoc analyses suggested that in 
those with elevated serum uric acid, oxypurinol improved clinical status, whereas the 
opposite occurred in those with lower uric acid levels. In the oxypurinol cohort as a whole, 
those who improved had significantly greater reductions in serum uric acid levels than 
those who worsened. These findings are difficult to interpret. On the one-hand the post-hoc 
analyses suggest benefit in those with high uric acid levels and that the greater the fall 
following oxypurinol in such patients, the better the outcome, they also raise the possibility 
that oxypurinol can cause harm in some. 
 
Potential Significance of These Studies 
Abnormalities in peripheral and coronary arterial responses are accepted to signify 
endothelial dysfunction and are associated with other markers of cardiovascular disease 
(500). Improvements in these parameters have been shown to follow treatment with 
thiazolidinediones (501;502) and agents such as ACE inhibitors (503-505), HMG COA 
reductase inhibitors (502,505-509), and amlodipine (503).  Most of these agents have been 
shown to be effective in reducing cardiovascular event rates and mortality. While direct 
comparisons are flawed and difficult, the magnitude of the changes effected by xanthine 
oxidase inhibition seems comparable to those caused by these agents (bar the exception 
outlined above) (472;505;506;510).  Further, the reductions in BNP levels seen were 
comparable to those induced by ACE inhibition, angiotensin II antagonists (511), beta-
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blockade (512) and spironolactone (513).  It is therefore possible, but entirely speculative, 
that allopurinol could have a similar impact on clinical outcomes as these agents.  The side 
effect profile of allopurinol is also comparable to other treatments but the cost is not; 
allopurinol is cheap making it an attractive preventative treatment. 
 
Data have shown that following stroke, each additional 0.1 mmol/l increase in serum uric 
acid is associated with a 27% increased relative risk of a recurrent cardiovascular event 
(388). Data also show that following stroke, 300 mg allopurinol causes a sustained  
reduction in serum uric acid from a mean of 0.35 mmol/L (SD 0.09) to 0.22 mmol/L (SD 
0.05) (unpublished data).  Using a secondary prevention stroke trial as an example, it would 
therefore be reasonable to expect a 27% relative risk reduction in cardiovascular event rate 
with this treatment.  With a predicted cardiovascular event rate of 6/100 patient years, or 
16% over 3.5 years (as used to design and seen in the recent ESPRIT trial (138)), 
approximately 3000 patients would be required to be followed for a mean of 3 years to 
confirm this benefit.  It is important to remember that this figure may actually be less 
because the beneficial effects of allopurinol on endothelial function would be expected to 
contribute to the treatment effect regardless of changes in uric acid. For example, in those 
studies involving a single dose of allopurinol or oxypurinol which showed benefit, the 
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Ref. Population Intervention Change Following Treatment 
(480) CHF, ↑ uric acid Intra-arterial infusion 
of allopurinol 
Improvement in FEF  *  
(480) CHF, ↑ uric acid 1 week allopurinol 
300mg † 
Improvement in lower limb 
endothelial function. 
(482) CHF 3 months allopurinol 
300mg † 
Fall in BNP levels from baseline.  
No change in exercise tolerance 
(481) CHF 1 month 300mg 
allopurinol  † 
Improvement in FEF *  
(484) CHF 1 month oxypurinol 
600 mg 
Increase in LVEF 
(486) CHF Single intra-venous 
oxypurinol infusion 
Increase in LVEF 
(485) CHF 6 months oxypurinol 
600 mg 
No change in functional status 
(479) CHF 2 months allopurinol 
300 mg 
No change in heart rate variability 
parameters 
(478) Idiopathic DCM Intra-coronary infusion 
of allopurinol 
Reduction in MVO2. Increase in 
myocardial efficiency 
(488) CHD and LVSD Single intra-venous 
oxypurinol infusion 
Increase in LVEF and reduction in 
end systolic ventricular volume 




Attenuation of coronary 
vasoconstrictor response * and 
increase in coronary blood flow 
CHF = congestive cardiac failure. FEF = forearm endothelial function. BNP = brain 
natriuretic peptide. DCM = dilated cardiomyopathy. MVO2 = Myocardial O2 consumption. 
LVSD = left ventricular systolic dysfunction. * = in response to intra-arterial Ach infusion, 
† = cross over design, § =  control arm, || = ischaemia induced % change in BA diameter. 
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Ref. Population Intervention Change Following Treatment 
(489) Acute ischaemic 
stroke 
6 weeks allopurinol 
(300 or 100 mg) § 
Reduction in ICAM-1 levels 
following 300 mg allopurinol 
(490)  Type 2 DM 1 month 300mg od 
allopurinol  †§ 
Improvement in FEF  * 
(491) Type 1 DM 2 weeks  allopurinol 
300 mg 
Reduction in GSSG/GSH 
(492) Type 2 DM 2 weeks allopurinol 100 
mg 
Reduction of lipid peroxidation 
and total antioxidant power in 
blood / saliva 
(493) ↑ cholesterol, ↑ 
BP 
Single infusion of 
oxypurinol  § 
Improvement in FEF  * in ↑ 
cholesterol  patients  
(494) ↑ cholesterol 4 weeks 300mg 
allopurinol † 
No change in FEF * 
(495) Smokers Single 600mg po dose 
allopurinol †§ 
Improvement in FEF  * 
(496) ↑ uric acid, ↑ CV 
risk. 
3 months 300mg 
allopurinol § 
Improvement in FEF  || 
(497) Metabolic 
Syndrome 
1 month allopurinol 
300 mg 
Increase in FBF ¥ respective to 
baseline (3.8±0.1 %, p<0.01)  
(498) OSA 2 weeks allopurinol 300 
mg 
Improvement in FEF *,‡ 
DM = diabetes mellitus. FEF = forearm endothelial function.* = in response to intra-
arterial Ach infusion, † = cross over design, FBF = forearm blood flow, § =  control arm, 
|| = ischaemia induced % change in BA diameter. OSA = obstructive sleep apnoea. 
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Gaps in the Clinical Trial Data 
 
There are no adequately powered clinical endpoint trials of uric acid lowering strategies 
such as xanthine oxidase inhibition and there are no small scale studies in patients with 
stroke or that examine markers of cerebrovascular health. 
 
Summary 
The epidemiological evidence to support a role of elevated serum uric acid in 
cardiovascular disease is cogent.  These associations are seen across healthy populations 
(albeit less consistently), those with cardiovascular risk factors and in those with 
established cardiovascular disease.  While a clear pathophysiological role for uric acid in 
the development of cardiovascular disease has yet to be established, there are data to  
support detrimental and prothrombotic effects on platelet and endothelial function.  Post-
hoc analyses suggest that some of the beneficial effects of proven treatments for 
cardiovascular disease may be due to changes in serum uric acid level study. (458;472;474).  
Furthermore, xanthine oxidase mediated oxidative stress is likely to have a significant role 
in the development of atherosclerosis and several small studies have shown that xanthine 
oxidase inhibition improves endothelial function and markers of oxidative stress in a 
variety of disease states (478;480-482;487;488;490;493-496), although not yet with regard 
to markers of stroke risk or in those with stroke.  Thus, even if serum uric acid is simply a 
marker of oxidative stress, there is a wealth of epidemiological, animal and now clinical 
data to suggest the benefits of strategies to lower uric acid and inhibit xanthine oxidase.  
Data from the OPT-CHF study raise the possibility that benefit may only be seen in those 
with elevated serum uric acid and that treatment may be detrimental in those with low 
serum uric acid. Large scale trials with clinical endpoints are justified to address this 
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important question in the context of heart failure, coronary disease and in broader 
categories of cardiovascular risk.  Despite being an old drug, allopurinol may prove to be a 
cheap, effective and novel preventative therapy for the 21st century. 
 
4.02 Chapter Aims and Hypothesis 
 
The hypothesis was that elevated serum uric acid would be associated with a poor outcome 
following acute stroke; that it would be associated with increased stroke risk in those with 
hypertension; and that use of allopurinol would improve cerebrovascular health in a 
primary and secondary prevention cohort. The aim was therefore to evaluate the association 
between serum uric acid and functional outcome after stroke (study one) and the 
association between serum uric acid and stroke risk in hypertensive patients (study two) 
and to test whether allopurinol, the most widely used uric acid lowering drug, improves 
cerebrovascular health in those with diabetes (study three) and recent subcortical stroke 
(study four).   
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4.03 Study One - Baseline Serum Uric Acid and 90-Day Functional Outcomes 
Following Acute Ischaemic Stroke 
 
The study hypothesis was that elevated serum uric acid would be associated with a poor 
outcome following acute stroke. A retrospective analysis of clinical trial data was 
performed to test this. 
 
4.03.1 Study One Methods 
The relationship between serum uric acid measured early after stroke and 90-day outcome 
were evaluated using data from the Virtual International Stroke Trials Archive (VISTA) 
resource. Full details of the VISTA resource are described elsewhere (514). Briefly, VISTA 
represents an archive of either complete datasets or the placebo component from clinical 
trials in acute stroke. The original data can be searched to select trials and/or patients 
fulfilling certain selection criteria or with fields containing certain information, such as 
serum uric acid level or functional outcome. Analyses on natural history are encouraged but 
exploration of treatment effects is prevented; in some cases trial datasets were donated 
under confidentiality rules that preclude identification of the trial in published analyses. 
The VISTA dataset continues to expand, but at the time of access for this study it contained 
data from 15 trials and over 15,000 patients. 
 
Data were extracted from the VISTA dataset, where serum uric acid had been measured 
during conduct of an acute stroke trial within 6 hours of symptom onset. Only a single trial 
in VISTA routinely measured baseline uric acid.  All patients had ischaemic stroke 
confirmed by brain imaging and baseline stroke severity (Scandinavian Stroke Scale (SSS)) 
(515) and demographic details were recorded. Follow up was for 3 months at which point 
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Descriptive statistics were used to describe the population with mean (±SD) and or number 
(%) used. Poor outcome was defined as death or dependency at 90 days (modified Rankin 
scale (mRs) (516) score > 2 or death within 90 days). Uric acid levels were converted to 
mmol/l. The relationship between baseline differences (including uric acid) and poor 
outcome was assessed and univariate differences between groups were explored. The 2 test 
(binary variables) and Student’s t test (continuous variables) were used. Univariate  and 
then multivariate logistic regression analysis was performed to assess the relationship 
between uric acid and outcome and to control for variables that differed significantly 
between outcome groups or that are known to predict stroke outcome. Natural logarithmic 
transformations of data were employed when exploratory analyses showed these to be 
merited. The linearity assumption was verified using the Box-Tidwell test. 
 
Patients known to be alive at day 90 but for whom the mRs grading was unknown were 
excluded from the regression analyses. Sensitivity of the findings to this assumption was 
investigated by repeating the analyses twice, with missing scores entered as good and poor 
outcomes respectively. Mean values were imputed where data were missing for continuous 
variables. 
 
All statistical analyses were performed using Minitab version 15 (Minitab inc. PA, USA).  
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4.03.2 Study One Results 
 
In total, 852 patients were included. Mean age was 68 (±12) years and 524 participants 
(61.5%) were male. Mean baseline SSS was 27 (±9.2), mean systolic blood pressure was 
160 (±27) mmHg and mean diastolic blood pressure 88 (±15) mmHg. Mean baseline uric 
acid was 0.35 (±0.11) mmol/l. These and other baseline characteristics are shown in table 
4.3.  
 
Age, years 68.3 (12.1) 
Male 524 (61.5) 
SSS, units 27 (9.2) 
SBP, mmHg 160.5 (27) 
DBP, mmHg  88.4 (14.9) 
Creatinine (µmol/l) 92.7 (24.3) 
Cholesterol (mmol/l) 5.6 (1.2) 
Glucose (mmol/l) 7.57 (2.9) 
Uric Acid (mmol/l) 0.35 (0.11) 
Ischaemic Heart Disease 165 (19.4%) 
Diabetes Mellitus 164 (19.3%) 
Hypertension 467 (54.8%) 
Atrial Fibrillation 156 (18.3%) 
Congestive Cardiac Failure 74 (8.7%) 
Table 4.3 – Study One Baseline Demographic Variables. Expressed as n (%) for 
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Outcomes 
Eleven patients could not be assigned to an outcome group as they were known to be alive 
but had no day 90 mRs score recorded. Four patients had no age recorded, 8 had no 
baseline measurement of heart rate and 2 had no baseline blood pressure measurement.  At 
90 days, 434 patients (51.6%) had suffered a poor outcome, 141 of whom had died. 
 
Univariate Analysis 
On univariate analyses (table 4.4), greater age, lower baseline SSS, higher systolic blood 
pressure, higher serum glucose, higher serum creatinine, female sex, a history of 
hypertension, atrial fibrillation, diabetes mellitus and cardiac failure were associated with 
increased odds of a poor outcome, as were greater serum uric acid levels  (OR 1.57, 95% CI 
1.02-2.42). Natural logarithmic transformation of data was utilized for serum uric acid, 
creatinine and glucose levels. 
 
Variable Coefficient OR CI P 
Uric Acid * 0.451001 1.57 1.02-2.42 0.042 
Age 0.0381584 1.04 1.03-1.05 < 0.001 
Male -0.307936 0.73 0.56-0.97 0.015 
BSSS -0.136462 0.87 0.85-0.89 < 0.001 
Creatinine * 0.784949 2.19 1.26-3.82 0.006 
SBP 0.0065294 1.01 1-1.01 0.012 
Glucose * 1.03505 2.82 1.8-4.41 < 0.001 
Hypertension 0.309976 1.36 1.04-1.79 0.026 
AF 0.697322 2.01 1.4-2.89 < 0.001 
CHF 0.511970 1.67 1.02-2.74 0.04 
Table 4.4. Relationship Between Baseline Variables and Stroke Outcome on 
Univariate Analysis. * = natural logarithmic transformation employed. 
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Multivariate Analysis 
Multivariate analysis revealed that only greater age, lower baseline SSS and higher serum 
glucose and systolic blood pressure were independently associated with a poor outcome 
(table 4.5). Uric acid level was not independently associated with poor outcome (OR 1.3, 
95% CI 0.73-2.31 (for log transformed data)). 
 
Variable Coefficient OR CI P 
Age 0.0273775 1.03 1.01-1.04 0.001 
Uric Acid * 0.234900   1.3 0.7-2.31 0.42 
Male -0.215531 0.81 0.56-1.15 0.24 
BSSS -0.135167 0.87 0.85-0.89 < 0.001 
Creatinine * 0.303908 1.36 0.65-2.84 0.42 
SBP 0.0084116 1.01 1-1.01 0.01 
Glucose * 0.775222 2.17 1.29-3.66 0.004 
Hypertension -0.0091985 0.99 0.7-1.4 0.96 
AF 0.217369 1.24 0.8-1.92 0.33 
CHF 0.0750884 1.08 0.6-1.95 0.80 
Table 4.5. Relationship Between Baseline Variables and Stroke Outcome on 
Multivariate Analysis. * = natural logarithmic transformation employed. 
 
Results were similar whether the 11 missing mRs scores were substituted by good or poor 
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Variable OR # CI # OR (*) CI (*) 
Age 1.03 1.01-1.04 1.02 1.01-1.04 
Uric Acid * 1.41 0.8-2.49 1.28 0.73-2.26 
Male 0.84 0.59-1.19 0.79 0.56-1.13 
BSSS 0.88 0.86-0.9 0.87 0.85-0.89 
Creatinine * 1.19 0.57-2.48 1.45 0.69-3.02 
SBP 1.01 1-1.01 1.01 1-1.01 
Glucose * 1.10 1.04-1.16 1.95 1.18-3.24 
Hypertension 0.97 0.69-1.37 0.99 0.71-1.4 
AF 1.18 0.77-1.82 1.3 0.84-2 
CHF 1.09 0.61-1.96 1.08 0.6-1.94 
Table 4.6. Relationship With Poor Outcome (mRs > 2) – Multivariate Sensitivity 
Analysis. Missing outcome data assumed to represent poor (#) or good (*) outcome 
respectively. * = natural logarithmic transformation employed. 
 
 
4.03.3 Study One Discussion 
 
This study failed to demonstrate an independent association between serum uric acid and 
day 90 functional outcome after acute ischaemic stroke.  An association was seen between 
increasing uric acid levels and odds of poor outcome on univariate analyses but not on 
multivariate analysis. It is however possible given the upper limit of the 95% confidence 
intervals that such an association does exist. 
 
This study used a robust dataset from a large, rigorously monitored randomized controlled 
trial with near complete ascertainment (98.7%) of 90-day functional outcomes.  Data 
collection was restricted to studies where uric acid was measured acutely within a known 
time frame and where modified Rankin scale scores were measured. All patients were 
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recruited and enrolled with a mean time of 4.5 hours from ictus and all those included in 
this analysis had baseline serum uric acid and stroke severity measured. The group included 
a wide range of ages and outcomes similar to those seen in other large trials (517). 
Reassuringly, variables such as increasing age, blood pressure, serum creatinine and worse 
baseline stroke severity predicted poor outcome as has been shown previously. By using 
day 90 mRs as the outcome measure, results of this study can be readily interpreted in a 
fashion that is clinically relevant and meaningful. However, the fact this was a clinical trial 
population is also a potential weakness - the patients are naturally highly selected and thus 
not guaranteed to be truly representative of the wider population.  Log transformations of 
data were utilized because exploratory analyses suggested it appropriate and, while this 
makes direct comparison with other work difficult, it was appropriate.  A further potential 
weakness is that the analysis was based upon a single measurement of uric acid and small 
intra-individual variation in uric acid levels is known to occur (518). This will reduce the 
apparent strength of any association. However, in a study of the potential role of uric acid 
in the acute setting, a spot measurement is the most relevant. 
  
The literature to date overwhelmingly supports an association between elevated serum uric 
acid and increased incidence of cardiovascular events and mortality (519). More 
uncertainty surrounds the relationship between levels of serum uric and likelihood of 
recovery after stroke. As mentioned, it has been previously demonstrated that higher uric 
acid measured early after stroke is independently associated with reduced likelihood of a 
favourable outcome, an increased risk of recurrent vascular events (388) and an increased 
risk of early clinical deterioration (390). Others have shown increasing uric acid to be 
independently associated with increased odds of good outcome at 7 days (395). This study 
showed an association between increasing serum uric acid and increased odds of poor 
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outcome on univariate analysis but, given the results of multivariate analysis, does not 
support any of the previous findings.  
 
These differences are intriguing. This and previous studies have used similar techniques, 
first exploring univariate differences between outcome groups then using multiple logistic 
regression to control for factors known to influence outcome. There were, however, 
differences in trial methodology that may explain this apparent discrepancy. Previous 
studies were retrospective analyses of registry datasets with differing endpoints. For 
example, one previous analysis utilized placement at 90 days (alive, placed in own home or 
care or dead) as the outcome measure whereas work suggesting benefit of elevated uric acid 
utilized day 7 Mathew scale score. Both these have potential drawbacks; placement at 90 
days could be confounded by socioeconomic factors, while the Mathew scale is poorly 
validated and day 7 outcomes are less informative than those at day 90. The present study is 
the first analysis from a clinical trial utilizing the most widely accepted and utilized 
measure of functional outcome available. These data raise the possibility that no such 
independent association exists, although the estimated odds ratio is similar to that found in 
previous work and the confidence intervals overlap; it may be that the study had limited 
statistical power to detect an independent effect of the magnitude found in previous studies. 
 
Regardless, these findings do not discount the possibility that uric acid reduction is a viable 
and promising strategy to reduce cardiovascular risk. Uric acid contributes to several key 
stages of the atherosclerotic process and may have detrimental effects on platelet, 
endothelial and smooth muscle cell function (438;440;520;521) and may have a role in the 
development of MRI detected ischaemic cerebral white matter hyper-intensities (522).  
These findings support the notion that elevated serum uric acid will increase cardiovascular 
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event rate and could link with worse outcome after stroke. On the other hand, uric acid is 
widely accepted to have antioxidant activity and some speculate that elevated levels may be 
a beneficial response to the oxidative stress that characterises vascular disease states (430).  
This may apply in ischaemic stroke: brain uric acid levels increase in a rat model of 
permanent cerebral ischemia (432;433) and infusion of uric acid reduces infarct volume and 
improves behavioural outcome in a rat transient ischemia model (434). Human data also 
support the antioxidant properties, where uric acid administration has been shown to 
increase serum antioxidant capacity in healthy volunteers (436) and reduce markers of 
oxidative stress in those treated with thrombolytic therapy for acute ischaemic stroke (523). 
Temporary iatrogenic hyperuricaemia may afford the beneficial antioxidant effects of uric 
acid without the detrimental effects of chronically elevated levels on the vasculature.  
 
In summary, this study found no significant independent association between serum uric 
acid level soon after ischaemic stroke onset and 90-day outcome. Prospective trials are 
needed to clarify the role of uric acid management in the post stroke period and as a 
preventative measure in cardiovascular disease. 
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Study Two - Serum Uric Acid and Stroke Mortality in Patients with Hypertension 
 
The study hypothesis was that elevated serum uric acid would be associated with increased 
stroke risk in those with hypertension. A retrospective analysis of a large registry dataset 
was performed to test this. 
 
4.04.1 Study Two Methods 
 
The relationship between serum uric acid and mortality in a group of hypertensive patients 
domiciled in the West of Scotland was evaluated. Data from the Glasgow Blood Pressure 
Clinic were used. This is a secondary and tertiary referral centre for patients from the West 
of Scotland area.  Patients are reviewed at least annually.   Demographic and clinical data 
are routinely gathered on all patients and entered into a computer database, which currently 
holds data on those who have attended since November 1967. The study design was 
evaluated by and approved by the West Medical Research Ethics Committee, who felt 
formal application and review were unnecessary. 
  
Subjects are followed up by record linkage (524) to death records held and supplied by the 
Registrar General of Scotland, which provide accurate causes of death.  Causes of death are 
described according to the ninth and tenth revisions of the World Health Organisation 
International Classifications of Diseases (ICD-9 and ICD-10).  The primary outcome event 
was defined as death due to stroke (ICD-9 430-438). Secondary outcomes were total 
mortality, coronary heart disease mortality (ICD-9 410-414.9) and total vascular mortality 
(stroke, coronary (defined above) and peripheral vascular disease deaths (440-447.6). 
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Statistical Analysis 
Descriptive statistics were used to describe the population with mean (±SD) or number (%) 
used.  Baseline demographic variables and outcomes were compared between those who 
had uric acid levels measured compared to those who did not. The relationship between 
baseline differences (including uric acid) and the primary outcome was assessed and 
univariate differences between groups were explored. The 2 test (binary variables) and 
Student’s t test (continuous variables) were used. The average serum uric acid throughout 
the study was used for analyses. Average levels of blood pressure and other blood 
parameters were also used. 
 
A Cox proportional hazards model was used to assess the relationship between last 
measured uric acid and primary outcome after adjustment for differences between the 
groups or other factors which may influence occurrence of the primary outcome. All 
statistical analyses were performed using SPSS software – version 11.5.  Results of the Cox 
proportionally hazard modeling are expressed as hazard ratios with 95% confidence 
intervals. The same statistical procedures were followed for the secondary outcomes.  The 
risk between uric acid and stroke mortality appeared J-shaped so further analysis based 
upon uric acid quintiles was performed. 
 
4.04.2 Study Two Results 
 
Data from 11,399 hypertensive patients who attended the clinic between 6th November 
1968 and 23rd April 2003 were analysed. Uric acid results were available for 6202 patients 
(54.4%). The date of the last record linkage was 10th July 2004. Mean follow up duration 
was 184 (SD 93.7) months with a median of 175 months. Baseline demographic variables 
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are shown in table 4.7. Those who had serum uric acid levels measured were less likely to 
be smokers, more likely to be diabetic, hyperlipidaemic, have established vascular disease 
and to be taking anti-hypertensive therapy. Mean blood pressures and mean cholesterol 
levels were however lower.  
 
Variable Whole Group 
n = 11399 
Uric Acid 
Measured 
n = 6202 
No Uric Acid 
Measured 
n = 5197 
P Value 
Age; years 49.3 (13.7) 49.1 (13.4) 49.5 (14) 0.06 
Male Sex 5482 (48.1%) 2949 (47.5%) 2533 (48.7%) 0.21 
Smoker 3313 (29.1%) 1728 (27.9%) 1585 (30.4%) 0.002 
Cholesterol > 5 mmol/l 7444 (65.3%) 4355 (70.2%) 3089 (59.7%) <0.0001 
Diabetes Mellitus 545 (4.8%) 363 (5.9%) 182 (3.5%) <0.0001 
IHD 523 (4.6%) 301 (4.9%) 222 (4.3%) 0.14 
CVA 345 (3%) 204 (3.3%) 141 (2.7%) 0.07 
PVD 470 (4.1%) 273 (4.4%) 197 (3.8%) 0.10 
Any CVD 1191 (10.4%) 686 (11.1%) 505 (9.7%) 0.019 
Mean SBP; mmHg 157.8 (22.4) 156.5 (19.5) 159.3 (25.3) <0.0001 
Mean DBP; mmHg 93.9 (11.2) 92.3 (9.7) 95.9 (12.5) <0.0001 
BMI; kg/m2 27.7 (5.4) 27.8 (5.4) 27.6 (5.5) 0.08 
Mean Cholesterol; mmol/l 6.04 (1.15) 6.1 (1.1) 5.9 (1.1) <0.0001 
Mean Creatinine; µmol/l 99.1 (54.5) 98 (46.6) 102.5 (70.9) <0.0001 
ACE Inhibitor 2648 (23.2%) 1796 (29%) 852 (16%) <0.0001 
Beta Blocker 6104 (53.5%) 4071 (65.6%) 2033 (39.1%) <0.0001 
Calcium Channel Blocker 3512 (30.8%) 2427 (39.1%) 1085 (20.9%) <0.0001 
Diuretic 7120 (62.5%) 4250 (68.5%) 2870 (55%) <0.0001 
P values represent those obtained on comparison of those who had uric acid levels 
measured compared to those who did not. Two sample t-tests were employed for 
continuous variables, while chi-squared tests were used for binary variables. 
Table 4.7. Study Four Baseline Demographic Variables 
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Uric Acid Data 
The mean first serum uric acid was 0.34 mmol/l (SD 0.14). The mean last serum UA was 
0.35 mmol/l (SD 0.18) while the mean average serum uric acid level during the study was 
0.35 mmol/l (SD 0.14). These data and uric acid quintiles are shown in table 4.8. In total, 
2431 (39.2%) of individuals had only one serum uric acid measured, 1039 (16.8%) had 
two, 660 (10.6%) had three and 2072 (33.4%) had four or more uric acid measurements.  
 
Uric Acid Data 
Whole Group Mean (SD); mmol/l 
First Uric Acid 0.34 (0.14) 
Last Uric Acid 0.35 (0.18) 
Mean Uric Acid 0.35 (0.14) 
Uric Acid Quintiles Range; mmol/l N (%) 
1st Uric Acid Quintile 0.01 to 0.25 1242 (20.1%) 
2nd Uric Acid Quintile 0.26 to 0.30 1235 (19.9%) 
3rd Uric Acid Quintile 0.31 to 0.35 1278 (20.6%) 
4th Uric Acid Quintile 0.36 to 0.41 1207 (19.5%) 
5th Uric Acid Quintile 0.42 to 5.5 1240 (19.9%) 
Table 4.8. Study Four Uric Acid Data. Uric acid quintiles are based upon mean 
serum uric acid levels. 
 
Higher serum uric acid was significantly associated with male sex, beta-blocker, diuretic 
and calcium channel antagonist therapy, established cardiovascular disease and 
hyperlipidaemia, and increases in age, serum creatinine concentration, blood pressure, total 
serum cholesterol concentration and body mass index (table 4.9). 
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Continuous Variables Regression Coefficient P value 
Age; years 0.001 <0.0001 
Mean SBP; mmHg 0.001 <0.0001 
Mean DBP; mmHg 0.001 <0.0001 
Mean Cholesterol; mmol/l 0.007 <0.0001 
Mean Creatinine; µmol/l 0.001 <0.0001 
BMI; kg/m2 0.003 <0.0001 
Binary Variables Present Absent P value 
Male Sex 0.39 0.31 <0.0001 
Smoker 0.34 0.35 0.55 
Cholesterol > 5 mmol/l 0.35 0.33 <0.0001 
Diabetes Mellitus 0.35 0.35 0.44 
IHD 0.36 0.35 0.07 
CVA 0.36 0.35 0.21 
PVD 0.36 0.35 0.19 
Any CVD 0.36 0.35 0.009 
ACE Inhibitor 0.35 0.35 0.87 
Beta Blocker 0.35 0.34 <0.0001 
Calcium Channel Blocker 0.35 0.34 0.007 
Diuretic 0.35 0.33 <0.0001 
For continuous variables linear regression analysis was employed and the regression 
coefficients refer to the increase in serum uric acid seen for each unit increase in the 
variable. For binary variables, the levels shown are the mean average serum uric acid 
according to whether the variable was present or absent and the p values refer to those 
obtained on 2 sample t testing. 
Table 4.9. Relationship Between Baseline Variables and Increasing Serum Uric Acid 
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Outcome Data 
In the total study group there were 713 (6.3% of patients) stroke deaths, 1462 (12.8%) IHD 
deaths, 2532 (22.7%) vascular deaths and 4137 (36.3%) deaths in total. In those who had 
serum uric acid measured, there were 354 stroke deaths (5.7%), 723 (11.7%) IHD deaths, 
1290 (20.8%) vascular deaths and 2124 (34.2%) deaths in total table 4.10). 
 
Outcome Data 
Variable Whole Group 
n = 11399 
UA Measured 
n = 6202 
No UA 
Measured 
n = 5197 
P Value 
Death 4137 (36.3%) 2124 (34.2%) 2013 (38.7%) <0.0001 
IHD Death 1462 (12.8%) 723 (11.7%) 739 (14.2%) <0.0001 
Stroke Death 713 (6.3%) 354 (5.7%) 359 (6.9%) 0.008 
Any Vascular 
Death 
2532 (22.7%) 1290 (20.8%) 1302 (25.1%) <0.0001 
Table 4.10. Outcome in the Whole Hypertensive Patients Study Group and Where 
Serum Uric Acid was Measured. P values refer to Chi-squared testing. 
 
4.04.2.1 Relationships with Stroke Mortality 
On univariate analysis male sex, smoking, diabetes, peripheral vascular disease, stroke, any 
established vascular disease, diuretic therapy and increases in age, SBP, DBP, serum 
cholesterol concentration, serum creatinine concentration and serum uric acid were 
associated with a significant increase in stroke mortality.  Increasing BMI was associated 
with a reduction in stroke mortality (table 4.11).  
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Variable Hazard Ratio 
(HR) 
95% Confidence 
Interval for HR 
p-value 
Age 1.093 1.081 to 1.104 <0.001 
Male Sex 1.273 1.033 to 1.568 0.024 
IHD 1.517 0.976 to 2.359 0.08 
CVA 5.093 3.663 to 7.082 <0.001 
PVD 2.386 1.611 to 3.534 <0.001 
Smoker 1.388 1.116 to 1.726 0.004 
Any CVD 2.939 2.287 to 3.776 <0.001 
Diabetes Mellitus 1.630 1.115 to 2.383 0.018 
BMI; kg/m2 0.972 0.951 to 0.994 0.01 
Mean SBP; mmHg 1.029 1.026 to 1.033 <0.001 
Mean DBP; mmHg 1.032 1.023 to 1.041 <0.001 
Mean Creatinine; µmol/l 1.004 1.002 to 1.005 <0.001 
Mean Uric Acid; µmol/l 1.861 1.19 to 2.911 0.006 
Mean Cholesterol; mmol/l 1.413 1.042 to 1.254 0.005 
ACE Inhibitor 0.775 0.595 to 1.008 0.051 
Beta-Blocker 1.163 0.922 to 1.468 0.20 
Calcium Channel Blocker 0.984 0.789 to 1.227 0.89 
Diuretic 1.877 1.438 to 2.451 <0.001 
Table 4.11. Risk of Stroke Death (Unadjusted) in Hypertensive Patients. 
 
Following adjustment for the predictive variables, male sex, smoking, diabetes, stroke, and 
increases in age, SBP, DBP and serum creatinine were associated with a significant 
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Variable Hazard Ratio 
(HR) 
95% Confidence 
Interval for HR 
p-value 
Age 1.086 1.071 to 1.101 <0.001 
Male Sex 1.552 1.21 to 1.99 0.001 
CVA 3.156 2.232 to 4.465 <0.001 
PVD 1.312 0.866 to 1.988 0.20 
Smoker 1.52 1.203 to 1.921 <0.001 
Diabetes Mellitus 1.623 1.085 to 2.426 0.018 
BMI 0.983 0.96 to 1.007 0.17 
Mean SBP 1.015 1.008 to 1.022 0.001 
Mean DBP 1.025 1.011 to 1.039 <0.001 
Mean Creatinine 1.002 1.001 to 1.004 0.006 
Mean Uric Acid 0.947 0.278 to 3.222 0.93 
Mean Cholesterol 1.015 0.919 to 1.120 0.77 
Diuretic 1.144 0.843 to 1.554 0.39 
Table 4.12. Risk of Stroke Death (Adjusted) in Hypertensive Patients. 
 
On exploratory analysis, the relationship between uric acid and stroke mortality appeared J-
shaped (figure 4.3) with risk lowest in the second quartile of serum uric acid levels (figure 
4.4).  Compared to those in the second quintile of uric acid levels, risk was significantly 
increased in those in the lowest quintile and increased from the third to the fifth quintile 
(table 4.13).  
 
Following adjustment for other significant variables, a significant J-shaped relationship 
remained across the quintiles of uric acid with stroke mortality (table 4.14).   
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Variable Hazard Ratio 
(HR) 
95% Confidence 
Interval for HR 
p-value 
Mean Uric Acid 1.861 1.19 to 2.911 0.006 
Uric Acid First Quintile 1.652 1.135 to 2.404 0.009 
Uric Acid Second Quintile 1 ----- ----- 
Uric Acid Third Quintile 1.79 1.235 to 2.595 0.002 
Uric Acid Fourth Quintile 1.948 1.347 to 2.817 <0.001 
Uric Acid Fifth Quintile 2.207 1.531 to 3.181 <0.001 
Table 4.13. Risk of Stroke Death (Unadjusted for Other Variables) in Hypertensive 
Patients. 
 
Variable Hazard Ratio 
(HR) 
95% Confidence 
Interval for HR 
p-value 
Age 1.085 1.071 to 1.1 <0.001 
Male Sex 1.555 1.206 to 2.006 0.001 
CVA 3.192 2.253 to 4.522 <0.001 
PVD 1.285 0.848 to 1.948 0.24 
Smoker 1.519 1.202 to 1.920 <0.001 
Diabetes Mellitus 1.651 1.104 to 2.469 0.015 
BMI 0.984 0.96 to 1.008 0.19 
Mean SBP 1.015 1.008 to 1.022 <0.001 
Mean DBP 1.024 1.010 to 1.038 0.001 
Mean Creatinine 1.002 1.001 to 1.004 0.006 
Mean Cholesterol 1.016 0.920 to 1.122 0.76 
Diuretic 1.143 0.841 to 1.555 0.39 
UA First Quintile 1.777 1.186 to 2.661 0.005 
UA Second Quintile 1 --- --- 
UA Third Quintile 1.468 0.993 to 2.169 0.054 
UA Fourth Quintile 1.521 1.028 to 2.251 0.036 
UA Fifth Quintile 1.434 0.953 to 2.159 0.08 
Table 4.14. Risk of Stroke Death (Adjusted) in Hypertensive Patients. 
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Figure 4.3. Risk of Death Across Serum Uric Acid Quintiles in 
Hypertensive Patients. 
Figure 4.4. Survival Free From Stroke Across Uric Acid 
Quintiles in Hypertensive Patients. 
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4.04.2.2 Relationships with Total Mortality 
On univariate analysis male sex, smoking, diabetes, ischaemic heart disease, peripheral 
vascular disease, stroke, any established vascular disease, beta-blocker, calcium channel 
and diuretic therapy and increases in age, SBP, DBP, serum cholesterol concentration, 
serum creatinine concentration and serum uric acid were associated with a significant 
increase in total mortality.  Increasing BMI was associated with a reduction in total 
mortality (table 4.15). 
  
Variable Hazard Ratio 
(HR) 
95% Confidence 
Interval for HR 
p-value 
Age; years 1.075 1.07 to 1.079 <0.001 
Male Sex 1.431 1.314 to 1.559 <0.001 
IHD 1.927 1.638 to 2.267 <0.001 
CVA 2.357 1.957 to 2.839 <0.001 
PVD 2.593 2.221 to 3.027 <0.001 
Smoker 1.589 1.456 to 1.734 <0.001 
Any CVD 2.306 2.065 to 2.574 <0.001 
Diabetes Mellitus 1.603 1.371 to 1.874 <0.001 
BMI; kg/m2 0.987 0.979 to 0.996 0.004 
Mean SBP; mmHg 1.024 1.022 to 1.026 <0.001 
Mean DBP; mmHg 1.026 1.022 to 1.030 <0.001 
Mean Creatinine; µmol/l 1.004 1.003 to 1.004 <0.001 
Mean Uric Acid; µmol/l 2.052 1.759 to 2.394 <0.001 
Mean Cholesterol; mmol/l 1.138 1.096 to 1.183 <0.001 
ACE Inhibitor 0.904 0.815 to 1.002 0.05 
Beta-Blocker 1.236 1.123 to 1.361 <0.001 
Calcium Channel Blocker 1.14 1.044 to 1.245 0.004 
Diuretic 1.888 1.692 to 2.105 <0.001 
Table 4.15. Risk of Death (Unadjusted) in Hypertensive Patients. 
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Following adjustment for the predictive variables, male sex, smoking, diabetes, ischaemic 
heart disease, peripheral vascular disease, stroke, and increases in age, SBP, DBP, serum 
cholesterol concentration, serum creatinine concentration and serum uric acid were 
associated with a significant increase in total mortality.  Calcium channel antagonist use 
was associated with a reduction in total mortality (table 4.16). 
 
Variable Hazard Ratio 
(HR) 
95% Confidence 
Interval for HR 
p-value 
Age 1.075 1.069 to 1.081 <0.001 
Male Sex 1.574 1.424 to 1.740 <0.001 
IHD 1.248 1.049 to 1.486 0.012 
CVA 1.44 1.18 to 1.757 <0.001 
PVD 1.571 1.323 to 1.864 <0.001 
Smoker 1.721 1.564 to 1.893 <0.001 
Diabetes Mellitus 1.508 1.274 to 1.784 <0.001 
BMI 0.995 0.986 to 1.005 0.36 
Mean SBP 1.008 1.004 to 1.011 <0.001 
Mean DBP 1.019 1.013 to 1.025 <0.001 
Mean Creatinine 1.003 1.002 to 1.003 <0.001 
Mean Uric Acid 1.437 1.015 to 2.035 0.041 
Mean Cholesterol 1.05 1.008 to 1.094 0.019 
Beta-Blocker 1.04 0.933 to 1.158 0.48 
Calcium Channel Blocker 0.9 0.815 to 0.994 0.038 
Diuretic 1.069 0.942 to 1.212 0.30 
Table 4.16. Risk of Death (Adjusted) in Hypertensive Patients. 
 
There was no evidence that the relationship between serum uric acid and total mortality was 
J-shaped (figure 4.5). 



























4.04.2.3 Relationships with Vascular Mortality 
On univariate analysis male sex, smoking, diabetes, ischaemic heart disease, peripheral 
vascular disease, stroke, any established vascular disease, beta-blocker and diuretic therapy 
and increases in age, SBP, DBP, serum cholesterol concentration, serum creatinine 
concentration and serum uric acid were associated with a significant increase in vascular 






Figure 4.5. Survival Free From Any Death Across Uric Acid 
Quintiles in Hypertensive Patients. 
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Variable Hazard Ratio (HR) 95% Confidence 
Interval for HR 
p-value 
Age 1.077 1.071 to 1.082 <0.001 
Male Sex 1.494 1.339 to 1.668 <0.001 
IHD 2.251 1.852 to 2.735 <0.001 
CVA 2.688 2.149 to 3.363 <0.001 
PVD 2.701 2.223 to 3.282 <0.001 
Smoker 1.655 1.48 to 1.85 <0.001 
Any CVD 2.64 2.307 to 3.023 <0.001 
Diabetes Mellitus 1.715 1.412 to 2.084 <0.001 
BMI; kg/m2 0.991 0.980 to 1.002 0.12 
Mean SBP; mmHg 1.027 1.025 to 1.029 <0.001 
Mean DBP; mmHg 1.033 1.028 to 1.037 <0.001 
Mean Creatinine; µmol/l 1.004 1.003 to 1.004 <0.001 
Mean Uric Acid; µmol/l 2.148 1.8 to 2.562 <0.001 
Mean Cholesterol; mmol/l 1.183 1.127 to 1.241 <0.001 
ACE Inhibitor 0.894 0.783 to 1.020 0.09 
Beta-Blocker 1.369 1.207 to 1.554 <0.001 
Calcium Channel Blocker 1.104 0.985 to 1.237 0.09 
Diuretic 2.114 1.829 to 2.443 <0.001 
4.17. Risk of Vascular Death (Unadjusted) in Hypertensive Patients. 
 
Following adjustment for the predictive variables, male sex, smoking, diabetes, ischaemic 
heart disease, peripheral vascular disease, stroke, diuretic therapy and increases in age, 
SBP, DBP, serum cholesterol concentration, serum creatinine concentration and serum uric 
acid were associated with a significant increase in vascular mortality (table 4.18). 
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Variable Hazard Ratio 
(HR) 
95% Confidence 
Interval for HR 
p-value 
Age 1.077 1.069 to 1.084 <0.001 
Male Sex 1.702 1.496 to 1.935 <0.001 
IHD 1.465 1.190 to 1.803 <0.001 
CVA 1.636 1.287 to 2.079 <0.001 
PVD 1.585 1.277 to 1.967 <0.001 
Smoker 1.787 1.581 to 2.019 <0.001 
Diabetes Mellitus 1.566 1.27 to 1.931 <0.001 
BMI 1.001 0.989 to 1.014 0.85 
Mean SBP 1.011 1.007 to 1.015 0.001 
Mean DBP 1.025 1.017 to 1.033 <0.001 
Mean Creatinine 1.003 1.002 to 1.003 <0.001 
Mean Uric Acid 1.793 1.233 to 2.607 0.002 
Mean Cholesterol 1.091 1.036 to 1.149 0.001 
Beta-Blocker 1.111 0.965 to 1.280 0.14 
Diuretic 1.216 1.028 to 1.439 0.023 
Table 4.18. Risk of Vascular Death (Adjusted) in Hypertensive Patients. 
 
There was no evidence that the relationship between serum uric acid and vascular mortality 
was J-shaped (figure 4.6). 
 

























4.04.2.4 Relationship with Ischaemic Heart Disease Mortality  
On univariate analysis male sex, smoking, diabetes, ischaemic heart disease, peripheral 
vascular disease, stroke, any established vascular disease, beta-blocker, calcium channel 
antagonist and diuretic therapy and increases in age, SBP, DBP, serum cholesterol 
concentration, serum creatinine concentration and serum uric acid were associated with a 






Figure 4.6.  Survival Free From Vascular Death Across Uric 
Acid Quintiles in Hypertensive Patients. 
 - 193 - 
Variable Hazard Ratio 
(HR) 
95% Confidence 
Interval for HR 
p-value 
Age 1.066 1.059 to 1.073 <0.001 
Male Sex 1.692 1.459 to 1.961 <0.001 
IHD 2.847 2.248 to 3.607 <0.001 
CVA 1.709 1.186 to 2.464 0.008 
PVD 2.736 2.112 to 3.544 <0.001 
Smoker 1.778 1.533 to 2.063 <0.001 
Any CVD 2.591 2.161 to 3.107 <0.001 
Diabetes Mellitus 1.949 1.523 to 2.494 <0.001 
BMI; kg/m2 1.002 0.988 to 1.017 0.767 
Mean SBP; mmHg 1.025 1.023 to 1.028 <0.001 
Mean DBP; mmHg 1.033 1.027 to 1.04 <0.001 
Mean Creatinine; µmol/l 1.004 1.003 to 1.004 <0.001 
Mean Uric Acid; µmol/l 2.146 1.696 to 2.714 <0.001 
Mean Cholesterol; mmol/l 1.227 1.151 to 1.309 <0.001 
ACE Inhibitor 0.958 0.806 to 1.140 0.63 
Beta-Blocker 1.607 1.348 to 1.916 <0.001 
Calcium Channel Blocker 1.206 1.038 to 1.401 0.015 
Diuretic 2.166 1.782 to 2.632 <0.001 
Table 4.19. Risk of IHD Death (Unadjusted) in Hypertensive Patients. 
 
Following adjustment for the predictive variables, male sex, smoking, diabetes, ischaemic  
heart disease, peripheral vascular disease, diuretic and beta-blocker therapy and increases in 
age, SBP, DBP, serum cholesterol, creatinine and uric acid concentrations were associated 
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Variable Hazard Ratio 
(HR) 
95% Confidence 
Interval for HR 
p-value 
Age 1.066 1.056 to 1.077 <0.001 
Male Sex 1.896 1.594 to 2.257 <0.001 
IHD 1.996 1.55 to 2.57 0.012 
CVA 1.045 0.703 to 1.555 0.83 
PVD 1.693 1.269 to 2.259 <0.001 
Smoker 1.859 1.579 to 2.189 <0.001 
Diabetes Mellitus 1.746 1.339 to 2.276 <0.001 
BMI 1.012 0.996 to 1.029 0.15 
Mean SBP 1.01 1.004 to 1.015 0.001 
Mean DBP 1.022 1.012 to 1.033 <0.001 
Mean Creatinine 1.002 1.001 to 1.004 <0.001 
Mean Uric Acid 1.7 1.004 to 2.878 0.048 
Mean Cholesterol 1.159 1.082 to 1.241 <0.001 
Beta-Blocker 1.28 1.05 to 1.561 0.015 
Calcium Channel Blocker 0.9 0.76 to 1.067 0.22 
Diuretic 1.267 1.008 to 1.593 0.042 
Table 4.20. Risk of IHD Death (Adjusted) in Hypertensive Patients. 
 
There was no evidence that the relationship between serum uric acid and coronary mortality 
was J-shaped (figure 4.7). 
 



























4.04.2.5  Sex Specific Analysis 
 
Serum uric acid level was strongly associated with total mortality in females but not males 
on exploratory univariate analysis. Similar was found for CHD mortality and vascular 
mortality and this sex difference remained apparent on multivariate analysis (table 4.21). 
 
With regard to stroke mortality a significant J shaped relationship was observed in females. 
This was not observed in males where only the lowest quintile of uric acid levels linked 
with increased risk (table 4.21). On multivariate analysis, only the highest quintile of uric 
acid linked with increased stroke risk in females, while the lowest linked with increased 
risk in males (table 4.22). 
Figure 4.7. Survival Free From Coronary Heart Disease Death 
Across Uric Acid Quintiles in Hypertensive Patients. 
 - 196 - 
 
Males Females  








Total Mortality 1.16 0.77 to 1.74 0.48 8.84 6.06 to 12.91 <0.00
1 




1.25 0.79 to 1.97 0.36 10.71 6.97 to 16.46 <0.00
1 
Stroke Mortality  
1st Quintile 
2nd Quintile 










1.48 to 4.99 
-- 
0.78 to 2.33 
0.79 to 2.29 














0.99 to 2.61 
-- 
1.27 to 3.51 
1.52 to 4.32 









Table 4.21. Risk of Total, Vascular, Coronary and Stroke Death on Univariate Analysis 
According to Sex in Hypertensive Patients.. HR = hazard ratio. Hazard ratios shown are 














Males Females  
























1.343 to 5.182 
-- 
0.78 to 2.61 
0.83 to 2.69 

















0.87 to 2.40 
-- 
0.90 to 2.54 
0.98 to 2.90 








Table 4.22. Risk of Stroke Mortality on Multivariate Analysis According to Sex in 
Hypertensive Patients. Adjustment variables are as shown in table 4.14. HR = hazard 





4.04.3 Study Two Discussion 
 
The results of this study suggest that increasing serum uric is associated with increased risk 
of stroke, total, vascular and coronary mortality in treated hypertensive patients but that the 
relationship between stroke mortality and serum uric acid appears J-shaped. Sex specific 
analyses also suggest that such a relationship with stroke risk is only apparent in females. 
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The relationship between uric acid and cardiovascular risk is well documented and 
increasingly accepted (521). However, many studies have not specifically evaluated stroke 
mortality (383;396;525;526) and, in studies where this has been examined, there has often 
been little evidence of an association, even when it was apparent for all cardiovascular 
endpoints.  It is important to note however that all studies to date have been limited by 
relatively low stroke rates.  For example, in an analysis of data from the SHEP trial (384), 
there were only 243 strokes. In an analysis from the Syst-Eur trial (387), there were only 
128 strokes, of which only 36 of these were fatal. In the Syst-China trial (386), there were 
only 87 strokes, although these did make up the majority of cardiovascular endpoints. In 
analysis of data from the NHANES study (396) there were only 111 strokes and in the 
PIUMA study analysis, there were only 48 strokes (383).  
 
The population studied here (those with treated hypertension) represent a group where the 
relationship between stroke rate and mortality is particularly unclear. Some studies have 
shown an association (380;386;402) while others have not (384;387).  In the Syst-China 
study (386), a 50 µmol/l increase in serum uric acid afforded a relative hazard ratio of 1.28 
(95% CI 1.1 to 1.5) for stroke mortality, although there was no significant association with 
all stroke events. Whether results from a Chinese population with a disproportionately high 
haemorrhagic stroke risk and low serum cholesterol can be widely generalised is 
questionable. An association has been seen with stroke risk in patients with diabetes (380), 
where serum uric acid levels above the median were associated with increased stroke risk 
(HR 1.91, 95% CI 1.24 to 2.94) although the number of strokes was again small (114 in 
total). In a large observational cohort of patients aged > 55 years of age (Rotterdam study 
data (402)) an association was seen with stroke incidence (HR 1.18, 95% CI 1.06 to 1.3). In 
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total, there were 381 stroke events; the largest number to date. However, subgroup analysis 
suggested this association was only present in females and in those with no previous 
hypertension.  
 
There were 354 stroke deaths in this study; the highest number in any study to date, and the 
largest study of those with hypertension. This allows thorough analysis of any 
relationships. The impact of sex in many studies is difficult to assess but those who have 
addressed it suggest the association exists only in females, or is at least more prominent 
(402;525;526), although other studies show no such difference (387). In the Rotterdam 
study for example, no association was seen in males but an association was present in 
females.  This study showed similar with a highly significant relationship was present in 
females but not males. There are known differences in uric acid metabolism between the 
sexes; women have a lower total body uric acid pool, presumably due to oestrogen 
mediated differences in renal excretion (527).  Despite uric acid being higher in post 
menopausal women (528), menopausal status has little effect on the association between 
uric acid and cardiovascular disease (396).  It is therefore possible, but speculative, that 
raised serum uric acid in females reflects a different mechanism than in males; perhaps 
increased xanthine oxidase activity and the associated superoxide anion production.  It is 
also possible that changes in uric acid have less impact on those with higher baseline risk 
and higher rates of traditional risk factors; such as the males studied here. The possibility of 
a sex specific effect of uric acid lowering strategies on cardiovascular outcomes should be 
considered in the design of future clinical trials, although because of higher baseline risk, 
measures such as allopurinol use may prove most effective in males because of ancillary 
effects such as xanthine oxidase inhibition. 
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A J-shaped relationship between serum uric acid and cardiovascular risk has also been seen 
in many previous studies (383;385;396;525) and also with regard to stroke risk (380;386).  
This study found similar with regard to stroke risk but not total, vascular or coronary 
mortality. Why these differences exist is unclear.  There are plausible explanations. It has 
been speculated that this J-shaped relationship reflects the putative detrimental effects of 
elevated uric acid on endothelial and platelet function and vascular smooth muscle and the 
association between lower serum uric acid and low plasma antioxidant activity.  It is also 
possible that some of the increased risk seen with lower uric acid is due to poor nutrition or 
other illnesses which may contribute to cardiovascular risk - hypouricaemia is more 
common in hospitalised patients, with concomitant medications and in those with liver 
disease or neoplasia (529).  Why this should be particular to stroke risk here is not clear. 
 
There are strengths to this study including its size, the prospective nature of the data 
collection and the large number of fatal strokes. There are however, some weaknesses. The 
long study period means several of these events may have occurred before aggressive 
preventative strategies became commonplace and treatment regimens for hypertension have 
changed over the years. For example, there is now less emphasis placed upon diuretic 
therapy which increases serum uric acid. Whether this impacts upon the contemporary 
relevance of the results is unclear but possible. 
 
In summary, data from this study suggest that serum uric acid is associated with increased 
stroke mortality and that this relationship is J-shaped, unlike that between uric acid and 
total, vascular and coronary mortality. 
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4.05 Study Three - Allopurinol and Basal Nitric Oxide Production in the Cerebral 
Circulation of those with Diabetes; a Randomised Trial 
 
The study hypothesis was that the XO inhibitor allopurinol would enhance nitric oxide 
bioavailability in the cerebral circulation of patients with type 2 diabetes. This would be 
reflected by enhancement of the effects of L-NMMA, which produces transient reductions 
in cerebral blood flow (CBF).  A randomized, double blind, placebo controlled crossover 
study was performed to test this.  
 
4.05.1 Study Three Methods 
 
The study was performed in the University Division of Cardiovascular and Medical 
Sciences at the Western Infirmary, Glasgow. The study was approved by the local research 
ethics committee and was registered in the ISRCTN database (ISRCTN 68849312). 
 
Male patients aged over 40 years old with type 2 diabetes of duration less than 5 years and 
stable glycaemic control (HbA1c below 9.0%) were studied. Oral biguanide therapy was 
permitted, although those on insulin or sulphonylurea therapy were excluded. Further 
exclusion criteria were: greater than 70% extra-cranial internal carotid artery (ICA) stenosis, 
known coronary arterial disease, significant co-morbidity or frailty likely to cause either 
death or difficulty with protocol adherence within 3 months, significant renal impairment 
(defined as serum creatinine concentration over 250 µmol/L) and contra-indication to or 
indication for administration of allopurinol. Patients taking sulphonylurea therapy were 
later included following a protocol amendment. Exclusion criteria were chosen to minimise 
the theoretical risks of sub-endocardial myocardial ischaemia following L-NMMA, to 
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minimise potential risks of allopurinol treatment and to ensure carotid flow readings were 
not falsely elevated because of intrinsic carotid disease. 
 
Patients were identified during out-patient attendance at hospital clinics. All participants 
gave written informed consent to participate and underwent full Bruce protocol exercise 
tolerance testing prior to randomisation to exclude sub-clinical coronary arterial disease. If 
evidence of this was found, further participation was not permitted. All drug treatments 
remained unchanged throughout the study period. 
 
Study Assessment 
Study visits took place in the Investigations Ward of the Acute Stroke Unit in the Western 
Infirmary and were supervised by one of the study investigators.  The participant schedule 













































Figure 4.8. Study Three Participant Study Schedule 
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Baseline assessment of mean flow velocity in the ICA and middle cerebral artery (MCA) 
was performed, along with measures of ICA diameter and area. Peripheral (radial) pulse 
wave analysis (PWA) and (carotid-radial) pulse wave velocity (PWV) measurements were 
also performed.  On completion of these measurements, a 45 ml infusion of 0.8 
µmol/kg/min of L-NMMA dissolved in normal saline was given intravenously over 15 
minutes. L-NMMA was obtained from Clinalfa. Assessment of ICA and MCA parameters 
was repeated upon cessation of infusion and at 10, 20 and 30 minutes thereafter. PWA and 
PWV measurements were repeated upon cessation of infusion and at 15 and 30 minutes 
thereafter.  Carotid insonation was performed using an Acuson Aspen 128 with a 5-Mhz 
linear transducer (Acuson, Mountain View, CA, USA) and measurements were taken 1 cm 
distal to the carotid bifurcation. MCA insonation was performed using a TCD 100M 
(Spencer Technologies, Seattle, WA, USA) and readings were taken at, or as near as 
possible to, a depth of 50 cm. Ultrasound examinations were performed by a sonographer 
with several years’ experience of neurovascular ultrasound. PWA and PWV measurements 
were made using a SphygmoCor device (Atcor Medical, Sydney, Australia) by operators 
with several years experience.  
 
Following baseline assessment, participants were randomised to receive either 300 mg of 
allopurinol or matching placebo orally once daily. Dosing began on the day of baseline 
assessment and continued for two weeks after which participants returned for further 
assessment as described above. A two-week washout period then ensued after which repeat 
assessment, a two week dose of the other agent (placebo or allopurinol) and the final 
assessment occurred. All haemodynamic studies were conducted as near to midday as 
feasible and subjects were asked to refrain from caffeine for 24 hours prior to each study. 
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At each study visit, blood was drawn to allow measurement of routine biochemistry and 
haematology parameters and circulating markers of endothelial/inflammatory function 
(VEGF, sICAM, eSelectin and CRP). For these tests, serum was frozen and stored for 
subsequent analysis using ELISA techniques. 
  
Randomisation and Treatment Allocation 
Allopurinol tablets were manufactured by Alpharma. Placebo tablets were manufactured by 
Penn Pharmaceuticals. Both were encapsulated to appear identical, in the Pharmacy 
Production Unit at the Western Infirmary Hospital. Study treatments were collected by one 
of the investigators on the day of the baseline and the first post-washout study visit. 
Concordance with therapy was assessed by questioning and pill counts where available. 
Investigators remained blinded to serum uric acid data until the end of the study to prevent 
unmasking of treatment allocation.  Randomisation was performed by the pharmacy 
department and the randomisation code was held by an independent study pharmacist. The 




The primary endpoint was change in ICA flow induced by the L-NMMA infusion 
expressed as area under flow / time curve (AUC) measured from the start of infusion to 20 
minutes after its completion (530;531).  Based on previous pilot data (530), it was 
calculated that a sample size of 20 patients would enable detection of a clinically significant 
improvement in L-NMMA responsiveness (to approximately 75% of that seen in non-
diabetic individuals), with 90% power (alpha = 5%). Secondary endpoints were the intra-
individual percentage change in ICA flow following L-NMMA infusion (from baseline to 
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10 minutes post infusion), change in systolic and diastolic blood pressure (SBP and DBP) 
and middle cerebral artery flow velocity (MCAv) induced by the L-NMMA infusion 
(expressed as AUC), change in augmentation index (AI, measured during PWA) and PWV, 
and change in circulating markers of endothelial/inflammatory function.   
 
AUCs were calculated using the trapezoidal method with the aid of NCSS software (Utah 
USA). A negative AUC signifies a reduction in flow (or blood pressure for example) 
following L-NMMA infusion and a positive area under the curve indicates an elevation in 
flow.  The difference between the AUCs pre and post each intervention period were 
calculated and compared (allopurinol minus placebo) using paired non-parametric tests 
(Wilcoxon signed rank test). A positive difference in AUCs represents an improvement in 
basal NO activity during that study phase and a positive difference between the study 
periods represents improvement in favour of allopurinol. For the AI and PWV, pre infusion 
values and the change immediately following infusion were compared between study 
periods using the same approach as taken for AUCs. The difference between pre and post 
treatment values was compared for the circulating markers of endothelial/inflammatory 
function. As a sensitivity analysis, a mixed effects model was generated to adjust for any 
effect of treatment ordering and to incorporate information from patients who did not 
complete all of the study visits. 
 
4.05.1.1 Rationale for Use of L-NMMA Responsiveness a Measure of 
Cerebrovascular Function 
Endothelial dysfunction is key to the development of cardiovascular disease with 
maintenance of normal endothelial function dependant upon production of endothelial nitric 
oxide (NO). Studies have also shown this to be involved in maintenance of resting cerebral 
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blood flow (CBF) (532) and a dynamic effect of NO on cerebral autoregulation has been 
demonstrated via studies of infusion of NG-monomethyl-L-arginine (531) (L-NMMA). L-
NMMA is an analogue inhibitor of endothelial nitric oxide synthase (eNOS) and thus basal 
NO activity; in healthy volunteers, L-NMMA lowers CBF (531) and has also been shown 
to reduce forearm blood flow (533), to increase large artery stiffness (534) and to increase 
blood pressure (535). The magnitude of the response is dependent upon basal NO activity 
and thus endothelial health; for example, the bigger the fall in CBF following L-NMMA, 
the better the cerebrovascular endothelial function. 
 
This CBF response is reduced in those with established type 2 diabetes, where little effect 
of L-NMMA is seen (530) and this may predispose them to hypoxic or ischaemic 
cerebrovascular insult. In a recent prospective case-controlled study (530), L-NMMA 
produced a mean reduction in ICA flow (expressed as the area under the flow-time curve) 
of 12.8% (SD 17.8) in healthy volunteers compared to only 2.1% (SD 21.7) in those with 
diabetes. The response to L-NMMA is therefore a valid measure and improvements in 
peripheral responses have been shown following treatment with agents proven to impact on 
cardiovascular morbidity and mortality, such as statins and ACE inhibitors (536;537). 
Whether therapy can improve the impaired response of the cerebrovasculature to L-NMMA 
in diabetes or other conditions is as yet untested.  
 
The mechanism of the impaired response seen in diabetes is unclear. Superoxide anions 
(·O2-) inactivate NO (538), inhibit endothelium-dependent vasorelaxation (539) and are 
implicated in diabetes related endothelial dysfunction. While many sources of ·O2- exist in 
the vascular endothelium, xanthine oxidase (XO) activity has been shown to be important 
(408) and, as outlined, inhibition of this enzyme (with allopurinol) improves peripheral and 
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cardiac endothelial function in many cardiovascular disease states (521). If 
pharmacological attenuation of XO activity improved cerebrovascular NO bioavailability in 
patients with diabetes, this would suggest a role for XO activity in the pathogenesis of 
diabetic cerebrovascular disease and provide a potential means to improve stroke 
prevention. 
 
4.05.1.2 Rationale for Use of Pulse Wave Analysis and Pulse Wave Velocity as 
Measures of Arterial Function and Health 
The relationship between brachial cuff blood pressure and risk of cardiovascular disease 
(and in particular of stroke) is clear and could be described as one of the few certainties in 
medicine. At all ages and across the range of blood pressure down to at least 115/75mmHg, 
the risk of death from stroke and cardiac disease increases in a log-linear fashion (155). In a 
recent meta-analysis of data from over 1 million adults, a doubling of rate of death from 
stroke and cardiac disease was seen with each 20mmHg higher systolic blood pressure (or 
10 mmHg higher diastolic blood pressure).  The simplicity of measurement of cuff brachial 
blood pressure and the legion of evidence (157) showing that a reduction in these values 
leads to reduction in morbidity and mortality means this will likely remain a cornerstone of 
cardiovascular risk prediction and in particular for stroke where the evidence for a link 
between other risk factors such as cholesterol and incidence is less compelling. 
 
However, evidence has emerged that measures of central blood pressure parameters, which 
are the values to which target organs are exposed, and measures of stiffness of arteries are 
also important and linked, independently of brachial cuff blood pressure, to risk of 
cardiovascular disease (540;541).  Some support for the use of these parameters can be 
gained from brachial cuff measurements; analysis of Framingham data suggest that cardiac 
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events are more closely related to systolic brachial cuff pressure and that events may 
actually be inversely related to diastolic pressure for any given systolic level (542). This 
suggests that pulse pressure, and thus increasing stiffness of large arteries, is in important 
factor in the development of cardiovascular disease. 
  
It is important to note that in normal healthy individuals the central and peripheral pulse 
pressures differ with pulse pressure rising more peripherally because of an increase in 
systolic pressure (543). This however alters with age; in young adults, the brachial pulse 
pressure pulse may be 50% greater than in the ascending aorta while they are similar in the 
elderly. This presumably reflects increasing vascular stiffness and is not best quantified by 
brachial cuff measures. Measures to directly quantify central pressure parameters and 
arterial stiffness are naturally invasive but non-invasive estimation of central pressures can 
now be achieved. 
 
The most widely employed methods are those of pulse wave analysis and measurement of 
pulse wave velocity which employ the use of arterial applanation tonometry. Such an 
example is the Sphygmocor system which incorporates a thin probe with a high-fidelity 
strain gauge transducer with a small pressure-sensitive ceramic sensor area linked to a 
computer and software to aid automated calculation of indices.   The probe is held over the 
skin at the point of maximal arterial pulsation. For PWA, this is done at a single site, most 
readily the radial artery at the wrist, and at two sites during measurement of PWV (for 
example at the radial and carotid artery or carotid and femoral artery).  In all individuals the 
aortic pulse wave is augmented by the reflection of blood at arterial bifurcation points, so 
called points of impedance discontinuity. The sum of all these reflected waves will behave 
like one single wave at each large artery origin in the aorta. In the young, or those with 
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highly elastic aortas, this wave returns during late systole or diastole, whereas in the elderly, 
it arrives in early systole and augments the pulse pressure. The augmentation index is a 
measure of the degree to which the reflected wave contributes to the pulse pressure and is 
defined as the magnitude of this augmented pressure divided by the pulse pressure. A rise 
in the augmentation index and thus early arrival of the reflected wave should therefore 
reflect the increasing arterial stiffness that occurs with age and cardiovascular risk factor 
states. Ideally, this would also be measured directly in the aorta but measures from the 
radial site have been shown to correlate well with aortic and carotid values (544;545) when 
a transfer function is employed to allow their approximation. The transfer function is also 
utilized to estimate the central systolic, diastolic blood and pulse pressures; all from the 
radial site. 
 
A variety of studies have linked these parameters to cardiovascular risk factor states. For 
example, a recent study of over 12000 individuals in England and Wales (546) found that 
the pulse pressure ratio (aortic pulse pressure : peripheral pulse pressure, increases in which 
should link to increased arterial stiffness) and augmentation index were higher in those with 
hypertension, hypercholesterolaemia, diabetes and in smokers and in those with established 
cardiovascular disease in comparison to healthy controls.  These findings remained 
consistent across the age range.  Studies have also linked increasing augmentation index to 
increases in cardiovascular mortality and morbidity in those with end-stage renal disease 
(547) and in those undergoing percutaneous coronary intervention (548;549) although only 
one of these utilized transfer function based measurements from the radial site (551) and 
not all studies yielded positive associations, including a study of nearly 500 individuals 
with hypertension (550).  Date also exist to suggest that transfer function based estimation 
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of central blood pressure values can better predict outcomes in comparison to peripheral 
measures (551), although again data conflict (552). 
 
It is therefore of interest to ask whether differences in central parameters explain observed 
differences in cardiovascular event reduction between drug classes which do not appear 
explained by differences in brachial blood pressure level. Also, it would provide 
encouraging evidence of benefit if any new or novel therapy, not aimed directly at lowering 
blood pressure, improved some of these measures of arterial stiffness. The CAFÉ study 
investigators addressed the first question.  The CAFÉ study (553) was a sub-study of the 
ASCOT trial (554), where an amlodipine ± perindopril based regimen led to fewer 
cardiovascular events or procedures in comparison to an atenolol ± bendrofluazide based 
regimen (HR 0.84, 95 % CI 0.78 to 0.9, p <0.0001). This was not completely accounted for 
by differences in blood pressure in a post-hoc analysis (555). In the CAFÉ study, which 
included 2199 participants from 5 ASCOT centres, there was little difference in brachial 
systolic BP (0.7 mmHg, 95% CI -0.4 to 1.7, p=0.2) but substantial reductions in the 
amlodipine arm were seen regarding central aortic systolic (4.3 mmHg, 95% CI 3.3 to 5.4 
mmHg, p<0.0001) and pulse (3 mmHg, 95% CI 2.1 to 3.9 mmHg, p<0.0001) pressures. 
These indices also linked to clinically relevant endpoints with 10mmHg increments in 
central pulse pressure associated with an 11% increase in risk of events (HR 1.11, 95% CI 1 
to 1.23 per 10 mmHg increment). 
 
The pulse wave velocity is the measurement of speed of the pressure waves traveling along 
an arterial segment, usually calculated from measurements at a proximal (for example 
carotid) and distal (for example radial) site.  The distance between these sites is measured 
with a tape measure and using ECG gating, the time taken for the arterial pulse to transmit 
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this distance between can be determined allowing the velocity of the pulse wave to be 
calculated. A higher pulse wave velocity suggests increased arterial stiffness has been 
shown to link with increased mortality in a cohort with severe renal disease (556), 
hypertension (557), established cardiac disease (558) and in a healthy cohort (559).  For 
example, in a cohort from the Rotterdam study revealed a hazard ratio of 2.45 (95% CI 1.29 
to 4.66) for development of coronary disease and 2.28 (95% CI 1.05 to 4.96) for stroke in 
those in the highest tertile of pulse wave velocity compared to those in the lowest.  The 
mean PWV in the whole cohort was 13.3 (SD 2.9), although individual tertile ranges were 
not given. In a hypertensive cohort (557), mean PWV in those who suffered a coronary 
event was significantly higher at 12.8 (SD 3.2) compared to 11.4 (SD 3.1) in those who did 
not (p<0.0001) and each SD increment (3.5 m/s) conveyed a RR of 1.39 (95% CI 1.08 to 
1.79, p=0.01) for coronary events. As yet, there is no data to confirm that reductions in 
PWV lead to reductions in cardiovascular events. 
 
It is also of interest that an increase in both the AI and PWV has been seen following L-
NMMA seen in a previous study of healthy volunteers (534). This study incorporated a 
range of doses of L-NMMA (from 0.1 to 3 mg/kg/minute) and effect was only seen with 
the higher doses, which were higher than used here. This response has not yet been 
evaluated in those with diabetes and this is important to establish as it is possible that there 
are regional differences in basal NO production between different vascular beds and that 
responses to treatment may similarly differ (560). 
 
Thus, it is relevant and rational to measure these parameters in studies of putative new 
preventative strategies in those at risk of stroke. However, there is an important note of 
caution when interpreting the results of such studies; if an agent were to yield similar 
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benefits to those seen in the CAFÉ study in terms of the AI or to give a 50% improvement 
toward values in healthy controls in those with diabetes, 135 and 388 participants per group 
respectively would need to be recruited to ensure 90% power (alpha 0.05). Benefit is 
therefore unlikely to be seen in small pilot studies, or at least good statistical power is 
unlikely. 
 
4.05.2 Study Three Results 
 
Fourteen patients were recruited between September 2006 and August 2007. Nineteen 
suitable patients were identified and approached and 5 declined participation. Eleven of 
those recruited completed follow up. One patient was deemed unsafe to continue as he had 
significant ST segment shift on his exercise tolerance test, one failed to attend for further 
assessment after visit one and one withdrew consent after attendance for exercise tolerance 
testing. One patient was unable to receive L-NMMA during his last study visit (because of 
lack of supply) leaving 10 who completed the study protocol. Data from this participant 
were included in analyses of blood markers and non L-NMMA dependent parameters. No 
other adverse event occurred during the study. The study was terminated early due to a 
national lack of availability of L-NMMA.  
 
Of these recruited, mean age (SD) was 53.1 (10.8) years. Demographic details, including 
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Smoker 4 (28.6) 
Hyperlipidaemia 5 (35.7) 
Hypertension 12 (85.7) 
Oral Hypoglycaemic Agent 11 (78.6) 
Anti-platelet Therapy 9 (64.3) 
ACE Inhibitor or ARB Therapy 11 (78.6) 
Diuretic Therapy 5 (35.7) 
Lipid Lowering Therapy 13 (92.3) 
Calcium Channel Antagonist Therapy 6 (42.9) 
Baseline Serum Creatinine 88 (16.9) µmol/l * 
Baseline Serum Glucose 9.9 (4.5) mmol/l * 
Baseline Serum Uric Acid 0.33 (0.07) mmol/l * 
Baseline Internal Carotid Artery (ICA) Flow 619 (SD 162) ml/min * 
Baseline Change in ICA Flow (ml) -789 (IQR -4194 to 7233) ml † 
Baseline SBP 154 (SD 11) mmHg * 
Baseline Change in SBP (mmHg*min) -133 (IQR -205 to 94) † 
Baseline DBP 85 (SD 6.8) mmHg * 
Baseline Change in DBP (mmHg*min) 66 (IQR -60 to 276) † 
Baseline MCAv 39.8 (SD 4.4) * 
Baseline Change in MCAv (m/s*min) 14 (IQR -29 to 53)  † 
Baseline Augmentation Index (AI) 23.9% (SD 6.86) * 
Baseline Change in AI 1.7% (SD 10.6) * 
Baseline Pulse Wave Velocity (PWV) 8.3 (SD 2.25) m/s * 
Baseline Change in PWV -0.025 (0.89) m/s * 
Table 4.23. – Study Three Baseline Variables (at first study visit). Expressed as n 
(%) for categorical variables and mean (SD) for continuous variables * except 
for area under curve measurements where median values and interquartile 
ranges (IQR) are given †. These values (†) refer to changes following L-NMMA 
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Baseline Visit Response to L-NMMA Infusion 
Mean (SD) ICA flow rate pre L-NMMA infusion was 619 (162) ml / min. The median area 
under the change in ICA flow/time curve following L-NMMA infusion was -789 ml (IQR -
4194 to 735) (p=0.16 for test of median difference less than zero). ICA flow fell by a 
median of 4.8% (95% CI -17.3 to 9.4, p=0.25) following L-NMMA infusion. This, and 
baseline values for the other parameters, are shown in table 4.24. There was no change in 
blood pressure parameters where AUCs were considered, although systolic and diastolic 
blood pressures were raised immediately post infusion (by 3.6 mmHg, 95% CI -0.8 to 8.0 
mmHg and 5.6 mmHg, 95% CI 1.2 to 9.9 mmHg respectively). No change was seen in 
PWA or PWV parameters following LNMMA. 
 
Effect of Allopurinol on Response to L-NMMA Infusion 
Allopurinol treatment significantly augmented the reduction in ICA (expressed as area 
under the flow time curve) following L-NMMA infusion (p=0.032, median improvement in 
ICA flow reduction following LNMMA of 3144 (95% CI 375 to 7143) mls). Allopurinol 
did not significantly influence response of other measured parameters to L-NMMA (4.24). 
ICA flow fell by a median of 11.9% (95% CI -2.5 to 23.3, p=0.04) following LNMMA 
after treatment with allopurinol, The effect of allopurinol on the group and intra-individual 
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Variable Following 
Placebo 
Allopurinol Difference Between 
Periods * 
P value † 
Change in ICA 
Flow (ml) 
-1314 (-3359 to 
419) 
1134 (-964 to 
7872) 
3144 (375 to 7143) 0.032 
Change in SBP 
(mmHg*min) 
20 (-260 to 158)  116 (-248 to 
501) 
14 (-461 to 588) 0.92 
Change in DBP 
(mmHg*min) 
-55 (-220 to 86)  -162 (-206 to 
94) 
-56 (-218 to 90) 0.48 
Change in MCA 
MFV (m/s*min) 
-41 (-112 to 108)  -38 (-146 to -9) -35 (-174 to 45)  0.36 
Table 4.24 – Change in Haemodynamic Parameters / Response to L-NMMA During 
Study Three. N = 10 included. All values refer to the change in area under the time 
curve. * = estimated difference in medians and the 95% CI on Wilcoxon signed rank 
test. † = for paired Wilcoxon signed rank test. 
 
A mixed effects model sensitivity analysis adjusted for the order in which participants 
received allopurinol and placebo.  The results were consistent with the main analysis 
(p=0.046 for allopurinol versus placebo) and found no significant order effect (p=0.51). 

















Figure 4.9. Intra-patient Change in ICA Flow Following L-NMMA Infusion in Study 
Three. Each data point represents the difference in response to LNMMA between 
study periods for one individual (in mls).  For each study phase, values were 
calculated as the difference between the pre and post intervention area under the 
flow-time curve. The difference between study phases was then calculated 
(allopurinol minus placebo) and positive values (to the right) represent improvement 
in response following allopurinol and negative values improvement following 
placebo. 
 
Figure 4.10. Change in ICA Flow Following L-NMMA Infusion in Study Three. 
The values shown represent the median (± 1 SE) change in ICA flow following 
intervention with allopurinol or placebo. The p value refers to between group 
comparisons on non-parametric testing (Wilcoxon signed rank test). A greater 
reduction in ICA flow following L-NMMA represents an improved response. 
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Effect of Allopurinol on Peripheral Vascular Reactivity 
The pre-infusion AI or PWV did not differ significantly between the treatment periods 
(estimated median difference between placebo and treatment periods of -4.3% (95% CI -11 
to 7%, p=0.56) and -0.32 m/s(95% CI -2.1 to 7.8, p=0.39) respectively).  The response to 
L-NMMA did not differ significantly between the treatment periods for both the AI 
(estimated median difference between placebo and treatment periods of 7%, 95% CI -11.5 
to 23%, p=0.54) and PWV (estimated median difference of -0.7 m/s, 95% CI –7.6 to 1.85, 
p=0.68) (table 4.25). 
 
Variable Baseline 









P value || 
AI (%)†  23.5 (18.5 to 
29.5) 
-3 (-14.5 to 
4.5) 
2 (-6.00 to  
10) 
-4.3 (-11 to 
7)  
0.56 
PWV (m/s) † 9 (7.6 to  
9.6) 




-0.32 (-2.1 to 
7.8) 
0.39 
Table 4.25. Change in Measures of Peripheral Vascular Reactivity During Study Three. 
† = values refer to difference between pre-infusion values. ‡ = values shown are median 
and interquartile range.   § = values shown are estimated difference in medians and the 
95% CI on Wilcoxon signed rank test.  || = for paired Wilcoxon signed rank test. 
 
Effect of Allopurinol on Circulating Markers of Inflammation/Endothelial Function 
No significant differences were seen in any marker (table 4.26). The VEGF level rose 
during allopurinol treatment, although this did not reach statistical significance and s-ICAM 
levels seemed to be lower following allopurinol treatment. However, with all blood markers, 
the confidence intervals for the differences between study periods were large. 
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Variable Placebo Allopurinol Difference 
Between 
Periods * 
P value † 
VEGF (pg/ml) -14 (-67 to 59.1) 66.9 (5.9 to 
119.6) 
91 (-53 to 151) 0.08 
s-ICAM (ng/ml) 73.6 (-85.3 to 
96.5) 





0.01 (-14.6 to 
10.3) 
2.4 (-12.9 to 
17.1) 
16 (-19 to 26) 0.45 
CRP (mg/l) 0.09 (-0.3 to 
0.75) 
0.195 (-0.01 to 
1) 
0.33 (-0.48 to 
1.29)  
0.40 
Table 4.26.  Change in Markers of Endothelial Function During Study Three. N = 11 
included. Median values (interquartile range) are given for each study period. A negative 
difference in medians represents improvement in favour of allopurinol. * = estimated 
difference in medians. † = for paired Wilcoxon signed rank test. 
 
4.05.3 Study Three Discussion 
 
L-NMMA can be used as a pharmacological tool to assess the extent of underlying NO 
activity.  In the cerebral vasculature, L-NMMA reduces CBF through restriction of NO 
activity and the higher the basal NO activity, the larger the effect.  In this study, treatment 
with allopurinol enhanced this effect implying that it improves basal levels of NO activity 
and raises the possibility that use of allopurinol could improve cerebrovascular health. The 
response to L-NMMA improve toward the previously published (530) 12.8% (95% CI 3.29 
to 22.31%) fall in ICA flow seen in healthy volunteers (from a non-significant 4.8% (95% 
CI -17.3 to 9.4) reduction at baseline to an 11.9% (95% CI -23.3 to 2.5) fall following 
allopurinol treatment). 
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The potential beneficial effects of allopurinol on the vasculature are two fold; it reduces XO 
mediated ·O2-. production and serum uric acid. The XO system has been shown to be an 
important source of ·O2-. in the vasculature (408) but this is the first human study to show 
that inhibition of XO improves cerebral NO bioavailability. Most large, well-conducted 
epidemiological studies suggest that increasing serum uric acid is associated with increased 
cardiovascular event rate and mortality (519), possibly via detrimental effects on platelet, 
smooth muscle and endothelial function (521), and UA reduction may impact favourably 
on cardiovascular risk (472). 
 
Previous studies, typically also utilising cross over design and brief treatment duration, 
have shown a beneficial effect of XO inhibition on measures of forearm or coronary 
endothelial function in patients with or at high risk of vascular disease (521) - including in 
patients with diabetes. One previous small study (492) failed to show benefit of allopurinol 
on markers of oxidative stress (such as the lipid peroxidation assay) in patients with 
diabetes, although there were large differences in the levels of baseline HbA1c and cardiac 
risk factors such as smoking with levels worse in those randomised to allopurinol. This 
study is the first to show benefit of allopurinol on cerebrovascular endothelial function.  
Whether these improvements are driven by change in uric acid or XO activity is unclear but 
previous work suggests the later (483), although as mentioned, uric acid reduction may 
bring other benefits in the longer term.  
 
There are strengths to this study; it utilised a rigorous protocol, with which there is 
considerable experience, and a similar baseline response to L-NMMA was found compared 
to that seen in previous work (530). The response to L-NMMA is a valid measure; it is an 
analogue inhibitor of eNOS and infusion has previously been shown to reduce both CBF 
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(531) and forearm blood flow (533), to increase large artery stiffness (534) and to increase 
blood pressure (535). Also, improvements in these responses have been shown following 
treatment with other agents proven to impact on cardiovascular morbidity and mortality 
(536;537).  
 
There are limitations to the study and areas that require further study. Fewer patients were 
included than intended because of the lack of ongoing availability of L-NMMA, reducing 
the statistical power of the study. The unfortunate supply problem affected several centres 
in the UK. Even so, the consistency of effect seen is reassuring; 8 of 10 patients who 
completed the protocol experienced an improvement in cerebrovascular NO availability 
during the allopurinol phase. The dosing period was short (a limitation of many previous 
studies) and it is possible that any changes in vascular function afforded by a reduction in 
XO activity and ·O2-. production may be short lived and soon by-passed by other sources of 
·O2-.  The effect of more prolonged XO inhibition requires clarification. Also, while it is an 
appropriate measure to study, this study has only examined the effect on eNOS activity and 
other forms of NO and ·O2-. production may be important in both disease and health. 
 
No improvement was seen in blood markers or measures of peripheral arterial stiffness in 
this study. Pre-infusion measures of arterial stiffness did not differ significantly between 
the study periods and neither did the response to L-NMMA. These results contrast with a 
previous study where forearm blood flow responses were improved following allopurinol 
(490) but a different technique was employed here and the study was not specifically 
powered to detect differences in these parameters. Also, at the baseline visit, the increase in 
AI or PWV following L-NMMA seen in previous studies of healthy volunteers (534) was 
not replicated. This is perhaps because the response is impaired in those with diabetes or 
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because of the comparatively low dose of L-NMMA used. Study to further evaluate this 
response in those with diabetes would be of use. Importantly, it is possible that there are 
regional differences in basal NO production between different vascular beds and that 
responses to treatment may similarly differ (560). 
 
In summary, this study showed that XO inhibition with allopurinol improves cerebral NO 
bioavailability and suggest a beneficial effect of allopurinol on cerebrovascular health. 
Further investigation to establish the use of allopurinol in stroke prevention is required.   
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4.06 Study Four - The Effect of Allopurinol on the Cerebral Vasculature of Patients 
with Subcortical Stroke 
 
The hypothesis was that allopurinol would improve cerebrovascular reactivity in a cohort of 
patients with recent subcortical stroke. A randomised, blinded, placebo controlled trial was 
performed to test this hypothesis.   
 
4.06.1 Study Four Methods 
The study was performed in the University Division of Cardiovascular and Medical 
Sciences at the Western Infirmary, Glasgow. The study was approved by the West Medical 
research ethics committee and was registered in the ISRCTN database (ISRCTN 06452574). 
 
Patients aged over 18 years old with subcortical stroke between two weeks and six months 
prior to randomisation were studied. Exclusion criteria were: >70% extra-cranial internal 
carotid artery stenosis, known coronary arterial disease, significant co-morbidity or frailty 
likely to cause death within 3 months or likely to make adherence to study protocol difficult 
for patient, contra-indication to or indication for administration of allopurinol (as detailed 
in summary of medicinal product characteristics), concurrent azathioprine or 6-
mercaptopurine therapy, contra-indication to administration of acetazolamide, serum 
creatinine > 250µmmol/l, enrolment in another clinical trial and women of childbearing 
potential. Exclusion criteria were chosen to minimise the potential risks of allopurinol 
treatment and acetazolamide infusion and to ensure carotid flow readings were not falsely 
elevated because of intrinsic carotid disease. 
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Patients were identified during admission to the Acute Stroke Unit at the Western Infirmary 
and out-patient attendance at hospital clinics. All participants gave written informed 
consent to participate. All drug treatments remained unchanged throughout the study period, 




Study visits took place in the Investigations Ward of the Acute Stroke Unit in the Western 
Infirmary and were supervised by one of the study investigators.  The participant schedule 
is shown in figure 4.11. 
 
Assessment of mean flow velocity in the ICA and middle cerebral artery (MCA) was 
performed, along with measures of ICA diameter and area. Peripheral (radial) pulse wave 
analysis (PWA) and (carotid-radial) pulse wave velocity (PWV) measurements were also 
performed.  On completion of these measurements, a 15 mg/kg ml infusion of 
acetazolamide was given intravenously over 3 minutes. Assessment of ICA and MCA 
parameters and PWA and PWV measurements were repeated at 15 thereafter.  Carotid 
insonation was performed using an Acuson Aspen 128 with a 5-Mhz linear transducer 
(Acuson, Mountain View, CA, USA) and measurements were taken 1 cm distal to the 
carotid bifurcation. MCA insonation was performed using a TCD 100M (Spencer 
Technologies, Seattle, WA, USA) and readings were taken at, or as near as possible to, a 
depth of 50 cm. Ultrasound examinations were performed by a sonographer with several 
years’ experience of neurovascular ultrasound. PWA and PWV measurements were made 
using a SphygmoCor device (Atcor Medical, Sydney, Australia) by operators with several 
years experience.  
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Following baseline assessment, participants were randomised to receive either 300 mg of 
allopurinol or placebo orally once daily (on a 1:1 basis). Dosing began on the day of 
baseline assessment and continued for 90 days after which participants returned for further 
assessment as described above. All haemodynamic studies were conducted as near to 
midday as feasible and subjects were asked to refrain from caffeine for 24 hours prior to 
each study. 
 
At each study visit, blood was drawn to allow measurement of routine biochemistry and 
haematology parameters and circulating markers of endothelial/inflammatory function 
(VEGF, sICAM, eSelectin and CRP). For these tests, serum was frozen and stored for 
































Figure 4.11. Study Four Participant Study Schedule. 
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4.06.1.1 Rationale for Use of Response to Acetazolamide as a Measure of 
Cerebrovascular Function 
Impaired regulation of the subcortical microvasculature has been proposed as a pathogenic 
mechanism in first and recurrent lacunar cerebral infarction and in vascular dementia (561). 
This impaired regulation can be assessed using a standard non-invasive ultrasound protocol 
which measures cerebral vasomotor reactivity (CVR), the compensatory dilatatory capacity 
of cerebral resistance vessels in response to increased arterial carbon dioxide concentration, 
which can be manipulated by an acetazolamide infusion (562-564). The magnitude of the 
change in cerebral blood flow is the measure of CVR and is a functional assessment of the 
cerebral vasculature (562).  Impaired CVR occurs in a variety of cardiovascular risk states 
(565;566), correlates with the severity of leucoencephalopathy seen on magnetic resonance 
imaging (567) and confers an increased risk of ischaemic stroke, possibly due to increased 
rigidity in the arteriolar wall and to failure of the cerebral vasculature to compensate for 
fluctuations in perfusion pressure (566;568). Importantly, CVR can be improved with statin 
(569) and ACE inhibitor (562) therapy, both strategies known to reduce incidence of stroke 
in high-risk individuals and is thus a useful therapeutic target upon which to test new 
treatments. 
 
CVR as measured by response to acetazolamide is thus a valid measure and a 15mg/kg or 
1g dose of acetazolamide leads to maximal vasodilatory effect (570) with a peak effect at 
approximately 15 minutes (571).  Acetazolamide is a reversible inhibitor of the enzyme 
carbonic anhydrase which catalyses the reaction; 
CO2 + H20 = H2CO3 = H+ + HCO3-. 
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It is presumed that the effect of acetazolamide on cerebral blood flow is mediated by the 
increase in extracellular pCO2 and decrease in extracellular pH it affords. Both of these 
changes lead to dilatation of small cerebral blood vessels (572). However, it is important to 
note that acetazolamide may have a direct effect on smooth muscle of the blood vessel wall 
(573) and thus acts through both endothelium dependent and independent mechanisms. It is 
possible therefore that changes in CVR assessed by this means may not truly reflect 
benefits or otherwise of a treatment such as allopurinol, whose vascular effects are 
mediated by a reduction in oxidative stress and improved endothelial function. Assessment 
of effect on measures such as L-arginine reactivity or infusion on L-NMMA may have thus 
be a more appropriate measure (574;575) but is unsuitable in this population due to 
concerns with its administration in those with established cardiovascular disease. 
 
Randomisation and Treatment Allocation 
Allopurinol tablets were manufactured by Alpharma. Placebo tablets were manufactured by 
Penn Pharmaceuticals. Both were packaged in identical fashion in the Pharmacy Production 
Unit at the Western Infirmary Hospital. Study treatments were collected by one of the 
investigators on the day of the baseline and the first post-washout study visit. Concordance 
with therapy was assessed by questioning and pill counts where available. Investigators 
remained blinded to serum uric acid data until the end of the study to prevent unmasking of 
treatment allocation.  Randomisation was performed by the pharmacy department and the 
randomisation code was held by an independent study pharmacist. The code was not broken 
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Statistical measures 
The primary endpoint was the change in MCA flow velocity induced by the acetazolamide 
expressed as the percentage change measured at 15 minutes after the infusion compared to 
the 0 minute value (termed CVR). Based on previous data (562), it was calculated that a 
sample size of 25 patients per group would enable detection of a clinically meaningful 10% 
improvement in CVR following allopurinol treatment with 90% power (alpha = 5%, 
assumed standard deviation 10%). Secondary endpoints were change in augmentation index 
(AI, measured during PWA) and PWV, and change in uric acid levels and circulating 
markers of endothelial/inflammatory function during the study. Approval was sought and 
obtained to recruit 80 participants, which would allow detection of a smaller yet potentially 
significant 3.7% improvement in CVR with 90% power. 
 
The difference in CVR values between the follow-up and baseline visits were compared 
between treatment groups. For the AI and PWV, 0 minute values at the baseline visit and 
follow-up visit were compared. The difference between pre and post treatment values was 
compared for the circulating markers of endothelial/inflammatory function. As data were 
non-normally distributed, the Mann-Whitney test was used for all between group 
comparisons. Minitab Software (version 15, California USA). 
 
4.06.2 Study Four Results 
 
Fifty participants were recruited between March 2006 and May 2008. Forty-five of those 
recruited completed the protocol. Two participants withdrew consent prior to the baseline 
visit, one felt unwell following acetazolamide infusion so did not wish to continue, one had 
an unreliable TCD window so that MCA velocities could not be reproducibly measured and 
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one participant (who had stopped study medication) did not attend on two occasions for the 
follow-up visit. Data from this latter participant were included in analyses of baseline levels 
of blood markers and CVR. All these participants were randomised to the allopurinol group. 
There were two serious adverse events, both of which occurred in the allopurinol group but 
were deemed unrelated to treatment; one participant developed tonsillitis and required 
hospital admission while another developed acute appendicitis. One participant in the 
placebo group suffered gout. The study was terminated after recruitment of 50 participants. 
 
Of these recruited, mean age (SD) was 58.3 years (SD 10.4). Demographic details, 
including baseline drug therapy, risk factor burden, renal function and uric acid levels are 
shown table 4.27. Baseline variables were broadly similar although the proportion 
established on diuretic and ACE inhibitor or angiotensin receptor blocker therapy was 
higher in the placebo group.  
 
Baseline Response to Acetazolamide Infusion 
At the baseline visit, MCAv increased by a mean of 15.5 m/s (SD, 12) and by 36.3% (SD 
26) following acetazolamide infusion in the whole group and by 36.5% (SD 27.9) and 
36.2% (SD 4.9) in the allopurinol and placebo groups respectively. The AI and PWV did 
not alter following acetazolamide infusion. 
 
Change in CVR Following Allopurinol Treatment 
CVR did not change following treatment with allopurinol (median change in CVR 0.89% 
in the allopurinol group and -0.68% in the placebo group, p=0.64, (95% CI for estimated 
difference in medians -13.4 to 25.5%)) (figure 4.12). 
 







Completed Protocol 20 (80%) 25 (100%) 45 (90%) 
Age 59.4 (9.3) 57.3 (11.5) 58.3 (10.4) 
Smoker 9 (37.5%) 13 (52%) 22 (44.9%) 
Hyperlipidaemia 8 (33.3%) 7 (28%) 15 (30.6%) 
Hypertension 13 (54.2%) 16 (64%) 29 (59.1%) 
Previous CVA 4 (16.7%) 0 4 (8%) 
Diabetes 2 (8.3%) 3 (12%) 5 (10.2%) 
Anti-platelet Therapy 23 (95.8%) 24 (96%) 47 (95.9%) 
ACE Inhibitor or ARB Therapy 7 (29.2%) 20 (80%) 27 (55.1%) 
Diuretic Therapy 6 (25%) 11 (44%) 17 (34.7%) 
Calcium Channel Antagonist 
Therapy 
1 (0.04%) 3 (12%) 4 (8.2%) 
Beta-Blocker Therapy 5 (20.1%) 2 (8%) 7 (14.3%) 
Lipid Lowering Therapy 23 (95.8%) 23 (92%) 46 (93.9%) 
Oral Hypoglycaemic Agent 2 (8.3%) 3 (12%) 5 (10.2%) 
Serum Creatinine (µmol/l) 91.1 (19.2) 90.4 (21.8) 90.8 (20.4) 
Serum Glucose (mmol/l) 6 (1.8) 6.6 (2.4) 6.3 (2.2) 
Serum Uric Acid (mmol/l) 0.35 (0.1) 0.33 (0.09) 0.34 (0.09) 
SBP (mmHg) 133.9 (17.1) 142.9 (24.1) 138.6 (21.3) 
DBP (mmHg) 74.4 (11.8) 78.8 (11.4) 76.7 (11.7) 
MCAv (m/s) 42.6 (10.8) 44.6 (12.5) 43.7 (11.6) 
Augmentation Index (AI, %) 24.4 (12.3) 22.4 (11.5) 23.4 (11.8) 
Pulse Wave Velocity (PWV, 
m/s) 
7.6 (1.6) 8.1 (1.6) 7.8 (1.6) 
Any Serious Adverse Event 2 (8.3%) 0 2 (4%) 






















The AI did not change following treatment with allopurinol (median change 0% in the 
allopurinol group and 2 % in the placebo group, p=0.51). There was also no change in 
PWV (median change -0.3 m/s in allopurinol group compared to -0.35 m/s in the placebo 
group, p=0.42) (table 4.28). Uric acid level was significantly reduced by allopurinol 
treatment but there were no significant changes in the other blood parameters or markers of 




Figure 4.12. Percentage Change in Cerebrovascular Reactivity  
(CVR) Following Treatment in Study Four 
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AI (%)  23.35 (14.25 
to 52) 
2 (-3.75 to 
35) 
0 (-6 to 6) -1.5 (-7 to 4)  0.5 




-0.3 ( -1.25 to 
1.4) 
0.35 (-0.5 to 
1.5) 
0.42 
Table 4.28 - Measures of Peripheral Arterial Stiffness in Study Four. All values refer 
to the baseline pre-infusion values. ‡ = values shown are median and interquartile 
range.   § = values shown are estimated difference in medians and the 95% CI on 
Mann-Whitney testing.  || = for Mann-Whitney testing. 
 
 
Variable Placebo Allopurinol Difference Between 
Periods * 
P value † 
Uric Acid 
(mmol/l) 
0.02 (-0.02 to 
0.06) 
-0.12 (-0.2 to -
.05) 
-0.15 (-0.2 to -0.09) <0.0001 
VEGF (pg/ml) 11.8 (-60.6 to 
157.4) 
-11.4 (-50 to 
10.8) 
-27.3 (-12.5 to 42) 0.23 
s-ICAM 
(ng/ml) 
12.8 (-13.3 to 
93.7) 
10 (-68 to 56.7) -32.7 (-142.4 to 25.1) 0.3 
e-Selectin 
(ng/ml) 
-4.71 (-13.35 to 
11.72) 
-6.43 (-21.51 to 
8.06) 
-2.85 (-19.64 to 11) 0.72 
CRP (mg/l) 0.29 (-2.12 to 
0.76) 
0.03 (-0.41 to 
0.93) 
0.09 (-0.72 to 1.44) 0.87 
Table 4.29 – Change in Blood Parameters and Markers of Endothelial Function 
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4.06.3 Discussion 
 
This study found no effect of allopurinol treatment on CVR, as measured by response to 
acetazolamide infusion in patients with recent subcortical stroke. 
 
The lack of effect of allopurinol on CVR is not in-keeping with data which support the 
beneficial effect of allopurinol on the vasculature. The effect of XO inhibitors on measures 
of endothelial and cardiovascular function has been tested in many small studies (521). 
Trials have variously used oral or intravenous drug and typically involved a cross over 
design, with changes in arterial responsiveness as outcome measures, which have been 
shown to improve following treatment with CV risk-modifying drugs (510). Improvements 
following XO inhibition are seen in patients with type II diabetes and hypertension, 
hypercholesterolaemia, smokers, in those with elevated 10 year CV risk and 
hyperuricaemia, in stable coronary disease and in the context of heart failure (521), 
although beneficial effects were not seen in some studies in heart failure and 
hyperlipidaemia. This is the first study of the effect of allopurinol on a measure of 
cerebrovascular health in patients with previous stroke. Previous work from this unit has 
shown that allopurinol use is associated with a potentially beneficial attenuation of the rise 
in ICAM-1 levels after stroke (489) and improvements in cerebrovascular function in those 
with type 2 diabetes (576) hence the wish to evaluate whether allopurinol improves 
cerebrovascular health after stroke.  
 
This study employed a rigorous protocol, with which there is considerable local experience, 
and CVR measured in this fashion has previously been shown by this group and others to 
improve following treatment with statins and ACE inhibitors (561;569).  This study may 
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have failed to see benefit for several reasons. Firstly, the study size would allow detection 
of a 10% improvement in CVR with 90% power. This is the same magnitude of benefit that 
was previously seen with perindopril use but this study has limited power to detect smaller 
yet potentially beneficial improvements. This is compounded by the large variability seen 
in the change and measures of CVR. Also, by chance, all patients who withdrew before or 
early after starting medication had been randomised to the allopurinol group. Further, in 
this study, 94% of patients were established on statin therapy, compared to only 30% in 
similar studies of ACE inhibition (562), and over half were receiving ACE inhibition or 
ARB therapy, while 70% were on some form of anti-hypertensive therapy. The rate of 
concurrent ACE I / ARB therapy was more than double in the placebo group compared to 
those who received allopurinol. It may be that, in such a well treated cohort, the potential 
beneficial effect of allopurinol is less than originally anticipated.  The potential limitations 
of CVR measured in this way have already been discussed. It remains, however, a valid 
measure given the concerns surrounding other measures such as response to L-NMMA in 
those with established cardiovascular disease. 
 
Further, while the baseline levels of CVR in this study are comparable to previous studies 
in this patient group, there is considerable overlap in the literature between values reported 
in healthy volunteers (577), those with elevated cardiovascular risk, previous stroke and 
occlusive carotid disease (563). It is therefore difficult to estimate to what degree baseline 
CVR was impaired in this group and thus the degree of improvement that one would expect 
to see from effective therapy. 
 
Many previous studies have investigated the effect of a short treatment duration, and even 
single dose, of allopurinol treatment and have consistently revealed benefit on measures of 
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vascular function (521). It is of interest that 2 of the 3 published studies (487) (482;496) 
testing a longer treatment duration have failed to yield benefit. Any beneficial effects of 
xanthine oxidase inhibition on the vasculature may be short lived and by-passed by other 
sources of oxidative stress. It may also be that up-regulation of xanthine oxidase occurs 
with time, meaning any improvements may not be sustained for a prolonged period.  Uric 
acid levels were not elevated in this population and studies in the setting of heart failure 
suggest that the vascular effects of allopurinol are demonstrable only where xanthine 
oxidase activity is up-regulated and uric acid levels are increased (578), although the effects 
may not be mediated by uric acid reduction per se (483). 
 
In summary, this study did not confirm a beneficial effect of allopurinol on cerebrovascular 
reactivity. It may therefore be that previous encouraging findings will not therefore 
translate into important clinical benefits. Further study is required and results of this trial 
suggest this should focus on those with increased serum uric acid levels and aim to clarify 




These studies suggest uric acid is an important risk factor for adverse vascular outcome. 
Allopurinol may also be a promising preventative strategy.  Serum uric acid predicts poor 
functional outcome following acute stroke but not in an independent fashion. There was no 
evidence of an association with favourable outcome as other groups have found. Increasing 
serum uric acid was also shown to be predictive of increased risk of stroke, total, vascular 
and coronary mortality in treated hypertensive patients but interestingly, the relationship 
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between stroke mortality and serum uric acid appears J-shaped and most apparent in 
females. 
 
Allopurinol was shown to improve cerebral nitric oxide bioavailability suggesting a 
beneficial effect of allopurinol on cerebrovascular health. However, allopurinol did not 
improve cerebrovascular reactivity (as measured by response to acetazolamide infusion) in 
a group of patients with recent subcortical stroke. This raises interesting questions 
regarding the longevity of any positive effect of allopurinol as this, and other studies of 3 
month duration, have revealed no benefit. Further, subjects in this neutral study did not, on 
balance, have elevated serum uric acid and it has recently been suggested that only those 
with significantly elevated levels benefit in the setting of congestive cardiac failure.  
Further work should establish whether this is also true in those with regard to stroke 
prevention. 
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Stroke is a common disorder with dire consequences for the patient and for society and will 
increase in prevalence over the coming years. Following stroke, many patients 
unfortunately suffer a further stroke, and recurrent strokes account for approximately 25% 
of the total. Considerable scope therefore exists to improve both primary and secondary 
stroke prevention.  This thesis has addressed several areas at key stages in the prevention of 
stroke by developing strategies to better identify those at highest risk, attempting to better 
target pre-existing anti-platelet therapy and by beginning the evaluation of xanthine oxidase 
reduction and uric acid lowering therapy in the prevention of stroke. 
 
A clinical scoring system to aid diagnostic recognition in those with suspected transient 
ischaemic attack (TIA) was successfully developed and has the ability to reduce the referral 
of those without cerebrovascular disease to busy TIA clinics. This would have a substantial 
effect on waiting times for assessment; a key aim given the recent evidence that rapid 
assessment and treatment of those with TIA greatly reduces stroke risk. Further work to 
evaluate and introduce the score to routine clinical practice is required.  It is planned to 
incorporate use of the scoring system into the referral process to our TIA clinic. It will be 
established whether, when used by General Practitioners, the scoring system can identify 
those without TIA whilst safely identifying those with true TIA. The potential impact on 
services will also be assessed.  
 
Aspirin resistance was confirmed to be a common phenomenon, although the role of poor 
compliance with therapy as a cause in a substantial number of cases was established. This 
suggests that objective measures to confirm aspirin ingestion should be mandatory in future 
studies of aspirin resistance.  Aspirin resistance was also higher in those with 
cerebrovascular microembolic signals (MES) and carotid disease compared to those with 
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equivalent carotid disease and no MES. This provides a link to a well established and 
robust surrogate marker of outcome and thus a useful model to further study the benefits of 
guided anti-platelet strategies. An interventional clinical anti-platelet trial based upon 
individual aspirin responsiveness in high risk individuals such as those with MES is now 
warranted and funding will be sought for this in the near future. 
 
Increasing serum uric acid was found to be a predictor of poor functional outcome 
following acute stroke but not in an independent fashion. However, there was no evidence 
of an association with favourable outcome as other groups have found. Increasing serum 
uric acid was also shown to be predictive of increased risk of stroke, total, vascular and 
coronary mortality in treated hypertensive patients but interestingly, the relationship 
between stroke mortality and serum uric acid appears J-shaped and most apparent in 
females.  A study of the use of allopurinol in those with diabetes showed that XO inhibition 
improves cerebral NO bioavailability suggesting a beneficial effect of allopurinol on 
cerebrovascular health. However, a study of the effect of allopurinol treatment on 
cerebrovascular reactivity (as measured by response to acetazolamide infusion) in a group 
of patients with recent subcortical stroke revealed no positive effect.  This raises interesting 
questions regarding the longevity of any positive effect of allopurinol as it, and other 
studies of 3 month duration, have revealed no benefit. Further, subjects in this study did not 
on balance have elevated serum uric acid and it has recently been suggested that only those 
with significantly elevated levels benefit in the setting of congestive cardiac failure.  
Whether this is also true in those with stroke also requires to be clarified. A large study of 
the effect of allopurinol on carotid intima-media thickness, a robust and modifiable marker 
of vascular risk, in those with recent stroke is planned to address these questions. 
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The planned study is a randomised, double-blind placebo controlled pilot study to 
investigate benefit of 2 years allopurinol 300 mg on change in carotid intima-media 
thickness in those with recent stroke. Levels of endothelial progenitor cells and circulating 
markers of endothelial function and safety and clinical endpoint data will also be gathered 
assessed.  The trial will require approximately 500 participants to be followed for a two 
year period to ensure adequate power. The study hypothesis is that allopurinol will reduce 
IMT progression rate, increase levels of EPCs and reduce levels of circulating endothelial 
markers with no increase in serious adverse events. The study will begin in May 2009 and 
take five years to complete. 
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